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Eukaryotic translation initiation factor 5A (eIF5A) is the only known protein containing the 
unique amino acid, hypusine. eIF5A is present in all eukaryotic cells and is highly conserved, but its 
function is not well understood. The present investigation was undertaken to study the regulatory role 
of eIF5A in the induction of apoptosis in human cancer cell lines.  
Suppression of eIF5A1 using specific siRNA was shown to have no effect on the growth and 
proliferation of mammalian cells, although inhibition of the post-translational hypusination of eIF5A1 
resulted in G1 phase cell cycle arrest. Treatment of HT-29 human colon adenocarcinoma cells with 
eIF5A1 siRNA did, however, reduce their sensitivity to pro-apoptotic stimuli including nitric oxide, 
Actinomycin D, proteaosome inhibition and serum starvation. Furthermore, over-expression of 
eIF5A1 in HT-29 cells or Hela S3 human cervical carcinoma cells using adenovirus constructs 
strongly induced apoptosis in a time-dependent manner.  
The pro-apoptotic effect of eIF5A1 appears to reflect at least in part its ability to activate the 
mitochondrial pathway of apoptosis in that its up-regulation resulted in dissipation of mitochondrial 
∆Ψm, release of cytochrome c, activation of caspase 9 and caspase 3 and translocation of Bax from 
the cytosol to mitochondria. Similar effects were observed following treatment with eIF5A2, a second 
isoform of human eIF5A, and in addition eIF5A2 induced up-regulation of cleaved Bcl-2 which is 
thought to be pro-apoptotic. A mutant of eIF5A1 in which the conserved lysine, lysine50, that is post-
translationally modified to hyusine was switched to alanine [eIF5A1(K50A)] also proved capable of 
inducing apoptosis by activating the mitochondrial pathway. As well, eIF5A1 and eIF5A1(K50A) 
both induced strong up-regulation of p73, a homolog of the tumor suppressor p53, in Hela S3 cells 
containing null p53. The finding that up-regulation of eIF5A1 also resulted in activation of caspase 8 
indicates that it may be involved in regulation of the death receptor pathway of apoptosis as well. 
This contention is further supported by confocal microscopy studies indicating that, following its up-
regulation, eIF5A1 localizes to the inner surface of the plasma membrane in a time-dependent manner 
that correlates temporally with the induction of apoptosis. 
eIF5A1 and its post-translationally modified forms were isolated by 2-dimensional Western 
blotting and sequenced by mass spectrometry. These analyses indicated that eIF5A1 containing 
unmodified lysine50 is the form of the protein that accumulates coincident with induction of apoptosis 
either by up-regulation of eIF5A1 or treatment with NO. These observations, together with the 
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finding that eIF5A1(K50A) is capable of inducing apoptosis, indicate that it is the unhypusinated 
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Chapter 1 Introduction 
1.1 Apoptosis  
Apoptosis, also known as programmed cell death, is responsible for the deletion of unwanted 
cells and is critical for organ development, tissue homeostasis and elimination of defective or 
potentially dangerous cells in complex organisms (Reviewed by Arends and Wyllie, 1991). Apoptosis 
was originally observed and characterized by Kerr et al. (1972) when they were studying ischemic 
liver injury using electron microscopy. They observed a novel, controlled mechanism of cell death 
that is distinct from uncontrolled necrotic cell death. Apoptosis exhibits a characteristic morphology 
which includes cell shrinkage, plasma membrane blebbing, chromatin condensation, nuclear 
fragmentation, formation of apoptotic bodies and phagocytosis of apoptotic bodies by macrophages 
(Reviewed by Arends and Wyllie, 1991; Häcker, 2000). Apoptotic cells exhibit distinct biochemical 
characteristics such as activation of caspases, protein cleavage by caspases, phosphatidylserine (PS) 
exposure on the surface of plasma membrane and DNA fragmentation into 200 bp fragments by 
endonucleases (Hengartner, 2000).  
Apoptosis can be triggered by various stimuli including developmental signals, DNA 
damage, lack of survival signals, viral infection, disruption of the cell cycle and cellular stresses 
including chemotherapeutic agents, cytokines, ionizing radiation, osmotic stress and starvation 
(Martin, 1993a; Dragovich et al., 1998). It is considered to be a process that eliminates superfluous, 
ectopic, damaged or mutated cells without a concomitant inflammatory response in the surrounding 
tissues. In contrast to necrosis, which is a form of cell death that results from acute cellular injury and 
happens in an uncontrolled manner, apoptosis is highly regulated and generally confers advantages 
during the life cycle of an organism (Dragovich et al., 1998; Hengartner, 2000). It starts with an 
initiation phase that is largely dependent on cell type and apoptotic stimulus, followed by integration 
and amplification of these signals by second messengers. The death effector proteases and nucleases, 
which are activated by systematic biochemical events during the amplification phase (Dragovich et al., 
1998), participate in the degradation phase by cleaving target proteins and DNA (Arends et al., 1990; 
Ferri and Kroemer, 2000; Hengartner, 2000). Defects in the control of apoptotic pathways may 
contribute to a variety of diseases including cancer, autoimmune and neurodegenerative conditions 





Apoptosis is mediated in part by a family of proteins known as caspases, which are cysteine 
proteases that cleave at conserved aspartic acids (Reviewed by Earnshaw et al., 1999). In mammals, 
14 caspases have been identified so far, although not all of them participate in apoptosis. Members of 
the caspase family can be divided into three groups based on their functions: (1) the initiators of 
apoptosis, including caspase 2, 8, 9, 10 and 12; (2) the effectors/executioners of apoptosis, including 
caspase 3, 6 and 7; and (3) participants in cytokine activation, including caspase 1, 4, 5, 11, 13 and 14 
(Reviewed by Cohen, 1997; Thornberry, 1997; Nicholson, 1999; Degterev et al., 2003). Different 
initiator caspases are involved in the various types of stimuli-induced cell death. For example, 
caspase 8 and 10 and their adaptor Fas-associated death domain (FADD) are involved in death 
receptor-induced apoptosis. Caspase 9 and its adaptor Apaf-1 are involved in cellular stress (e.g., 
DNA damage, oncogene activation) -induced apoptosis (Cohen, 1997; Nicholson, 1999), whereas 
caspase 12 is involved in endoplasmic reticulum (ER) stress-induced apoptosis (Nakagawa et al., 
2000). 
Caspases produced as catalytically inactive zymogens are activated by proteolysis (Reviewed 
by Nicholson, 1999; Boatright and Salvesen, 2003). In detail, the initiator caspases, which exist in the 
cytosol as inactive monomers, have a protease domain and a long N-terminal prodomain that contains 
specific protein-protein interaction motifs to mediate its association with the adaptor proteins. 
Recruitment of the initiator caspase zymogens to the adaptor induces clustering and aggregation of 
the zymogens, stimulating their activation through self-proteolysis (Boatright et al., 2003). In 
contrast, the effector caspases, which also have a protease domain and a short prodomain, pre-exist as 
dimers in healthy cells. Their activation requires direct proteolytic cleavage of the protease domain by 
activated initiator caspases (Reviewed by Shi, 2002). Thus, initiators and executioners form a 
proteolytic caspase cascade. 
Active executioner caspases mediate the degradation of various cellular substrates (Reviewed 
by Fischer et al., 2003). For example, caspases cleave the inhibitor of caspase-activated 
deoxyribonuclease (ICAD), thereby activating caspase-activated deoxyribonuclease (CAD) which is a 
cytoplasmic endonuclease that, upon activation, enters the nucleus and degrades chromosomal DNA 
(Enari et al., 1998). The cleavage of DNA, which is a signature of apoptosis, has a protective function 
for the whole organism in that it reduces the likelihood of genes in a potentially active site being 
transferred from dying cells to the nucleus of viable neighboring cells (Arends et al., 1990). Caspases 
are also responsible for the proteolytic cleavage of a diverse array of structural and regulatory 
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proteins which are crucial for the maintenance of DNA repair, translation, cell cycle control, the 
cellular cytoskeleton, the nuclear scaffold and signal transduction (Kaufmann et al., 1993; Martin et 
al., 1995; Mashima et al., 1995; Song et al., 1996; Widmann et al., 1998). The action of these 
caspases gives rise to the apoptotic phenotype. 
Activated caspases are also thought to create a positive feedback loop that contributes to 
amplification of the death signal by processing and activating the zymogens of other members of the 
caspase family (Slee et al., 1999; Van de Craen et al., 1999; Viswanath et al., 2001) and by altering or 
reversing the function of certain cellular target proteins. For example, Bid, which is cleaved by 
caspase 8 in the extrinsic pathway, can activate the mitochondrial pathway, thus amplifying the 
apoptotic signal (Li et al., 1998; Luo et al., 1998). Bcl-2 and Bcl-xL, on the other hand, can be 
cleaved by effector caspases, which cause them to switch from anti- to pro-apoptotic molecules 
(Cheng et al., 1997; Clem et al., 1998; Fujita et al., 1998).  
 
1.1.2 Extrinsic apoptotic pathway 
Two pathways of caspase-mediated cell death have been described for mammals. The 
extrinsic or death receptor-mediated pathway is critical to immune homeostasis, whereas the intrinsic, 
mitochondria-dependent pathway is used extensively in response to extracellular cues and internal 
insults such as DNA damage, heat shock and oncogene activation (Reviewed by Danial and 
Korsmeyer, 2004).  
Initiation of the extrinsic apoptotic pathway requires the action of extracellular messengers, 
termed death ligands. The binding of death ligands to members of the membrane-bound tumor 
necrosis factor receptor (TNFR) family (e.g., TNFR1, Fas, and TRAIL receptor 1 and 2) is followed 
by the formation of the death-inducing signaling complex (DISC), which in turn results in the 
activation of procaspase 8 and 10 (Reviewed by Nagata, 1997; Ashkenazi and Dixit, 1998, 1999; 
Peter and Krammer, 2003). Caspase 8 is necessary for TNFα-, FasL- or TRAIL-induced apoptosis 
(Varfolomeev et al., 1998). On the other hand, although caspase 10 is activated in the signaling 
complexes induced by death ligand treatment, it does not play a critical role in the extrinsic pathway 





Expression of Fas Ligand (FasL) is restricted mainly to activated T cells and natural killer 
(NK) cells and to immune-privileged sites (Reviewed by Nagata, 1997). In response to Fas signaling, 
Fas receptors self-assemble into trimers upon binding with three FasL molecules at the cell surface. 
The clustering of Fas induces the recruitment of the adapter protein FADD, which bears both death 
domains (DD) and death effector domains (DED). FADD binds to Fas via the DD and recruits 
procaspase 8 via the DED (Chinnaiyan et al., 1995; Boldin et al., 1996). A high local concentration of 
procaspase 8 at DISC causes its autocatalytic activation and subsequent activation of the downstream 
effector caspases (Muzio et al., 1998). Activation of the Fas signaling pathway by the addition of 
FasL, or even receptor agonist antibodies, rapidly triggers cell death (Nagata, 1999; Yonehara, 2002; 
Adachi et al., 2003). 
 
1.1.2.2 TNFα 
Tumor necrosis factor α (TNFα) is produced mainly by activated macrophages and T cells in 
response to infection (Reviewed by Liu, 2005). Ligation of TNFα to TNFR1 recruits the TNF 
receptor-associated death domain (TRADD) to the receptor (Hsu et al., 1995). TRADD then triggers 
the recruitment and oligomerization of FADD, forming DISC. Oligomerized FADD then recruits 
procaspase 8 via its DED domain, a process that leads to the activation of caspase 8 (Chinnaiyan et al., 
1996; Varfolomeev et al., 1996). However, unlike FasL, TNFα is not cytotoxic to most cells because 
TRADD also recruits receptor-interacting protein (RIP) and TNFR-associated factor 2 (TRAF2) 
resulting in activation of the NF-κB-mediated survival pathway and Jun N-terminal protein kinase 
(JNK) (Rothe et al., 1995; Hsu et al., 1996). Although activated JNK is thought to play a pro-
apoptotic role in TNFα-induced signaling (Deng et al., 2003), the activation of NF-κB can block the 
activation of caspase 8 by activating a group of gene products that function cooperatively to suppress 
TNFα-mediated apoptosis (Beg and Baltimore, 1996; Wang et al., 1998). Therefore, the destiny of the 
cell depends on the balance between the apoptosis and survival signaling pathways (Reviewed by 
Wallach et al., 1999). TNFα-induced apoptosis requires NF-κB inhibition, which can be achieved by 





Another set of death receptors has been shown to respond to a different death ligand known 
as TNF-related apoptosis-inducing ligand (TRAIL). Unlike FasL and TNF, both of which are only 
transiently expressed in activated cells, TRAIL mRNA has been detected in a wide variety of tissues, 
most predominantly spleen, lung and prostate (Wiley et al., 1995). In humans, TRAIL may interact 
with any one of five membrane receptors (Reviewed by Bouralexis et al., 2005). The primary 
function of TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2), both of which have a 
cytoplasmic DD, is to elicit an apoptotic death response upon ligation of TRAIL by inducing DISC 
formation and caspase activation, events that are similar to those of the FasL and TNFα pathways 
(Chaudhary et al., 1997; MacFarlane et al., 1997). The other three receptors, TRAIL-R3/DcR1, 
TRAIL-R4/DcR2, and osteoprotegerin (OPG), have truncated, nonfunctional DDs (Degli-Esposti et 
al., 1997; Sheridan et al., 1997; Marsters et al., 1997; Pan et al., 1997; Emery et al., 1998). Since 
these receptors are not capable of activating the caspase cascade but may rather activate NF-κB and 
block apoptosis, they are considered as antagonistic “decoy” receptors for the DD-containing TRAIL- 
R1 and R2. Transient over-expression of the decoy receptors confers resistance to TRAIL-induced 
apoptosis (Degli-Esposti et al., 1997; Sheridan et al., 1997).  
Among members of the TNF family, TRAIL is unique for its potent anticancer effect and low 
toxicity toward normal tissues in vivo (Ashkenazi et al., 1999; Walczak et al., 1999). Indeed, while 
cancer cells are normally sensitive to TRAIL-mediated apoptosis, normal cells display relativly high 
resistance to TRAIL due to the expression of decoy receptors (Reviewed by LeBlanc and Ashkenazi, 
2003). 
 
1.1.3 Intrinsic apoptotic pathway 
In addition to their involvement in metabolism and energy generation, mitochondria also play 
an important role in the initiation of the mitochondrial apoptotic pathway, also known as the intrinsic 
pathway, by inducing the release of apoptogenic mitochondrial proteins (AMP) (Reviewed by Harris 
and Thompson, 2000; Lemasters et al., 1999; Zamzami and Kroemer, 2001; McBride et al., 2006). In 
detail, in response to cellular stress such as DNA damage, mitochondrial outer membrane 
permeabilization (MOMP) occurs, allowing the release of soluble proteins retained in the 
intermembrane space (IMS) of mitochondria (Reviewed by van Gurp et al., 2003). The first indication 
of the importance of mitochondria in apoptosis arose from the finding that cytochrome c is released 
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from the IMS into the cytoplasm in response to apoptotic stimuli (Liu et al., 1996), and that 
cytochrome c facilitates apoptosis by associating with the apoptotic protease activating factor 1 
(Apaf-1) in the presence of dATP or ATP. Apaf-1, which pre-exists in the cytoplasm as a monomer, 
contains a caspase recruitment domain (CARD) and an ATPase domain. The hydrolysis of 
dATP/ATP and the binding of cytochrome c promote Apaf-1 oligomerization, inducing the formation 
of a large multimeric Apaf-1:cytochrome c complex, termed apoptosome (Li et al., 1997; Hu et al., 
1999). The apoptosome recruits procaspase 9 via the respective N-terminal CARD, inducing auto-
proteolytic cleavage and activation of the caspase 9 zymogen (Li et al., 1997; Srinivasula et al., 1998; 
Zou et al., 1999).  
In addition to cytochrome c, second mitochondria-derived activator of caspases (Smac; also 
known as DIABLO) (Du et al., 2000; Verhagen et al., 2000), HtrA serine peptidase 2 (Htra2; also 
known as Omi) (Suzuki et al., 2001), endonulease G (Li et al., 2001) and apoptosis inducing factor 
(AIF) (Susin et al., 1999; Lorenzo et al., 1999) are also released from mitochondria of cells which are 
exposed to apoptotic stimuli. Smac and Htra2 enhance and accelerate caspase-dependent apoptosis by 
binding and neutralizing inhibitors of apoptosis (IAP) (Du et al., 2000; Verhagen et al., 2000; Suzuki 
et al., 2001). IAPs inhibit the activation of caspases through their baculovirus IAP repeat (BIR) 
domains (Takahashi et al., 1998). Endonuclease G and AIF, two other IMS proteins released after 
MOMP, accelerate the apoptosis process by facilitating DNA fragmentation (Susin et al., 1999; 
Lorenzo et al., 1999; Li et al., 2001; Candé et al., 2004).  
 
1.1.4 Cross-talk between the extrinsic and intrinsic pathways 
Although the death receptor pathway and the mitochondrial pathway are capable of operating 
independently, accumulating evidence suggests that the signaling from these two pathways for 
caspase activation can sometimes be interconnected (Li et al., 1998; Luo et al., 1998; Deng et al., 
2003). Bid, a pro-apoptotic BH3-only Bcl-2 family protein, is cleaved by caspase 8 in response to 
death receptor signaling, generating a truncated C-terminal fragment named tBid. tBid translocates 
from the cytosol to the mitochondrial outer membrane (MOM) to induce the release of cytochrome c, 
which in turn activates caspase 9 (Li et al., 1998; Luo et al., 1998). As well, in response to TNFα 
signaling, Bid can be cleaved by the activated JNK pathway, generating jBid (JNK-mediated cleaved 
Bid) (Deng et al., 2003). jBid translocates to mitochondria to induce the selective release of Smac, 
which functions to relieve the inhibition of caspase 8 activation (Du et al., 2000). In fact, cells have 
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been classified according to their response to apoptotic stimuli (Scaffidi et al., 1998). In type I cells, 
induction of apoptosis is accompanied by activation of large amounts of caspase 8 in the DISC, 
without the necessity for amplification of the apoptotic signal by proteolysis of tBid. In type II cells, 
the apoptosis signal generated from the activation of caspase 8 within the DISC is not strong enough, 
and therefore the mitochondrial amplification loop involving the generation of tBid and formation of 
the apoptosome is required in order to generate sufficient caspase activity to kill the cell. 
 
1.1.5 Caspase-independent apoptosis 
Recent studies have demonstrated that some types of cell death can occur in the absence of 
caspase activation. Indeed, in most, if not all, models of stress-induced apoptosis, and even death 
receptor-induced apoptosis, specific caspase inhibitors are unable to inhibit apoptosis (Xiang et al., 
1996; McCarthy et al., 1997; Deas et al., 1998; Pastorino et al., 1998; Dumont et al., 2000; Eby et al., 
2000; Cheng et al., 2001). This suggests that there are factors other than caspases that mediate 
apoptosis. Since mitochondrial permeability transition (PT) occurs in most of these cases, it is thought 
that some of these factors may reside normally in mitochondria, with AIF and endonuclease G being 
candidates (Susin et al., 1999; Li et al., 2001).   
 
1.1.5.1 AIF and chromatin condensation 
AIF is a highly conserved mitochondrial flavoprotein that is released from mitochondria after 
mitochondrial membrane depolarization and is thought to be capable of inducing apoptosis 
independently of caspases (Susin et al., 1999). Released AIF redistributes to the nucleus, where it 
induces chromatin condensation and large-scale DNA fragmentation (more than 50 kilo base pairs), 
events that resemble those observed in cells in which apoptosis is induced under conditions of caspase 
inhibition (Xiang et al., 1996; McCarthy et al., 1997; Deas et al., 1998; Pastorino et al., 1998; Dumont 
et al., 2000; Eby et al., 2000). Therefore, it has been suggested that AIF is responsible for at least 
some of the caspase-independent features of apoptosis (Candé et al., 2004). The mechanism by which 
AIF mediates chromatin condensation and DNA fragmentation is still not clear. It has been proposed 
that it might have a concealed nuclease activity, or that it might bind to DNA and recruit proteases 




1.1.5.2 Endonuclease G 
Endonuclease G is another mitochondrial protein that translocates to the nucleus during 
apoptosis (Li et al., 2001; Parrish et al., 2001). It belongs to a family of DNA/RNA non-specific 
nucleases (Rangarajan and Shankar, 2001), which can act on all types of nucleic acid including 
double-stranded DNA, single-stranded DNA, single-stranded RNA and RNA/DNA duplexes 
(Gerschenson et al., 1995). Upon apoptosis induction, endonuclease G translocates to the nucleus and 
induces oligonucleosomal fragmentation independently of caspases and CAD (Li et al., 2001; Parrish 
et al., 2001; van Loo et al., 2001; Hahn et al., 2004).  
Thus, there are two pathways leading to chromatin condensation and degradation during 
apoptosis (Reviewed by Zhang and Xu, 2002). One pathway involves caspases, ICAD and CAD, and 
leads to enhanced chromatin condensation and oligonucleosomal DNA fragmentation (Liu et al. 
1997c; Zhang et al., 1999). The other pathway is caspase-independent and involves AIF and 
endonuclease G, which lead to large-scale DNA fragmentation and nucleosomal fragmentation, 
respectively (Susin et al., 1999; Li et al., 2001).  
 
1.1.5.3 Role of mitochondria in caspase-independent apoptosis 
After MOMP, loss of large quantities of IMS proteins, many of which participate directly in 
the maintenance of mitochondrial homeostasis (Reviewed by Garrido and Kroemer, 2004), impacts 
mitochondrial respiration, ATP production and free radical production, resulting in an organelle 
dysfunction program (Cai and Jones, 1998; Luetjens et al., 2000; Mootha et al., 2001). It is thought 
that this is part of the reason some cells die in the presence of caspase inhibitors since these caspase 
inhibitors do not prevent MOMP (Munoz-Pinedo et al., 2006). Furthermore, from the perspective of 
being a factory for ATP generation mitochondria are also important for apoptosis, since the level of 
cellular ATP determines in part whether cell death occurs by necrosis or apoptosis (Reviewed by 
Chiarugi, 2005). If ATP levels fall profoundly, cells die via necrosis. If ATP levels are at least 
partially maintained, caspase activation and apoptosis follow mitochondrial PT (Eguchi et al., 1997; 




1.1.6 Bcl-2 family proteins 
B cell leukaemia/lymphoma-2 (Bcl-2) family proteins are the major regulators of the 
mitochondrial pathway. Their death-regulating activity depends on their ability to modulate MOMP 
and to regulate the release of AMP (Reviewed by Adams and Cory, 2001). Bcl-2 family proteins not 
only function at the point of convergence of multiple apoptotic signals, but also at the critical decision 
point immediately upstream of an irreversible commitment to apoptosis since MOMP is suggested to 
be a “point of no return” in the pathway to cell death (Reviewed by Newmeyer and Ferguson-Miller, 
2003).  
 
1.1.6.1 Homology of Bcl-2 family proteins 
Although the overall amino acid sequence homology among Bcl-2 family members is low, 
the homology is relatively high within four small segments, which are designated Bcl-2 homology 
(BH) regions. Based on their structural and functional characteristics, Bcl-2 family proteins are 
subdivided into three groups (Reviewed by Borner, 2003; Scorrano and Korsmeyer et al., 2003; 
Kuwana and Newmeyer, 2003; Danial and Korsmeyer, 2004): (1) multi-domain anti-apoptotic 
proteins such as Bcl-2, Bcl-xL, Mcl-1, Bcl-w and A1 which contain all four BH domains (BH1, BH2, 
BH3 and BH4); (2) multi-domain pro-apoptotic Bcl-2 family proteins such as Bax and Bak which 
contain only BH1, BH2 and BH3; (3) BH3-only proteins such as Bid, Bim, Bad, Bik, Bmf, Puma and 
Noxa that exhibit the most structural diversity since they only share the BH3 domain. Because some 
members promote apoptosis and some promote survival, it has been suggested that the relative 
amounts of the pro- and anti-apoptotic Bcl-2 family proteins help determine the susceptibility of cells 
to a death signal (Oltvai et al., 1993). 
 
1.1.6.2 BH1, BH2, BH3 and BH4 domains 
One of the unique features of Bcl-2 family proteins is the formation of heterodimers between 
anti- and pro-apoptotic members (Oltvai et al., 1993; Yang et al., 1995). This heterodimerization 
process is mediated by the insertion of the BH3-domain of a pro-apoptotic protein such as Bax or Bak 
into an elongated hydrophobic cleft composed of BH1, BH2 and BH3 on an anti-apoptotic protein 
such as Bcl-2 or Bcl-xL (Yin et al., 1994; Muchmore et al., 1996; Sattler et al., 1997). Since 
heterodimerization inhibits the activity of the partner proteins, BH1, BH2 and BH3 are crucial for the 
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functions of anti-apoptotic Bcl-2 family members (Muchmore et al., 1996; Sattler et al., 1997). In 
contrast, the BH3 domain of the pro-apoptotic proteins is essential for their protein binding and pro-
apoptotic activity (Chittenden et al., 1995). Replacement of the BH3 region of Bcl-2 with the BH3 
domain of Bax converts Bcl-2 from an inhibitor to an activator of cell death, indicating there are 
critical differences between the BH3 domains of anti- and pro-apoptotic Bcl-2 family members 
(Hunter and Parslow, 1996). 
The N-terminal BH4 domain, which is restricted to anti-apoptotic Bcl-2 family members, is 
also indispensable for their ability to suppress cell death (Huang et al., 1998; Shimizu et al., 2000). 
However, the exact mechanism of the anti-apoptotic function of the BH4 domain is still uncertain. It 
has been suggested that it regulates apoptosis by interacting with apoptosis regulatory proteins, such 
as Bad, Raf-1, Apaf-1 and Calcineurin (Wang et al., 1996; Yang and Korsmeyer, 1996; Shibasaki et 
al., 1997; Huang et al., 1998), as well as by facilitating heterodimerization with Bax, thereby 
inhibiting apoptosis (Hirotani et al., 1999).  
 
1.1.6.3 TMB 
Most of the Bcl-2 family proteins also have a C-terminal hydrophobic region that is proposed 
to be a transmembrane domain (TMB) due to its homology to the pore-forming subunits of the ion-
channel domain of the bacterial proteins, diphtheria toxin and colicins (Reviewed by Lazebnik, 2001). 
This has led to the suggestion that some Bcl-2 family proteins have pore- or channel-forming ability, 
with the TMB domain being responsible for the insertion of these molecules into the MOM, ER and 
outer nuclear membrane (Muchmore et al., 1996). Indeed, Bcl-2, Bcl-xL, Bax and Bid have all been 
demonstrated to form ion-channels in synthetic lipid membranes (Schendel et al., 1997; Minn et al., 
1997; Antonsson et al., 1997; Schendel et al., 1999). However it still needs to be determined if these 
proteins actually form ion channels in vivo and if this activity directly regulates apoptosis. 
 
1.1.6.4 Anti-apoptotic Bcl-2 family proteins 
Bcl-2 family proteins play an essential role in the regulation of MOMP and the release of 
IMS proteins. Bcl-2 and Bcl-xL are redundant in their capacity to protect cells from apoptosis (Chao 
et al., 1995). They mainly reside on the MOM where they bind to, and neutralize, pro-apoptotic Bcl-2 
family proteins, thus preventing the allosteric activation of Bax and Bak, subsequent MOMP and the 
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release of cytochrome c and AIF (Sedlak et al., 1995; Hunter and Parslow, 1996; Yang et al., 1997; 
Susin et al., 1999; Cheng et al., 2001). 
 
1.1.6.5 Pro-apoptotic multi-domain Bcl-2 family proteins 
1.1.6.5.1 Bax 
In healthy cells, inactive monomeric Bax is either located in the cytosol with its TMB 
inserted into the hydrophobic pocket formed by its BH1, BH2 and BH3 domains or loosely attached 
to the MOM (Suzuki et al., 2000; Schinzel et al., 2004). In response to stress signals, Bax undergoes a 
conformational change involving N-terminal exposure as well as the release of its C-terminal TMB 
(Schinzel et al., 2004). Bax is subsequently inserted into mitochondria as a homo-oligomer to trigger 
an apoptotic program of mitochondrial dysfunction that results in decrease in mitochondrial 
transmembrane potential, release of cytochrome c and, ultimately, apoptosis (Wolter et al., 1997; 
Jurgensmeie et al., 1998; Rosse et al., 1998; Finucane et al., 1999; Murphy et al., 1999; Putcha et al., 
1999; Antonsson et al., 2001; Shou et al., 2003). 
 
1.1.6.5.2 Bak 
Although Bax and Bak are functionally equivalent under most circumstances (Lindsten et al., 
2000; Wei et al. 2001), Bak localizes differently from Bax in healthy cells. Under normal conditions, 
monomeric inactive Bak resides on the MOM and the ER via association with Bcl-xL or Mcl-1 
(Griffiths et al., 1999; Willis et al., 2005), both of which negatively regulate the activation of Bak by 
masking its BH3 domain which is necessary for its oligomerization and pro-apoptotic function 
(Chittenden et al., 1995; Willis et al., 2005). In the event of death stimuli, Bak dissociates from Bcl-
xL and Mcl-1, exposing its N-terminal BH3 domain (Griffiths et al., 1999; Cuconati et al., 2003). 
Released Bak then either associates into homo-oligomers or forms higher-order complexes that 
contain both Bax and Bak (Wei et al., 2001; Mikhailov et al., 2003). Formation of these complexes is 
important for the induction of MOMP, and thus is critical for the killing activity of Bak and Bax 
(Mikhailov et al., 2003).  
 
1.1.6.5.3 Bax, Bak and apoptosis 
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Bax and Bak are essential for the activation of caspases and for the intrinsic apoptotic 
pathway (Ruiz-Vela et al., 2005). Indeed, cells in which the genes encoding these protein are 
disrupted are resistant to multiple apoptotic stimuli including protein kinase c inhibitor, UV light, 
growth factor deprivation, TNFα and oncogene activation (Wei et al., 2001; Degenhardt et al., 
2002a&b; Ruiz-Vela et al., 2005). In addition, all the BH3-only molecules absolutely require Bax and 
Bak to induce apoptosis, regardless of their selective binding affinity, and a deficiency in Bax and 
Bak renders the pro-apoptotic function of BH3-only proteins inactive (Cheng et al., 2001; Zong et al., 
2001). Thus, Bax and Bak are critical for the induction of apoptosis, and the definitive commitment to 
cell death occurs at the step of Bax and/or Bak activation.  
 
1.1.6.5.4 Bax, Bak and the ER 
A number of studies have indicated that Bax and Bak also function as a gateway to the 
intrinsic death pathway by functioning at the ER (Nutt et al., 2002; Zong et al., 2002). In response to 
ER stress, a small fraction of total cellular Bak and Bax translocates to the ER, where they undergo 
conformational changes and form oligomers. Oligomerization of Bax and Bak on the ER leads to 
damage of the ER membrane, thereby inducing the release of Ca2+ sequestered in the ER and Ca2+ 
accumulation in mitochondria (Scorrano et al., 2003). This transfer of Ca2+ from the ER to the 
mitochondria is in turn thought to initiate certain apoptotic signals (Reviewed by Demaurex and 
Distelhorst, 2003; Scorrano, 2003; Szabadkai and Rizzuto, 2004). 
 
1.1.6.6 BH3-only proteins 
BH3-only proteins, which act as sensors of cellular stress, require the cooperation of their 
multi-domain relatives to induce apoptosis. They interact with the hydrophobic groove on either anti- 
or pro- apoptotic multidomain Bcl-2 family members, with their BH3 domain, which is an 
amphipathic α-helix, serving as the binding motif. BH3-only molecules may exert their pro-apoptotic 
action via two mechanisms (Letai et al., 2002; Kuwana et al., 2005; Fletcher and Huang, 2006): (1) 
Bid, Bim and Puma have been termed “activators” since they can directly induce the activation of 
Bax and Bak, either by stimulating the translocation of Bax to the MOM or by local effects on Bak, 
resulting in MOMP and efflux of cytochrome c (Eskes et al., 2000; Wei et al., 2000; Kuwana et al., 
2002; Cartron et al., 2004); (2) The other BH3-only proteins, which include Bad, Bik and Noxa, are 
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termed “sensitizers” since they can directly interact with Bcl-2, Mcl-1 or Bcl-xL, occupying the 
pocket of these anti-apoptotic molecules and dissociating them from other BH3-only proteins or from 
Bax and Bak, thereby promoting MOMP and efflux of IMS molecules (Kuwana et al., 2005; Willis et 
al., 2005). The simple inhibitory effect of the “sensitizers” alone is insufficient to induce apoptosis, 
and hence they need to work in collaboration with the direct “activators” (Kuwana et al., 2005).  
 
1.1.6.6.1 Specificity of BH3-only proteins 
BH3-only proteins display selective binding activity to specific pro- and anti- apoptotic Bcl-2 
family members (Reviewed by Gélinas and White, 2005). In detail, Bim and Puma can potently 
engage all the prosurvival proteins (Letai et al., 2002; Chen et al., 2005). Bid and Bim can bind to 
Bax and Bak to promote their oligomerization (Cheng et al., 2001; Chen et al., 2005). In contrast, Bad 
binds tightly to Bcl-2, Bcl-xL and Bcl-W, but only weakly to A1 and not to Mcl-1. Noxa binds to 
Mcl-1 and A1, but not to Bcl-2 and Bcl-xL. Thus, apoptosis relies on the selective interactions 
between particular subsets of Bcl-2 family proteins. Indeed, release of Bak from Bcl-xL and Mcl-1 
and its subsequent activation require over-expression of both Bad and Noxa (Cheng et al., 2001; 
Willis et al., 2005), whereas over-expression of Puma alone is sufficient to induce Bak-mediated cell 
death (Willis et al.s, 2005). It has, therefore, been proposed that, depending on the death stimuli, more 
than one BH3-only protein may be activated to guarantee tight control over apoptosis and that the 
ability of these BH3-only proteins to associate with their anti-apoptotic partners is essential for their 
cell-killing function (Gustafsson and Gottlieb, 2007). 
 
1.1.6.6.2 Activation of BH3-only proteins 
Most BH3-only proteins are localized outside the mitochondria in living cells. They respond 
to selected death signals and are activated by transcriptional up-regulation, translocation and/or 
posttranslational modifications such as phosphorylation, ubiquitination and proteolytic cleavage 
(Reviewed by Puthalakath and Strasser, 2002). In detail, Bid is activated via proteolytic cleavage by 
caspase 8 in the death receptor signaling pathways (Li et al., 1998; Lou et al., 1998), and after 
cleavage the potency of Bid to induce apoptosis can be further enhanced by N-myristoylation (Zha et 
al., 2000). In response to TNFα signaling, Bid also can be cleaved by a protease activated by JNK, 
generating jBid which translocates to mitochondria and results in preferential release of Smac without 
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affecting cytochrome c (Deng et al., 2003). Bid also has been shown to be cleaved by other proteases, 
including granzyme B, calpain and lysozyme (Heibein et al., 2000; Sutton et al., 2000; Cheng et al., 
2001; Stoka et al., 2001). These mofications may trigger molecular rearrangement and exposure of 
the BH3 domain, allowing Bid to bind to, and inactivate, anti-apoptotic molecules.  
Bad, which is phosphorylated at multiple sites and sequestered by 14-3-3 in living cells, is 
rapidly dephosphorylated and released from 14-3-3 in response to growth factor deprivation (Zha et 
al., 1996). Released Bad translocates to the MOM where it associates with Bcl-xL and Bcl-2 to exert 
its cell-killing activity (Yang et al., 1995).  
In healthy cells, Bmf and Bim are localized to the actin cytoskeleton and the microtubules, 
respectively. Various types of intracellular damage, such as that induced by anoikis or treatment with 
taxol, cause their dissociation from the cytoskeleton and microtubules and their migration to the 
MOM, the site at which they perform pro-apoptotic functions (O'Connor et al., 1998; Puthalakath et 
al., 1999 and 2001). However, recent studies have indicated that Bim is also localized on the MOM 
via association with Mcl-1, Bcl-2 or Bcl-xL in healthy cells. In response to UV, granzyme B, 
Melphalan, TRAIL or oncogene-induced apoptotic stimuli, Bim is released from the anti-apoptotic 
proteins to directly activate Bax (Nijhawan et al., 2003; Opferman et al., 2003; Zong et al., 2003; 
Chen and Zhou, 2004; Gomez-Bougie et al., 2005; Han et al., 2004, 2005 & 2006).  
Puma, Noxa and Bik are transcriptionally activated by p53 in the event of DNA damage- or 
oncogenic stress- induced apoptosis (Oda et al., 2000; Nakano and Vousden, 2001; Yu et al., 2001; 
Villunger et al., 2003; Shore and Viallet, 2005). While Puma directly activates Bax, Noxa 
synergistically activates Bax with Puma by inactivating Mcl-1 and Bcl-xL (Nakajima and Tanaka, 
2007). On the other hand, Bik, which is newly synthesized in response to genotoxic stress, but not to 
ER stress, is integrated almost exclusively into ER membrane (Germain et al., 2002; Mathai et al., 
2002) where it initiates Bax and Bak-dependent release of Ca2+ from ER stores (Mathai et al., 2005), 
leading ultimately to the release of cytochrome c and apoptosis (Germain et al., 2002). 
  
1.1.7 Permeabilization of mitochondrial outer membrane 
Mitochondria are circumscribed by two membranes: the outer membrane, which is permeable 
to molecules up to 6 kDa due to the presence of the abundant voltage-dependent anion channel 
(VDAC), and the inner membrane which is virtually impermeable (Zalman et al., 1980; Narita et al., 
1998). The limited permeability of the inner membrane not only allows the existence of a matrix that 
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is distinct from the cytoplasm, but also permits the generation of the inner mitochondrial 
transmembrane potential (∆Ψm) and pH gradient, both of which arise from the respiratory chain 
(Reviewed by Mayerand Oberbauer, 2003; Ohta, 2003; Kroemer et al., 2007; Schwarz et al., 2007).  
Apoptogenic mitochondrial proteins (AMP), which include cytochrome c, Smac/DIABLO, 
Htra2/Omi, endonulease G and AIF, are mainly localized in the IMS between the outer and inner 
membranes (Ohsato et al., 2002). Therefore, MOMP is essential for the release of AMP and the 
subsequent progression of the mitochondrial apoptotic pathway (Kroemer, 2003; van Gurp et al., 
2003). Although it has been shown that Bax and Bak are required for MOMP, not only in purified 
mitochondria but also in living cells (Wei et al., 2001; Ruiz-Vela et al., 2005), the nature and 
mechanism of MOMP still remain unknown. Several models have been proposed (Reviewed by 
Newmeyer and Ferguson-Miller, 2003). 
One possibility is that the release of cytochrome c is mediated by mitochondrial permeability 
transition (PT), an event that results in physical rupture of the MOM (Vander Heiden et al., 1997). 
PT, which consistutes an abrupt increase in mitochondrial inner membrane (MIM) permeability to 
solutes with molecular masses of <1,500 Da, is mediated by opening of the PT pore complex (PTPC), 
a multi-protein channel formed at the contact site between the MIM and MOM (Rviewed by Bernardi 
et al., 1994; Petit et al., 1996). PTPC is composed of VDAC and peripheral benzodiazepine receptor 
(PBR) on the MOM, adenine nucleotide translocator (ANT) on the MIM, and the matrix protein, 
cyclophilin D (Zamzami et al., 1998; Kroemer et al., 2007). PT can be triggered by various agents, 
including toxins, anoxia, reactive oxygen species (ROS) and Ca2+ overload (Reviewed by Zoratti and 
Szabo, 1995). Long lasting PT leads to the influx of solutes, causing expansion of the mitochondrial 
matrix and dissipation of ∆Ψm and the pH gradient. The expansion of the matrix results in sufficient 
swelling to physically rupture the MOM, triggering the release of IMS proteins and subsequent 
caspase activation (Reviewed by Bernardi, 1999). PT inhibitors specifically targeting ANT, 
cyclophilin D or VDAC have been shown to efficiently suppress apoptosis (Marchetti et al., 1996; 
Zamzami et al., 1996), supporting the notion that PT may mediate the mitochondrial pathway. It is 
thought that Bcl-2 family proteins are involved in this process (Reviewed by Harris and Thompson, 
2003; Breckenridge and Xue, 2004). It has been shown that Bax-mediated release of cytochrome c is 
dependent on PT pore opening (Marzo et al., 1998; Narita et al., 1998; Shimizu et al., 1999) and that 
Bax and Bak oligomers induce PT by directly interacting with components of the PTPC, such as ANT 
(Marzo et al., 1998) and VDAC (Narita et al., 1998; Shimizu et al., 1999). In contrast, the anti-
apoptotic proteins, Bcl-2 and Bcl-xL, which are antagonists of Bax and Bak, inhibit PT pore opening 
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induced by various reagents, including Ca2+, H2O2 and tert-butyl hydroperoxide, by directly binding 
to, and closing, VDAC (Shimizu et al., 1998 and 1999). Therefore, both pro- and anti-apoptotic 
members of the Bcl-2 family may regulate ∆Ψm and the release of cytochrome c by interacting with 
the components of PTPC, and PTPC serves as a crossroad of apoptosis regulation by members of the 
Bcl-2 family.  
In addition, there is evidence that Bax and Bak may induce MOMP independently of PT. 
Specifically, Bax and some other Bcl-2 family members share structural similarities with certain 
pore-forming proteins and are able to form pores in artificial lipid membranes (Muchmore et al., 
1996; Schendel et al., 1997; Minn et al., 1997; Antonsson et al., 1997; Schendel et al., 1999). It is 
therefore conceivable that, upon apoptotic stimulation, Bax and Bak undergo conformational changes 
to form a transmembrane pore across the MOM, causing loss of ∆Ψm and efflux of IMS proteins 
without simultaneously inducing swelling of mitochondria and PTPC opening (Jurgensmeier et al., 
1998). Furthermore, the insertion of Bax and Bak oligomers into the MOM may simply destabilize 
the mitochondrial membrane, thereby triggering the release of AMP without the necessity to form 
specific pores (Reviewed by Kroemer et al., 2007; Schwarz et al., 2007).  
In summary, several models, all of which eventually lead to the permeabilization of both the 
MIM and the MOM, release of AMP, mitochondrial dysfunction and apoptosis, have been proposed. 
The precise mechanism utilized may vary depending on cell type and the nature of the apoptotic 
stimulus (Reviewed by Kroemer et al., 2007). 
 
1.1.8 p53 and apoptosis 
The tumor suppressor, p53, coordinates the cellular response to different kinds of stresses 
including DNA damage, hypoxia, oncogene activation, anoikis and redox stress (Reviewed by Fuster 
et al., 1997; Sionov and Haupt, 1999; Haupt et al., 2003; Helton and Chen, 2007). Under normal 
conditions, the cellular level of p53 protein is relatively low due to its tightly regulated degradation 
through the ubiquitin pathway (Chowdary et al., 1994; Honda et al., 1997). Various stimuli activate 
p53 by increasing its stability and/or inducing posttranslational modifications that enhance its activity 
(Reviewed by Lavin and Gueven, 2006). Activated p53 induces either reversible cell cycle arrest and 
DNA repair or permanent withdrawal from cell proliferation followed by the induction of apoptosis or 
senescence (Reviewed by Sionov and Haupt, 1999; Roos and Kaina, 2006; Helton and Chen, 2007). 
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Cell type, stimulus type, the extent of DNA damage as well as the absolute level of p53 are factors 
that decide the particular cell fate (Midgley et al., 1995; Chen et al., 1996; Fei et al., 2002).   
p53 regulates cell cycle arrest and DNA repair by binding with specific DNA sequences and 
activating the transcription of target genes encoding proteins involved in cell cycle control including 
p21, 14-3-3σ, Gadd45, Mdm2, PCNA and BTG2 (Sax and El-Deiry, 2003; Vousden et al., 2006). In 
addition, p53 regulates apoptosis by stimulating the expression of various apoptosis-related genes 
including Bax, Puma, Noxa, Apaf-1, Fas and TRAIL-R2 as well as redox-related p53-induced genes 
such as PIG2, PIG3, PIG6, PIG7, PIG8, PIG11 and the p85 regulatory subunit of phosphatidyl-3-OH 
kinase (Reviewed by Levine, 1997; El-Deiry, 1998; Vousden and Lu, 2002; Sax and El-Deiry, 2003). 
p53 also transcriptionally represses the expression of key anti-apoptotic proteins including Bcl-2, Bcl-
xL and survivin of the IAP family (Miyashita et al., 1994; Hoffman et al., 2002). In addition, 
however, p53 can induce apoptosis independently of its transcription regulatory activity (Caelles et al., 
1994; Kokontis et al., 2001). Several reports have shown that p53 translocates to mitochondria in 
response to cell stress-induced apoptosis, both in vivo and in vitro (Marchenko et al., 2000; Sansome 
et al., 2001; Mihara and Moll, 2003; Erster et al., 2004; Endo et al., 2006). Once reaching 
mitochondria, p53 either associates with anti-apoptotic Bcl-2 and Bcl-xL to inhibit their protective 
function (Mihara et al., 2003), or complexes with pro-apoptotic Bak or Bad to directly induce Bak 
oligomerization and MOMP (Leu et al., 2004; Jiang et al., 2006).  
p53 is the most intensively studied apoptosis factor contributing to cancer. Indeed, it is 
inactivated in more than 50% of human cancers (Hainaut and Hollstein, 2000). The mechanisms 
responsible for the inactivation of p53 include gene deletion or mutation, over-expression of Mdm2, 
which is a negative regulator of p53, and inactivation by oncoproteins encoded by DNA tumor 
viruses such as the E6 protein of human papillomavirus (HPV) and the Simian virus 40 (SV40) large 
T antigen (Mietz et al., 1992; Leach et al., 1993; Patterson et al., 1994; Marchetti et al., 1995; Haitel 











1.2.1 Hypusine  
Hypusine, an unusual amino acid, was originally isolated from bovine brain and identified as 
N6-(4-amino-2-hydroxybutyl)lysine in 1971 (Shiba, et al., 1971). The name “hypusine” reflects the 
fact that it comprises moieties of hydroxyputrescine and lysine. eIF5A (eukaryotic initiation factor 
5A) is the only cellular protein known to contain hypusine (Cooper et al., 1983). Formation of 
hypusine on the eIF5A precursor is one of the most specific polyamine-dependent biochemical 
reactions known, and there are two enzymes, deoxyhypusine synthase (DHS) and deoxyhypusine 
hydroxylase (DHH), involved in this two-step posttranslational modification (Park et al., 1982). In the 
first step, the aminobutyl moiety of the polyamine, spermidine, is transferred by DHS in an NAD+-
dependent reaction to the ε-amino group of a specific lysine residue in eIF5A to form deoxyhypusine 
(Imaoka and Nakajima, 1973; Park et al., 1981, 1982 & 1988; Wolff et al., 1990). This intermediate 
does not accumulate and is immediately subjected to the second step of the modification (Abbruzzese 
et al., 1986; Park, et al., 1991) in which DHH catalyzes the hydroxylation of the deoxyhypusine 
residue to hypusine (Park et al., 1982 & 1988; Abbruzzese et al., 1986 & 1988). Hypusine persists in 
this protein without further modification or reversion to lysine (Gordon et al., 1987b; Park et al., 
2003). There is a recent report of efficient reversal of deoxyhypusine synthesis in a cell-free system 
(Park et al., 2003). However the deoxyhypusine hydroxylation is thought to be irreversible (Park et 
al., 2003). The fact that nature has committed two enzymes to produce one hypusine residue on a 
single protein underscores the importance of this modification (Xu and Chen, 2001) and raises the 
possibility that different post-translationally modified eIF5A proteins may have different functions.  
 
1.2.2 Properities of eIF5A  
eIF5A, which was previously named eIF4D, was originally isolated as a small protein factor 
(18 kDa in size) from the ribosomal fraction of rabbit reticulocyte lysates (Kemper et al., 1976; Benne 
et al., 1978). Hypusine-containing eIF5A is thought to be ubiquitous in eukaryotes (Gordon et al., 
1987; Park, 1988; Hu et al., 2005), and cells typically contain at least two eIF5A genes, one DHS 
gene and one DHH gene (Park et al., 2006). In fact, proteins closely related to eIF5A have been found 
in all types of living organisms, including archaea, also known as archaebacteria (Bartig et al., 1992), 
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and eubacteria, also known as bacteria (Glick and Ganoza, 1975 & 1976). In archaea, eIF5A is named 
archaeal initiation factor 5A (aIF5A). While both aIF5A and archaeal DHS have been identified, 
DHH or its homolog was not detected in archaea (Park et al 2006). However, various archaea are 
reported to contain hypusine- or deoxyhypusine-containing eIF5A1, or a mixture of both (Bartig et 
al., 1990). The mechanism as to how deoxyhypusine is hydroxylated in archaea is still unclear. 
Eubacterial eIF5A, which is named elongation factor P (EF-P), appears to be ubiquitous in eubacteria 
(Lipowsky et al., 2000) and is essential for viability and protein synthesis in Escherichia coli (Aoki et 
al., 1997). Although eubacteria lack a hypusine-containing eIF5A equivalent as well as DHS and 
DHH enzymes (Liao et al., 1998; Gerloff et al., 1998), the sequence similarity among eIF5A, aIF5A 
and EF-P suggestes that they are homologous proteins (Kyrpides and Woese, 1998). Thus, 
eIF5A/aIF5A/EF-P is considered a universally conserved protein. 
The gene encoding eIF5A has been cloned from several eukaryotes including yeast 
Saccharomyces cerevisiae (Mehta et al., 1990; Schnier et al., 1991), slime mould Dictyostelium 
discoideum (Sandholzer et al., 1989), dinoflagellate Crypthecodinium cohnii (Chan et al., 2002), 
Arabidopsis (Wang et al., 2001), corn (Dresselhaus et al., 1999), tobacco (Chamot and Kuhlemeier, 
1992), alfalfa (Pay et al., 1991), carnation (Wang et al., 2001), Caenorhabditis elegans (Wilson et al., 
1994), zebrafish Danio rerio (Woods et al., 2005), frog Xenopus tropicalis (Klein et al., 2002), 
Drosophila melanogaster (Harvey et al., 1997), silkworm Bombyx mori (Hu et al., 2005), chicken 
(Rinaudo et al., 1993), rabbit (Smit-McBride et al., 1989a), cattle (Moore et al., 2005) and human 
(Smit-McBride et al., 1989a). eIF5A is highly conserved from yeast to human. Indeed, eIF5A from 
various eukaryotes shares an overall amino acid sequence homology of 50-95% (Si et al., 1996; 
Jenkins et al., 2001; Molitor et al., 2004). Most of the conserved regions are clustered in the N-
terminus of the protein, especially around the hypusine site. A sequence of 12 amino acids around the 
hypusine residue, Ser-Thr-Ser-Lys-Thr-Gly-Hpu-His-Gly-His-Ala-Lys, not only is completely 
conserved among all eukaryotes (Chamot and Kuhlemeier, 1992), but also cannot be found in any 
other protein in the database (Park et al., 1993), suggesting an important role for hypusination of 
eIF5A. Furthermore, eIF5A from slime mould, alfalfa, rat or human can substitute functionally for 
yeast eIF5A in strains where yeast eIF5A genes are disrupted (Magdolen et al., 1994; Koettnitz et al., 
1995; Maiti and Maitra, 1997). On the contrary, archaeal aIF5A when expressed in yeast is neither 
modified to contain hypusine, nor does it allow growth of cells deficient for yeast eIF5A (Magdolen 




1.2.3 Different isoforms of eIF5A 
At least two isoforms of eIF5A encoded by separate genes are present in eukaryotic cells 
(Park et al., 2006). Five isoforms of eIF5A were found in potato, exhibiting differential expression 
patterns in developing tuber and fruit (In et al., 1997). In tomato, four different isoforms that exhibit 
remarkable sequence identity (89%-92% at the amino acid level and 70%-80% at the nucleotide 
level) have been identified (Wang et al., 2001). In addition, two isoforms of eIF5A were found in 
tobacco, with one constitutively expressed and the other preferentially expressed in photosynthetic 
tissues (Chamot and Kuhlemeier, 1992).  
 
1.2.3.1 Yeast eIF5A 
Yeast has two isoforms of eIF5A, which are encoded by two separate genes, TIF51A (also 
known as HYP2) and TIF51B (also known as HYP1) (Schnier et al., 1991). These two eIF5A proteins 
not only share 92% identity, but also are more than 60% identical to human eIF5A (Schnier et al., 
1991). Although TIF51A and TIF51B fulfill very similar functions (Schwelberger et al., 1993), they 
are expressed under different oxygen conditions (Mehta et al., 1990). Under aerobic growth 
conditions, only TIF51A is transcriptionally active, leading to the expression of eIF5A1; whereas 
under anaerobic condition, TIF51A is turned off and eIF5A1 mRNA becomes very unstable, and thus 
yeast cells only express mRNA transcribed from TIF51B (Mehta et al., 1990). Interestingly, TIF51B 
will express aerobically only when TIF51A is disrupted, and TIF51A can substitute for TIF51B under 
anaerobic conditions when the latter is disrupted (Wohl et al., 1993). Expression of either TIF51A or 
TIF51B alone is sufficient for the normal growth of yeast under any metabolic conditions 
(Schwelberger et al., 1993; Magdolen et al., 1994). 
 
1.2.3.2 Human eIF5A 
There are two isoforms of eIF5A in all vertebrates examined so far, including human, fish, 
chicken and amphibians (Jenkins et al., 2001; Rinaudo et al., 1993; Wolff et al., 1992; Woods et al., 
2005). In Homo sapiens, eIF5A proteins are encoded by two different genes, although three intronless 




Human eIF5A1 cDNA was first isolated in 1989 (Smit-McBride et al., 1989a). The genomic 
sequence, roughly 5 kb, was determined (Koettnitz et al., 1995) and mapped to 17p12-p13 in 1995 
(Steinkasserer et al., 1995). However, eIF5A2, which is 84% identical and 94% similar to eIF5A1, 
was not described in human or mammalian cells until 2001, and then by two separate groups 
(Clement et al., 2001; Jenkins et al., 2001). Therefore, most of the published literature uses the 
general name, eIF5A, to stand for the eIF5A1 isoform. Although both genes are able to complement 
disrupted yeast eIF5A (Clement et al., 2003), it has been suggested that in human cells they bind 
to/interact with different mRNAs or proteins due to the differences in their C-terminal putative RNA 
binding domains and protein structures (Guan et al., 2001; Jenkins et al., 2001; Clement et al., 2003). 
In addition, their gene-expression patterns are distinct. eIF5A1 mRNA and protein appear to be 
present in all human tissues and cell types. In contrast, although eIF5A2 mRNA is detectable in most 
cell lines, it appears to be inefficiently translated (Clement et al., 2006). Thus, eIF5A2 protein is 
expressed only in certain tissues such as testis and brain, but it is over-expressed in certain cancers 
and cancer cell lines (Jenkins et al., 2001; Clement et al., 2003; Clement et al., 2006).  
The finding that there are several isoforms of eIF5A in cells not only prompts the proposal 
that different isoforms may facilitate the translation of different subsets of mRNAs required for 
specific physiological functions, but also implies the importance of this protein, since it has been 
suggested that having more than one copy for essential proteins might be a way to ensure survival of 
an organism (Sidow, 1996).  
 
1.2.4 Cellular localization of eIF5A 
Shi and colleagues (1996a) using indirect immunofluorescence and confocal microscopy in 
conjunction with subcellular fractionation demonstrated that eIF5A exists in the cytoplasm of 
mammalian cells in two forms: a soluble fraction and a fraction bound to the ER. The subcellular 
distribution pattern of eIF5A is not significantly altered in different stages of the cell cycle; nor is it 
changed by viral oncogene transformation or by treatment with RNA synthesis inhibitors (Shi et al., 
1997). Interestingly, treatment with puromycin, a protein synthesis inhibitor known to dissociate 
ribosomes, dramatically altered the distribution of eIF5A “from an ER network-like perinuclear 
structure to a patched dotted pattern dispersed throughout the cytoplasm” (Shi et al., 1997). This 
observation indicates that eIF5A may associate with ribosomes and thus is consistent with its putative 
function in protein synthesis. In situ staining of human tissue as well as localization studies in yeast 
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cells have both confirmed the cytoplasmic localization of hypusine-containing eIF5A (Valentini et al., 
2002; Cracchiolo et al., 2004).  
Although hypusinated eIF5A appears to be localized in the cytoplasm (Shi et al., 1997; 
Valentini et al., 2002; Cracchiolo et al., 2004), inhibition of hypusination using MG-132 or GC7 or by 
point mutation of the specific lysine residue of eIF5A that becomes hypusinated appears to change the 
cytoplasmic localization of eIF5A to whole-cell distribution (Jin et al., 2003b). This observation was 
interpreted as indicating that inhibition of hypusination prevents eIF5A from achieving its proper site 
in the cytoplasm, possibly polyribosomes (Jin et al., 2003b). There are also reports that eIF5A is 
localized in the nucleus as well as in the cytoplasm in untreated cells (Ruhl et al., 2003; Jao and Chen, 
2002). Moreover, this whole-cell distribution pattern was not changed by energy depletion, heat 
shock or inhibition of transcription, translation, polyamine synthesis and Crm1-dependent nuclear 
export (Jao and Chen, 2002). Even though eIF5A is thought to enter the nucleus by passive diffusion 
(Jao and Chen, 2002), the observation that it is present in both the nucleus and the cytoplasm is 
consistent with the notion that eIF5A may function as an RNA-binding protein, since many RNA-
binding proteins are distributed between the cytoplasm and nucleus (Shen et al., 2000). 
 
1.2.5 Structure of eIF5A 
There have been several studies of the crystal structure of eIF5A from different archaeal 
species including Methanococcus jannaschii (Kim et al., 1998), Pyrobaculum aerophilum (Peat et al., 
1998) and Pyrococcus horikoshii OT3 (Yao et al., 2003). The data suggest that eIF5A is comprised of 
two distinct anti-parallel β-sheet domains that are arranged in an elongated fashion and connected by 
a flexible peptide hinge. In the N-terminal domain, there is a protruding hairpin loop bearing the 
conserved lysine hypusination site that is pointing away from the main structure. This renders the 
hypusination site accessible to spermidine as well as DHS and DHH (Kim et al., 1998; Peat et al., 
1998; Yao et al., 2003). There is also a stretch of basic amino acids clustered around the hypusine 
residue, making it a possible nucleic acid-binding site (Xu and Chen, 2000). In addition, the C-
terminal domain contains a leucine-rich oligonucleotide/oligosaccharide binding (OB) fold, which is 
a common RNA-binding module that exists in prokaryotic cold shock protein A (CspA) as well as 
prokaryotic IF1 and eukaryotic eIF2α translation initiation factors (Wistow, 1990; Schnuchel et al., 
1993). These observations collectively suggest that eIF5A is capable of binding with nucleic acid, 
particularly RNA, with both the hypusine site and the OB domain being potential binding sites (Kim 
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et al., 1998; Peat et al., 1998; Yao et al., 2003). The 3D structure of human eIF5A is highly similar to 
that of aIF5A (Facchiano et al., 2001).  
Using exclusion chromatography under neutral isotonic conditions, Chung et al. (1991) 
demonstrated that native eIF5A largely exists in a tightly associated dimeric form under physiological 
conditions, and has the potential to undergo reversible association to form higher polymers. However, 
in another study it was shown that although eIF5A has the tendency to form dimers, the dimer is only 
loosely associated and will dissociate in the presence of DHS (Peat et al., 1998).  
 
1.2.6 Proposed functions of eIF5A 
The true function of eIF5A still remains unknown even after nearly three decades of intensive 
study. Recent studies have suggested that eIF5A is involved in translation, nucleocytoplasmic 
shuttling, mRNA turnover, cell proliferation and apoptosis (Kemper et al., 1976; Benne and Hershey, 
1978; Benne et al., 1978; Ruhl et al. 1993; Park et al., 1993b & 1997; Hanauske-Abel, 1995; Wang et 
al., 2001).      
 
1.2.6.1 Protein translation 
Based on its purification from the ribosomes of reticulocyte lysates and its stimulatory effect 
on the formation of the dipeptide analogue, methionyl-puromycin, in a cell free system, eIF5A1 was 
originally deemed to be a translation initiation factor that stimulates the initiation phase of protein 
synthesis via transient association with ribosomes (Kemper et al., 1976; Benne and Hershey, 1978; 
Benne et al., 1978). It was subsequently proposed that eIF5A facilitates ribosomal subunit joining and 
the positioning of the initiator tRNA for the synthesis of the first peptide bond (Schnier, et al., 1991). 
Hypusine modification was thought to be required for this biological activity of eIF5A, since the 
unmodified eIF5A precursor failed to stimulate methionyl-puromycin synthesis (Park, 1989; Smit-
McBride et al., 1989b; Park et al., 1991). The deoxyhypusine-containing intermediate form of eIF5A 
provided a degree of methionyl-puromycin synthesis stimulatory effect, but not as effectively as the 
hypusine-containing form (Park et al., 1991).  
More recently, this proposed function of eIF5A has been questioned due to lack of a clear 
correlation between eIF5A and general protein synthesis as well as the demonstration that complete 
and rapid intracellular depletion or inactivation of eIF5A in yeast cells does not significantly affect 
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protein synthesis or polyribosome profiles (Kang and Hershey, 1994; Zuk and Jacobson, 1998). In 
addition, eIF5A exhibits different expression and location patterns from those of other translation 
initiation factors. First, it is not only more abundant than the ribosomes in the cell (Hershey, 1994), 
but also ten times more abundant than the common initiation factors (Thomas et al., 1979). Second, it 
mainly localizes in the cytoplasm and associates with the ER-bound polyribosomes (Shi et al., 1997), 
whereas genuine translation factors only bind with ribosomes during initiation (Lockwood et al., 1972; 
Trachsel and Staehelin, 1978; Unbehaun et al., 2004). However, two recent studies have 
demonstrated hypusine-dependent and translation-dependent interaction of eIF5A with the structural 
components of the 80S ribosome complex as well as the translation elongation factors, eEF1A and 
eEF2 (Jao and Chen, 2006; Zanelli et al., 2006). In light of these findings, it has been proposed that 
eIF5A may participate in ribosome-related events such as protein folding rather than the synthesis of 
polypeptide chains per se (Jao and Chen, 2006). 
Although hypusine-containing eIF5A may not be required for global protein synthesis, it is 
thought to facilitate the translation of some specific subsets of mRNAs (Kang and Hershey, 1994). 
Treatment of mammalian cells with inhibitors of DHS or DHH induces cell cycle arrest at the G1/S 
boundary as well as inhibition of cell proliferation (Park et al., 1993b; Hanauske-Abel et al., 1994; 
Chen et al., 1996; Shi et al., 1996b; Tome and Gerner, 1997; Jin et al., 2003a). In addition, expression 
of eIF5A appears to be a cell cycle-sensitive event. For example, expression of eIF5A peaks at early 
G1 phase, but decreases dramatically upon entry into S phase and is very low at the S and G2/M 
phases (Dresselhaus et al., 1999; Chan et al., 2002; Jin et al., 2003a). Thus, the transition from G1 to 
S phase may be a hypusine-sensitive event, and eIF5A may be involved in the translation of proteins 
regulating this process. 
 
1.2.6.2  Nucleocytoplasmic shuttle protein 
There are also indications that eIF5A functions as an mRNA nuclear exporter. This 
hypothesis was initially proposed based on the finding that eIF5A appears to serve as a cellular 
cofactor binding to the human immunodeficiency virus type 1 (HIV-1) Rev transactivator protein 






1.2.6.2.1 Rev protein 
Rev is a viral auxiliary protein involved in the nuclear export of unspliced and partially 
spliced HIV-1 viral mRNAs, which serve as templates for the translation of viral structural protein or 
as viral genomes in the formation of progeny virus (Reviewed by Emerman, 1989; Cullen and Malim, 
1991). In the absence of Rev, only fully spliced HIV-1 mRNA can be exported to the cytoplasm 
(Malim and Cullen, 1991; Malim and Cullen, 1993). Rev, which mainly localizes in the nucleus, 
binds specifically to the Rev response element (RRE) sequence in its target viral mRNAs as well as to 
a number of cellular cofactors (Daly et al., 1989; Zapp and Green, 1989). Through the protein-protein 
interaction with its cofactors, Rev shuttles constantly between the nucleus and cytoplasm of host 
cells, coupling HIV-1 mRNAs to the cytoplasm (Cochrane et al., 1990; Meyer and Malim, 1994; 
Wolff et al., 1995). This bi-directional transport is mediated by two specific Rev sequences: a nuclear 
localization signal (NLS) that overlaps the RRE-binding domain, and a leucine-rich C-terminal 
activation domain that not only acts as a nuclear export signal (NES), but is also required for the 
interaction with cellular cofactors (Malim et al., 1989; Cochrane et al., 1990).  
 
1.2.6.2.2 Rev, Rex and eIF5A 
eIF5A has been identified as a cellular cofactor binding specifically to the C-terminal 
activation domain of Rev (Ruhl et al. 1993). In fact, in the absence of eIF5A or in eIF5A mutant 
constitutively expressed human T cells, viral replication and the function of Rev are blocked (Ruhl et 
al. 1993; Bevec et al., 1996; Junker et al., 1996; Hofmann et al., 2001). In addition, eIF5A gene 
expression is highly up-regulated not only in human peripheral blood mononuclear cells (PBMCs) of 
healthy individuals in response to T-lymphocyte-stimulating agents, but also in the PBMCs of HIV-1 
patients who have activated T lymphocytes (Bevec et al., 1994). Thus, up-regulation of eIF5A in 
activated T-cells has been suggested to contribute to efficient viral replication in these cells (Bevec et 
al., 1994). 
It has also been suggested that eIF5A is a cofactor for Rex (Katahira et al., 1995), which is 
the transactivator protein of human T-cell leukemia virus type I (HTLV-1) and is responsible for 
nuclear export and cytoplasmic expression of incompletely spliced viral mRNAs (Hidaka et al., 
1988). In somatic cells microinjected with export substrates, specific inhibitors of eIF5A were shown 
to block nuclear export of NESs derived from HIV-1 Rev and HTLV-1 Rex, supporting the 
contention that eIF5A serves as an essential cofactor for the nuclear export of Rev and Rex (Elfgang 
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et al. 1999). Consistent with this, by direct visualization of green fluorescent protein (GFP)-tagged 
eIF5A Jin and his colleagues (2000) found that eIF5A localizes in both the nucleus and the cytoplasm 
for a short time after expression, then steadily redistributes to the cytoplasm only. This observation is 
indicative of the putative nuclear exporting ability of eIF5A (Jin et al., 2003).  
 
1.2.6.2.3 eIF5A in anti-HIV therapy 
As a putative cellular cofactor of Rev, eIF5A is a novel target in anti-HIV therapeutic 
strategies. Several inhibitors of DHS and DHH enzymes have been developed and used in 
antiretroviral therapy. CNI-1493, which is a potent inhibitor of human DHS, inhibits the replication of 
macrophage- and T cell-tropic lab strains, clinical isolates as well as HIV-1 strains with multi-drug 
resistance by inhibiting the transactivation ability of Rev and does not have any effect on cell 
proliferation or cell viability (Hauber et al., 2005). Mimosine and deferiprone, both of which are iron 
chelators and hence inhibitors of DHH (Csonga et al., 1995; Caraglia et al., 1999; Kim et al., 2006; 
Park et al., 2006), also interfere with the translation of incompletely spliced retroviral mRNAs, thus 
suppressing replication of HIV-1 (Andrus et al., 1998). In addition, they trigger extensive apoptosis, 
particularly in cells that actively produce HIV-1 (Andrus et al., 1998). 1,8-Diaminooctane, an 
inhibitor of DHS, significantly reduces the replication of lentivirus feline immunodeficiency virus 
(FIV), which also depends on the Rev regulatory system, by decreasing the levels of unspliced and 
singly spliced retroviral mRNAs in the cytoplasm in a dose-dependent manner (Hart et al., 2002). 
The results of other studies, however, argue against the hypothesis that eIF5A is involved in 
Rev-dependent nuclear export. First, interaction between Rev (either free or RNA-bound) and eIF5A 
was not detected (Henderson and Percipalle, 1997; Lipowsky et al., 2000). Second, transient 
expression of Rev does not alter the cytoplasmic distribution of endogenous eIF5A (Shi et al., 1996; 
Valentini et al., 2002). Indeed, the function of eIF5A as a nucleocytoplasmic shuttle protein has also 
been questioned based on the observation that eIF5A does not shuttle between the nucleus and the 
cytoplasm (Shi et al., 1996; Shi et al., 1997; Valentini et al., 2002). Also, eIF5A appears to gain 
nuclear entry via passive diffusion instead of active shuttling (Lipowsky et al., 2000; Jao and Chen, 
2002). Moreover, since hypusinated aIF5A is essential for growth of archaea (Jansson et al., 2000) 
and archaea do not have nuclei, it has been suggested that the role of eIF5A in the nucleocytoplasmic 




1.2.6.3 eIF5A as an RNA binding protein 
It has been suggested that eIF5A serves as an RNA-binding protein (Liu et al., 1997), with 
both the hypusine residue and the C-terminal domain contributing to the interaction (Kim et al., 1998; 
Peat et al., 1998; Yao et al., 2003). Several studies indicated that hypusine-containing eIF5A is 
essential for transporting specific mRNAs to the cytoplasm. Intracellular depletion of eIF5A in yeast 
results in a marked accumulation of a specific set of mRNAs in the nuclear compartment (Liu and 
Tartakoff, 1997). Hanauske-Abel et al (1995) observed the disappearance of several specific sets of 
mRNAs, including those encoding enzymes critical for proliferation, from polyribosomes after the 
inhibition of hypusination, as well as the reappearance of these mRNAs after removal of the 
inhibition. Furthermore, inhibition of hypusine modification induces inhibition of S phase entry (Park 
et al., 1993b; Hanauske-Abel et al., 1994; Chen et al., 1996; Shi et al., 1996b; Tome and Gerner, 
1997; Jin et al., 2003a). It has, therefore, been proposed that hypusine-containing eIF5A may be 
required for nucleocytoplasmic export of a subset of specific mRNAs encoding proteins that are 
involved in proliferation (Hanauske-Abel, 1995). Based on these findings, together with the discovery 
of various isoforms of eIF5A, it has been suggested that each isoform of eIF5A is responsible for 
transporting a unique subset of mRNAs related to a specific stage of development (Park et al., 1993b 
& 1997; Hanauske-Abel, 1995; Wang et al., 2001). 
The ability of eIF5A to bind to specific RNAs has been demonstrated in several studies. RRE, 
U6 spliceosomal snRNA as well as RNAs encoding ribosomal L35a, plasminogen activation inhibitor 
mRNA-binding protein, NADH dehydrogenase subunit, ADP-ribose pyrophosphatase and several 
unknown proteins have been identified as potential RNA binding targets for eIF5A (Liu et al., 1997; 
Xu et al., 2004). In addition, there is a report identifying the specific RNA sequence that eIF5A may 
bind. This was achieved using the method of systematic evolution of ligands by exponential 
enrichment (SELEX) (Xu and Chen, 2001). It is estimated that eIF5A may interact with at least 800 
different mRNAs, which represent approximately 5% of total mRNAs (Xu et al., 2004).  
 
1.2.6.4 eIF5A interaction with proteins 
Motif analysis has indicated that eIF5A contains a stretch of basic amino acids, which is a 
typical nucleic acid binding domain, clustered at the hypusine site and a leucine-rich stretch, which 
commonly depicts capability for both protein-protein interaction and RNA-binding, at the C-terminal 
domain (Liu et al.,  1997b). These domains are also present in RNA-binding bimodular proteins such 
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as Rev and influenza virus NS1 protein (Malim et al., 1989; Wen et al., 1995; Liu et al., 1997C; Li et 
al., 1998). Therefore, instead of binding only with RNA, eIF5A is thought to use its bimodular 
structure to interact with both RNA and protein (Xu and Chen, 2000), with several protein targets 
having been identified (Beninati et al., 1995; Schatz et al., 1998; Singh et al., 1998; Chen and Jao, 
1999; Lee et al., 1999; Rosorius et al. 1999; Hofmann et al., 2001; Lipowsky, 2000) 
 
1.2.6.4.1 eIF5A and DHS 
Using a yeast two hybrid system to probe a HeLa cell library, Chen and Jao (1999) identified 
DHS as a binding target of eIF5A. This interaction was confirmed by two other groups using gel 
mobility-shift assay and tandem affinity purification (Lee et al., 1999; Jao and Chen, 2006). Although 
DHS exists natively as a tetramer with four potential active sites for eIF5A binding (Joe et al., 1995; 
Kang et al., 1995; Wolff et al., 1995; Tao and Chen, 1995; Liao et al., 1998), only one eIF5A 
precursor monomer complexes with each DHS tetramer (Lee et al., 1999). Interestingly, although 
NAD+ and spermidine are cofactor and co-substrate, respectively, for the DHS-mediated reaction with 
eIF5A, it was shown that the formation of the pre-eIF5A-DHS complex is not dependent on either 
NAD+ or spermidine, and also that the binding of NAD+ and spermidine to DHS does not depend on 
the presence of pre-eIF5A. This was interpreted as indicating that the binding of NAD+, spermidine 
and pre-eIF5A to the DHS tetramer occurs in a random order (Lee et al., 1999). In addition, DHS still 
stably complexes with deoxyhypusine-containing eIF5A after the reaction, and dissociates after the 
binding of DHH (Lee et al., 1999). 
 
1.2.6.4.2 eIF5A and L5 
Ribosomal protein, L5, which binds to 5S rRNA and has been implicated in the intracellular 
transport of 5S rRNA (Michael and Dreyfuss, 1996), is thought to be a cellular interaction partner for 
eIF5A (Schatz et al., 1998). Moreover, based on the finding that the nuclear export activity of Rev is 
enhanced by over-expression of L5 and inhibited by antibodies that recognize eIF5A or L5, it is 
proposed that Rev is exported in association with an eIF5A-L5 complex (Schatz et al., 1998). In 
detail, Rev and its binding mRNAs are thought to be exported through the 5S rRNA export pathway 
by their interaction with L5, and eIF5A may function as an adaptor to enhance the association 
between viral mRNAs and L5 (Schatz et al., 1998). In addition, eIF5A mutants in which Rev-
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mediated nuclear export is inhibited (Bevec et al., 1996) still bind to L5 protein, suggesting that 
eIF5A and L5 may be involved in intracellular trafficking of substrates other than Rev (Schatz et al., 
1998).  
 
1.2.6.4.3 eIF5A and Crm1 
In untreated mammalian cells as well as in Xenopus oocytes, eIF5A has been shown to 
accumulate in the region of the nuclear-pore-complex-associated intranuclear filaments, which is the 
initial docking site for export substrates on the nuclear-pore-complex (Rosorius et al., 1999). At this 
site, eIF5A interacts with Crm1, a general nuclear export receptor for substrates containing leucine-
rich nuclear export signals (NESs) (Fukuda et al., 1997; Ossareh-Nazari et al., 1997; Stade et al., 
1997). Most importantly, Crm1 is a well-known cellular cofactor for HIV-1 Rev (Bogerd et al., 
1998). In vitro binding studies have demonstrated that eIF5A is required for efficient interaction of 
Rev-NES with Crm1 (Hofmann et al., 2001). This has led to the proposal that eIF5A functions as an 
adaptor to enhance the interaction between Rev and Crm1. However, the interaction between eIF5A 
and Crm1 has been questioned. First, eIF5A does not have a canonical leucine-rich NES (Valentini et 
al., 2002), which is required for the interaction of Crm1 with its targets (Kutay and Guttinger, 2005). 
Second, in a yeast temperature-sensitive Crm1 mutant, there is no nuclear accumulation of eIF5A 
(Valentini et al., 2002). 
There is also evidence that eIF5A may interact with nuclear actin, which is associated with 
the nucleocytoplasmic filaments of the nuclear-pore-complexes, as well as Xenopus oocyte 
nucleoporins including nup62, nup98, nup153 and CAN/nup214, all of which have been implicated in 
nuclear export pathways (Hofmann et al., 2001). Consistent with its proposed interaction with these 
nuclear export-related proteins, eIF5A was shown to be exported from the nucleus to the cytoplasm in 
a leptomycin B-sensitive manner in African green monkey kidney epithelial cells and in Xenopus 
oocytes (Rosorius et al., 1999). 
 
1.2.6.4.4 eIF5A and exportin 4 
Exportin 4 (Exp4), a novel nuclear export receptor that shares high sequence homology with 
Crm1, has been suggested to be a much stronger (~1000 fold) binding partner of eIF5A than Crm1 
(Lipowsky et al., 2000). It belongs to the importin β superfamily that mediates many of the 
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nucleocytoplasmic transport events (Lipowsky et al., 2000). As for other members of the importin β 
superfamily proteins, the cycling of Exp4 between the nucleus and the cytoplasm depends upon 
GTPase Ran-coordinated, compartment-specific binding and release of cargo (Reviewed by Mattaj 
and Englmeier, 1998; Gorlich and Kutay, 1999). Ran switches between a GDP- and a GTP-bound 
form, with RanGTP highly enriched in the nucleus and RanGAP almost exclusively found in the 
cytoplasm. It has been proposed that Exp4 binds to hypusine-containing eIF5A in the nuclear 
environment in the presence of RanGTP, forming a trimeric eIF5A-Exp4-RanGTP complex that is 
subsequently transferred out of the nucleus, and then eIF5A is released from the cargo in the 
cytoplasm (Lipowsky et al., 2000).  
 
1.2.6.4.5 eIF5A and TGase 
eIF5A also appears to be a substrate for some transglutaminases (TGases), including human 
plasma coagulation Factor XIII (Beninati et al., 1995), guinea pig liver TGases (GPLTG) (Beninati et 
al., 1995) and tissue transglutaminases (tTGases) (Beninati et al., 1998; Singh et al., 1998). 
Transglutaminases are enzymes that catalyze covalent cross linking between proteins by forming ε(γ-
glutamyl)-lysine isopeptide bonds between peptide-bound glutamine and lysine residues, thereby 
stabilizing intra- and extra-cellular proteins into macromolecular assemblies (Folk and Finlayson, 
1977). TGases are involved in a variety of physiological activities, such as apoptosis, extracellular 
matrix formation and tumor cell proliferation (Fesus et al., 1987; Fesus et al., 1989; Melino et al., 
1994; Baldini et al., 2006). The hypusine residue of eIF5A is thought to function as the acceptor 
substrate for TGase which, after binding to eIF5A, catalyzes the formation of cross-links between the 
peptide chains of intracellular proteins and the hypusine residue (Beninati et al., 1995). Furthermore, 
eIF5A appears to specifically bind to the GDP-bound form, not the GTP-bound form of TGase (Singh 
et al., 1998). This has led to the proposal that the localization and function of eIF5A are regulated by 
the GTP-binding/GTPase cycle of TGase. eIF5A is thus retained in the cytoplasm through its 
association with GDP-bound TGase; upon GTP-GDP exchange, eIF5A is released and returns to the 
nucleus to participate in trafficking of specific sets of mRNAs or proteins (Singh et al., 1998).  
There is high tTGase activity in immune-competent cells of HIV+ persons (Amendola et al., 
1994). Based on the observation that induction of tTGase in these cells induces apoptosis (Amendola 
et al., 1994; Amendola et al., 1996) and that blocking the expression of tTGase in HIV-1 chronically-
infected cells significantly induces higher viral production (Amendola et al., 2001), tTGase is thought 
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to play a role in reducing viral production. Combined with the fact that its binding partner, eIF5A, is 
the putative cofactor of Rev, it has been suggested that tTGase may act as an effective and natural 
defence mechanism for the host by binding to eIF5A and retaining it in the cytoplasm, thereby 
blocking the export of viral mRNA into the cytoplasm and limiting viral production in HIV+ cells 
(Amendola et al., 2001). 
 
1.2.6.4.6 eIF5A and syntenin 
Syntenin, also known as syndecan binding protein, was identified as a binding partner of 
eIF5A by Li et al. (2004) using yeast two-hybrid screen. Syntenin binds to the cytoplasmic C-termini 
of various proteins, including syndecans, ephrins, pro-TGF- , IL-5-specific α-subunit (IL-5Rα) and 
neurofascin (Grootjans et al., 1997; Torres et al., 1998; Fernandez-Larrea et al., 1999; Cowan et al., 
2002; Geijsen et al., 2001; Koroll et al., 2001), and has been reported to play a role in protein 
trafficking (Fernandez-Larrea et al., 1999), activation of the transcription factor, Sox4 (Geijsen et al., 
2001), and in the organization of cell-cell and cell-matrix adhesions (Zimmermann et al., 2001). 
While syntenin is widely expressed in all human tissues investigated (Zimmermann et al., 2001), it is 
over-expressed in many types of human cancer (Koo et al., 2002; Boukerche et al., 2005). Recent 
studies have indicated that syntenin may play a critical role in tumor progression and metastasis (Koo 
et al., 2002; Helmke et al., 2004; Boukerche et al., 2005). 
It has been suggested that the N-terminal domain of eIF5A, but not the hypusine residue, is 
required for the interaction beween eIF5A and Syntenin (Li et al., 2004). Of interest is the finding that 
the interaction between eIF5A and syntenin antagonizes the ability of eIF5A to up-regulate p53, 
suggesting that syntenin may act as a negative regulator of the eIF5A-p53 signaling pathway (Li et 
al., 2004). 
  
1.2.6.5 mRNA decay 
Several studies with yeast and mammalian cells have indicated a possible role for eIF5A in 
the regulation of mRNA turnover (Zuk and Jacobson, 1998; Veress et al., 2000; Nishimura et al., 
2002; Valentini et al., 2002). A yeast temperature-sensitive eIF5A mutant was shown to exhibit 
decreased decay rates for several mRNAs, as well as a two-fold accumulation of uncapped mRNAs at 
the restrictive temperature (Zuk and Jacobson, 1998). In another study, mutation of the temperature-
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sensitive alleles of the yeast TIF51A gene caused defects in the degradation of short-lived mRNAs at 
the nonpermissive temperature, supporting a role for eIF5A in mRNA decay (Valentini et al., 2002). 
Since the accumulated RNAs in eIF5A mutants lack the 5’-cap, it has been suggested that eIF5A 
affects the decay of specific yeast mRNAs by acting downstream of the decapping step and upstream 
of the degradation by exonuclease (Zuk and Jacobson, 1998; Schrader et al., 2006). Furthermore, the 
nonsense-mediated decay (NMD) pathway, which targets mRNAs that have acquired premature 
translation termination codons (Review by Frischmeyer and Dietz, 1999), and Poly(A) binding 
protein 1, which is essential for mRNA decay (Review by Caponigro and Parker, 1996; Sachs and 
Varani, 2000), are both thought to be functionally related to the ability of eIF5A to regulate mRNA 
turnover in yeast (Valentini et al., 2002; Schrader et al., 2006). Inhibition of hypusine formation in 
mammalian cells using either deoxyspergualin or α-difluoromethylornithine (DFMO) has been shown 
to induce stabilization and accumulation of several kinds of decapped mRNA, prompting the 
suggestion that it is the hypusinated form of eIF5A that is involved in mRNA decay (Veress et al., 
2000; Nishimura et al., 2002).  
 
1.2.6.6 Cellular organizing activity of eIF5A 
Recent studies with yeast temperature-sensitive TIF51A mutants have implicated eIF5A in 
the maintenance of cell wall integrity and actin cytoskeleton organization (Zanelli and Valentini, 
2005; Chatterjee et al., 2006), both of which are crucial for progression of the cell cycle from G1 to S 
phase in yeast (Reviewed by Pruyne et al., 2004). These findings thus correlate with earlier 
observations that depletion of eIF5A or inhibition of hypusine formation results in cell cycle arrest 
(Schnier et al., 1991; Park et al., 1993b; Hanauske-Abel et al., 1994; Kang and Hershey, 1994; Chen 
et al., 1996; Shi et al., 1996b; Tome and Gerner, 1997). In addition, Weir and Yaffe (2004) reported 
that Mmd1p, which is a DHH homologue in fission yeast, is required for mitochondrial distribution, 
an event regulated by microtubules (Huffaker et al., 1988; Jacobs et al., 1988). Moreover, disruption 
of the DHH gene in budding yeast leads to increased sensitivity to the antimicrotubule drug, benomyl, 
further supporting the contention that hypusine-containing eIF5A is involved in the regulation of 




1.2.6.7 Cell growth and proliferation 
1.2.6.7.1 eIF5A and the growth of yeast cells  
Hypusinated eIF5A is essential for the growth of the yeast, Saccharomyces cerevisiae 
(Schnier et al., 1991; Sasaki et al., 1996; Park et al., 1998). Strains with both isoforms of eIF5A genes 
disrupted exhibit slowed or inhibited growth (Schnier et al., 1991) as well as enlarged cells arrested in 
G1 phase (Kang and Hershey, 1994). Blocking the hypusine modification in yeast either by 
substitution with a mutant eIF5A gene in which the specific lysine is mutated (Schnier et al., 1991) or 
by disruption or deletion of the DHS gene (Sasaki et al., 1996; Park et al., 1998) results in loss of cell 
viability and production of non-viable spores. However, deletion of the DHH gene only slightly 
inhibits growth (Park et al., 2006), suggesting a critical role for deoxyhypusine-containing eIF5A for 
the growth of yeast. It should be noted that in higher eukaryotic organisms, i.e., Caenorhabditis 
elegans (Sugimoto, 2004) or Drosophila melanogaster (Spradling et al., 1999), disruption of the 
DHH gene results in recessive lethality, indicating an essential function for hypusine-containing 
eIF5A. 
 
1.2.6.7.2 eIF5A and the growth of mammalian cells 
Mammalian cell growth and proliferation are regulated by the carefully balanced expression 
of proto-oncogenes to promote cell proliferation and tumour suppressor genes to inhibit proliferation 
(Reviewed by King and Cidlowski, 1998; Vermeulen et al., 2003). Accumulating evidence suggests 
that eIF5A and hypusine formation play a role in the regulation of mammalian cell proliferation. First, 
hypusine modification has been reported to occur in growing cells but not resting cells, and to 
increase following mitogen stimulation (Cooper et al., 1982). In addition, Chen (1983) found that 
fetal calf serum, the most widely used growth supplement for cell cultures, stimulates the hypusine 
modification of eIF5A in mouse neuroblastoma NB-15 cells. As well, inhibition of hypusination by 
using specific inhibitors of DHS or DHH or by depleting the polyamine, spermidine, inhibits the 
growth of mammalian cells by inducing reversible arrest at the G1/S boundary of the cell cycle, and 
the treated cells ultimately die (Park, 1987; Byers et al., 1992 & 1994; Jakus et al., 1993; Park et al., 
1993a, b & c; Park et al., 1994; Hanauske-Abel et al., 1994; Chen et al., 1996; Shi et al., 1996b; Tome 
and Gerner, 1997; Lee et al., 2002; Jasiulionis et al., 2007). These observations have prompted the 
proposal that the transition from G1 to S phase of the eukaryotic cell cycle is a hypusine-sensitive 
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event. Indeed, it has been suggested that eIF5A, especially hypusine-containing eIF5A, could perhaps 
be used as a diagnostic biomarker for in situ detection of aberrant cell proliferation (Cracchiolo et al., 
2004). 
 
1.2.6.8 eIF5A and apoptosis 
Apoptosis, the process by which damaged and unwanted cells are induced to die, is essential 
for the development and homeostasis of normal tissues (Reviewed by Arends et al., 1990; Dragovich 
et al., 1998; Hengartner, 2000; Ferri and Kroemer, 2000; Hengartner, 2000). Recent evidence 
indicates that eIF5A plays a role in apoptosis. For example, suppression of hypusine formation has 
been shown to induce apoptosis (Tome and Gerner, 1997; Tome et al., 1997; Caraglia et al., 1999; 
Beninati et al., 1998; Caraglia et al., 2001; Takeuchi et al., 2002). In particular, depletion of 
spermidine or treatment of cells with specific inhibitors of DHS or DHH, the two enzymes that 
mediate hypusination, induces cell death (Park et al., 1993b; Hanauske-Abel et al., 1994; Chen et al., 
1996; Shi et al., 1996b; Tome and Gerner, 1997; Tome et al., 1997; Jin et al., 2003). It should be 
noted that these treatments not only inhibit the formation of hypusine-containing eIF5A, but also 
induce the accumulation of hypusine-absent eIF5A, raising the possibility that it is the unmodified 
eIF5A that is involved in cell death. Such an interpretation, however, must be tempered by the fact 
that most of the inhibitors used in these studies are either polyamine analogues or iron chelators 
(Csonga et al., 1995; Liao et al., 1998; Caraglia et al., 1999; Kim et al., 2006; Park et al., 2006). Thus, 
in addition to their ability to inhibit hypusination, they also affect a number of other events in cellular 
metabolism (Chen et al., 1996; Kulp and Vulliet, 1996; Nishimura et al., 2005; Perry et al., 2005), 
raising the possibility that their ability to induce apoptosis may not reflect inhibition of hypusination.  
Additional evidence for the involvement of eIF5A in apoptosis has come from experiments 
with inhibitors of the ubiquitin-proteasome (UP) pathway. It is well known that inhibition of the UP 
pathway induces cell cycle arrest as well as apoptosis (Fujita et al., 1996; Drexler, 1997; Kitagawa et 
al., 1999; Wagenknecht et al., 1999; An et al., 2000; Naujokat et al., 2000; MacLaren et al., 2001; 
Sassone et al., 2006). Of particular interest is the finding that hypusine-containing eIF5A was shown 
to be down-regulated coincident with proteasome inhibitor-induced apoptosis, and this was 
accompanied by an accumulation of hypusine-absent eIF5A (Jin et al., 2003). This finding is 
consistent with the possibility that unhypusinated eIF5A plays a role in apoptosis. eIF5A has also 
been shown to be involved in heat-stress induced apoptosis. Incubation of MIA PaCa-2 human 
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pancreatic carcinoma cells or Jurkat human leukemic T cells at 51 oC for 30 min suppressed cell 
growth and led to cell death, and this was associated with almost complete disappearance of 
hypusine-containing eIF5A (Takeuchi et al., 2002).  
 
1.2.6.8.1 eIF5A and cytokines 
Some studies also suggest a regulatory role for eIF5A in cytokine-induced apoptosis. 
Exposure of human epidermoid carcinoma KB cells to interferon α (IFNα) induced cell growth 
inhibition and apoptosis, paralleled by a 75% decrease of hypusine synthesis (Caraglia et al., 1997). 
Treatment with epidermal growth factor (EGF) not only antagonised the anti-proliferative and 
apoptosis-inducing effects of IFNα in these experiments, but also reconstituted hypusine levels 
(Caraglia et al., 1999). Furthermore, GC7 and IFNα, which both inhibit hypusine synthesis, have been 
shown to have a synergistic effect on cell growth inhibition and apoptosis (Caraglia et al., 2003). 
Thus, these data suggest a pro-apoptotic function of inhibited hypusination, which potentiates the 
antitumor activity of IFNα. 
There is also evidence that eIF5A plays a role in death receptor-mediated apoptosis. 
Treatment of human lamina cribrosa cells with camptothecin and TNFα induces strong up-regulation 
of eIF5A, coincident with the induction of apoptosis (Taylor et al., 2004). In addition, blocking the 
expression of eIF5A using specific siRNA reduces TNFα-induced apoptosis by up to 80% (Taylor et 
al., 2004). 
 
1.2.6.8.2 eIF5A and tTGase 
eIF5A may also play a role in tTGase-induced apoptosis. TGases are involved in a variety of 
essential physiological activities, including apoptosis (Fesus et al., 1987; Fesus et al., 1989; Melino et 
al., 1994). tTGase is specifically expressed in cells undergoing apoptosis, and over-expression of 
tTGase induces apoptosis and inhibits cell proliferation (Beninati et al., 1998; Caraglia et al., 2001). 
Moreover, stable over-expression of tTGase in mouse embryonic fibroblast BALB/c 3T3 cells 
induced a 100-fold reduction of hypusine levels, which was attributed to depletion of the free 
polyamine pool and formation of γ-glutamyl polyamine conjugates (Beninati et al., 1998). These 
findings led to the proposal that apoptosis induced by tTGase is at least in part attributable to 




1.2.6.8.3 eIF5A and p53 
There is increasing evidence that eIF5A regulates p53-induced apoptosis. For example, over-
expression of eIF5A induces up-regulation of p53 mRNA and protein levels, as well as p53 targets 
including Bax and p21 (Li et al., 2004). As well, in a recent comparison of protein expression in 
HCT116 human colon carcinoma cells carrying wild-type p53 and corresponding isogenic p53 null 
cells, eIF5A was shown to be associated with p53 expression (Rahman-Roblick et al., 2007). DNA 
damage leading to apoptosis was induced in both cell types, and eIF5A mRNA and protein levels 
proved to be highly up-regulated in treated p53+/+ cells (Rahman-Roblick et al., 2007). Most 
interestingly, Rahman-Roblick et al. (2007) also discovered a p53-binding motif in the first intron of 
eIF5A, thereby verifying the role of eIF5A as a p53 target. 
 
1.2.6.8.4 eIF5A may be involved in the regulation of homeostasis 
Several molecules and pathways are partially cross-utilized in opposing processes like cell 
survival on one hand and cell death on the other. For example, multifunctional transcription factor 
proteins like p53 (Reviewed by Levine et al., 1997; Sionov and Haupt, 1999; Liebermann et al., 
2007), E2F (Loughran and La Thangue, 2000; Muller et al., 2001) and NF-κB (Reviewed by Dutta et 
al., 2006; Piva et al., 2006) play important roles in the regulation of apoptosis as well as cell survival 
and cell proliferation. Components of the MAPK signaling cascade including JNK, p38 and ERK also 
promote survival as well as cell death (Reviewed by Chang et al., 2003; Lin, 2003; Nishina et al., 
2003; Nishina et al., 2004; Wada and Penninger, 2004; Lu and Xu, 2006). In response to apoptotic 
stimuli, these “double-edge” molecules activate both survival and death-promoting pathways, which 
in turn interplay and compete until one eventually dominates and determines the fate of the cell. It has 
been suggested that this mechanism assures not only close regulation of these pathways, but also that 
mutations within one signaling cascade will to some extent affect the opposite process, thus 
contributing to homeostatic regulatory circuits (Reviewed by Maddika et al., 2007). That eIF5A may 
regulate both proliferation and apoptosis suggests that it could be involved in the maintenance of 




1.2.6.9 eIF5A and senescence 
Senescence is a state of terminal arrest in which cells are metabolically active for extended 
periods, but fail to re-enter the cell cycle even after mitogenic stimulation (Hayflick, 1965). Evidence 
suggesting that eIF5A may be involved in the regulation of senescence includes the finding that 
hypusine-forming activity is not only prominently serum-responsive, but also much higher in low 
passage young primary human embryo lung cells than in late passage senescent cells (Chen and Chen, 
1997a). Indeed, the senescing cells have little or no hypusine-forming activity (Chen and Chen, 
1997a). Moreover, unhypusinated eIF5A is up-regulated 1.3 fold in human skin epidermis from old 
individuals (89 years old) compared with that of young individuals (24 years old) (Gromov et al., 
2003). The senescence-related function of eIF5A was supported by another study in which eIF5A was 
shown to decrease during the senescence of human umbilical vein endothelial cells (Eman et al., 
2006). It should be noted that the change in hypusine-forming activity with advancing senescence 
appears to be mainly due to a decrease in DHS activity and in the amount of eIF5A precursor, while 
the eIF5A mRNA level is unaltered (Chen and Chen, 1997a). 
 
1.2.7 eIF5A and cancer 
Several reports have suggested a possible role for eIF5A in the development of cancer. 
Activation of myc oncogene, which is rearranged, amplified or mutated in many human tumor types 
(Reviewed by Arvanitis Felsher, 2006; Vita and Henriksson, 2006), induces up-regulation of eIF5A 
mRNA in vitro (Coller et al., 2000; Boon et al., 2001). In addition, eIF5A is up-regulated in many 
human lung adenocarcinomas, and enhanced eIF5A1 protein levels have been found in lung tumors 
with poor differentiation, K-ras mutations or p53 nuclear accumulation as well as in patients with 
poor survival prospects (Chen et al., 2003).  
 
1.2.7.1 DHS 
DHS, the enzyme mediating the first of two reactions leading to hypusination of eIF5A, has 
been identified as one of a signature set of amplified genes in cancer metastases (Ramaswamy et al., 
2003). In addition, DHS mRNA is over-expressed in several human cancer cell lines, including 
inflammatory breast cancer cell line Sum149, chronic myeloid leukemia cell line K526, breast 
adenocarcinoma cell line MCF7, prostate adenocarcinoma cell line PC3, colorectal adenocarcinoma 
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cell line Colo205, ovarian carcinoma cell line OVCAR4 and epithelial breast cancer cell line HS578T 
(Golen et al., 1999; Clement et al., 2006). These data suggest that DHS may play a role in cancer 
development and progression.  
 
1.2.7.2 Oncogenic role of eIF5A2 
There are two eIF5A genes in the human genome, eIF5A1 and eIF5A2. eIF5A2 resides in an 
unstable region of chromosome 3q26 (Guan et al., 2001), which is an area that often exhibits 
chromosomal alterations such as translocation, duplication or inversion in human ovarian carcinoma 
(Brass et al., 1997). Over-expression of eIF5A2 mRNA has been detected in many primary ovarian 
cancers and ovarian cancer cell lines (Guan et al., 2001; Jenkins et al., 2001) as well as in cells that 
have been derived from colorectal adenocarcinoma, leukemia and lymphoma (Jenkins et al., 2001; 
Clement et al., 2003 & 2006). In a study of confirmed human epithelial ovarian cancers, over-
expression of eIF5A2 protein was not only detected in 57.8% of the cases, but also was significantly 
associated with advanced ovarian cancer (Guan et al., 2004). In addition, eIF5A2 has been correlated 
with cell proliferation. For example, suppression of eIF5A2 expression decreases the growth of 
UACC 1598 cells, a human ovarian cancer line known to express high levels of eIF5A2 (Guan et al., 
2004).  
Based on its frequent up-regulation in human overian cancers as well as its apparent role in 
cell proliferation in such cancers, it has been proposed that eIF5A2 is an oncogene whose expression 
is related to the development of ovarian cancer (Guan et al., 2001). This contention is supported by 
the finding that injection of eIF5A2-transfected LO2 normal human liver cancer cells into nude mice 
induces tumor formation (Guan et al., 2004). Moreover, in a recent study of the gene expression 
profile of primary tumors from 32 patients who underwent radical surgery for gastric carcinoma, 
eIF5A2, together with Bik and aurora kinase B, were found to be over-expressed in most of the 
metastatic lymph node-positive (N+) cases, suggesting that it might be a useful prognostic predictor 
of metastatic lymph node status (Marchet et al., 2007). 
 
1.2.8 Objectives of the present study 
It is clear that eIF5A is an important protein that has been implicated in both cell proliferation 
and apoptosis. In the present study, the mechanism underlying the pro-apoptotic function of eIF5A 
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was examined in human cancer cell lines by suppressing its expression using specific siRNA and by 
over-expressing the protein using adenovirus constructs. Both isoforms of human eIF5A were 
examined in this study, but greater emphasis was given to eIF5A1. In addition, the roles of the post-
translationally modified forms of eIF5A in apoptosis were examined using 2D gel electrophoresis to 



























Chapter 2 Materials and Methods 
 
2.1 Cell Lines 
Three cell lines were used in this study. COS-7, an African green monkey kidney fibroblast-
like cell line, was purchased from American Type Culture Collection (ATCC) (Manassas, Virginia, 
USA). HT-29, a human colon adenocarcinoma cell line, and Hela S3, a human cervical 
adenocarcinoma cell line, which is a clonal derivative of the human cervical adenocarcinoma cell 
line, Hela, and is capable of suspension growth, were kind gifts from Anita Antes (University of 
Medicine and Dentistry of New Jersey, Newark, New Jersey, USA). Hela S3 cells were cultured in 
Minimum Essential Medium (Eagle) (E-MEM) (Sigma-Aldrich Canada Ltd., Oakville, Ontario, 
Canada) containing 2 mM L-glutamine, Earle’s Balanced Salt Solution adjusted to contain 1.5 g/l 
sodium bicarbonate, 0.1 mM non-essential amino acids (Sigma-Aldrich), 1.0 mM sodium pyruvate 
(Sigma-Aldrich) and 10% (v/v) double-heat inactivated fetal bovine serum (FBS). COS-7 cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich) with 4mM L-
glutamine, Earle’s Balanced Salt Solution adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l 
glucose (Sigma-Aldrich) and 10% double-heat inactivated FBS. HT-29 cells were maintained in 
RPMI 1640 (Sigma-Aldrich) supplemented with 2 mM L-glutamine, Earle’s Balanced Salt Solution 
adjusted to contain 2.2 g/l sodium bicarbonate, 1.0 mM sodium pyruvate, 10 mM HEPES (Sigma-
Aldrich) and 10% double-heat inactivated FBS. All media were also supplemented with an antibiotic 
and antimycotic mixture (Gibco, Invitrogen Canada Inc., Burlington, Ontario, Canada) to contain 100 
units/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml amphotericin B. Cultures were maintained 
in a humidified incubator at 37 oC under conditions of 5% carbon dioxide plus 95% air and were split 
twice weekly. To split cells that had reached confluence, the medium was removed, and the cells were 
harvested by incubation in 0.25% trypsin-EDTA (Gibco) until they began to detach. Addition of 
medium containing 10% FBS stopped the trypsin activity, and one eighth of the cell suspension was 




2.2 Isolation of protein and cell fractions 
2.2.1 Preparation of whole cell lysates  
For isolation of whole cell lysates, cells were trypsinized, collected in an Eppendorf tube 
(Eppendorf Canada, Mississauga, Ontario, Canada), washed twice with phosphate-buffered saline 
(PBS; 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4 and 137 mM NaCl, pH 7.4) and then 
resuspended in boiling lysis buffer (2% SDS and 50 mM Tris-HCl pH 7.4). For every 5 x 105 cells, 
200 μl of lysis buffer was used. Lysates were boiled at 95 oC for 5 min, and then sonicated at 5 volts 
for 30 seconds using a Sonic Dismembrator Model 100 (Fisher Scientific Ltd., Nepean, Ontario, 
Canada). All samples were centrifuged at 14,000g for 10 minutes at 4 oC in a Heraeus Biofuge Pico 
microcentrifuge (Heraeus, Heraeusstraße, Hanau, Germany) to remove debris. Supernatants were 
collected and stored at -20 oC.      
 
2.2.2 Preparation of cytosolic and mitochondrial/membrane extracts 
Cytosolic and mitochondrial/membrane extracts were prepared by first trypsinizing cells and 
washing them in PBS. The cells were resuspended (5 x 106 cells / 300 μl) in sucrose buffer (250 mM 
sucrose, 10 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA and 1 mM EDTA) containing 
0.025% digitonin (Sigma-Aldrich) to permeabilize the plasma membrane and 1 x protease inhibitor 
cocktail (Sigma-Aldrich). The suspension was incubated at room temperature for 10 min, and the cell 
lysates were then cleared by centrifugation at 14,000g for 10 min at 4 oC. The supernatant was placed 
in a new Eppendorf tube and designated as the cytosolic fraction.  
The resultant pellet of permeabilized cells was subsequently resuspended in 150 μl complete 
lysis buffer [2 M Thiourea, 7 M Urea, 30 mM Tris, 4% CHAPS (Sigma-Aldrich), 0.5% Triton X-100 
(Bioshop Canada Inc.) and 1 x protease inhibitor cocktail] and incubated on ice for 10 minutes with 
gentle shaking. The sample was then centrifuged at 14,000g for 10 minutes at 4 oC in a 
microcentrifuge (Heraeus) to remove debris. The supernatant was transferred to a new Eppendorf 




2.2.3 Protein quantitation using bicinchoninic acid 
The protein concentration of cell extracts was determined using the bicinchoninic acid (BCA) 
protein assay kit (Sigma-Aldrich) following the manufacturer’s instructions. The protein standards 
were prepared by diluting bovine serum albumin (BSA) protein standard solution (Sigma-Aldrich) 
with different amounts of cell lysis buffer (2% SDS and 50mM Tris-HCl pH 7.4) to generate a series 
of BSA solutions of different concentrations, which were 0 μg/ml, 25 μg/ml, 50 μg/ml, 100 μg/ml, 
150 μg/ml, 200 μg/ml, 400 μg/ml and 600 μg/ml. Samples were diluted in the cell lysis buffer in a 
ratio of 1:5. Ten μl of each standard and diluted sample were loaded in duplicate into wells of a 96-
well plate. Two hundred μl BCA solution, which was prepared by mixing 50 parts of reagent A with 1 
part of reagent B (both provided in the kit), was added to each well. The plate was covered with foil 
and incubated at 37 oC for 30 min. Absorbance values were measured at 562 nm using a Versamax 
Tunable microplate reader (Molecular Devices, Concord, Ontario, Canada). Protein concentrations of 
the samples were calculated by plotting their absorbances on the standard curve that was constructed 
from the absorbance values of the standards versus their concentrations. 
 
2.2.4 Protein quantitation using the Bradford method 
For samples harvested in lysis buffer containing high concentrations of chemicals that 
precluded the use of BCA, the Bradford assay was used to measure protein concentration. The 
standards for the Bradford method were prepared by diluting 1 μg, 2 μg, 2.5 μg, 3 μg, 3.5 μg, 4 μg, 
4.5 μg, 5 μg or 6 μg of the BSA protein standard (Sigma-Aldrich) in 600 μl of Bradford solution, 
which was in turn made by diluting 1 part of the stock Bradford reagent (Bioshop Canada Inc., 
Burlington, Ontario, Canada) with 3 parts of double-distilled water. Three μl each unknown sample 
was also diluted in 600 μl of diluted Bradford solution. Absorbance values were measured at 595 nm 
using a DU-64 spectrophotometer (Beckman, GMI Inc., Ramsey, Minnesota, USA). The protein 
concentrations of the samples were calculated by plotting their absorbances on the standard curve that 
was constructed from the absorbances of the standards versus their concentrations. 
 
2.2.5 SDS-PAGE  
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using the Mini-Protean 
3 cell from Bio-Rad (Bio-Rad Laboratories, Mississauga, Ontario, Canada). A 12% or 15% (w/v) 
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resolving gel was overlaid with a 5% (w/v) stacking gel. Five μg protein sample was diluted 1:3 in 4 x 
SDS gel loading buffer (320 mM Tris-HCl pH 6.8, 40% (v/v) glycerol and 8% (w/v) SDS) and boiled 
at 100 oC for 10 minutes before being loaded into the bottom of the wells using a special gel-loading 
pipet tip (Fisher Scientific Ltd.). Five μl of page ruler prestained protein ladder (Fermentas Canada 
Inc., Burlington, Ontario, Canada) was loaded into a separate well in order to track the running of 
samples. Proteins were then separated using SDS electrophoresis running buffer (25mM Tris, 250mM 
glycine and 0.1% (w/v) SDS) at 40 mAmps until the bromophenol blue reached the bottom of the 
resolving gel. The resolving gel was removed and soaked in chilled transfer buffer [25 mM Tris-HCl 
pH 8.3, 192mM Glycine and 20% (v/v) methanol] for 20 minutes. Hypond-P PVDF membrane 
(Amersham Biosciences, Amersham Health Inc., Mississauga, Ontario, Canada) was prepared by 
soaking in 100% (v/v) methanol for 10 seconds and incubation in chilled transfer buffer for 15 
minutes. Two pieces of blotting paper (VWR) were prepared by incubation in chilled transfer buffer 
for 5 minutes. An electroblotting cassette containing the gel, Hypond-P PVDF membrane and the 
blotting paper was assembled and placed in the Trans-blot SD semi-dry transfer cell (Bio-Rad 
Laboratories) according to the manufacturer’s instructions. Proteins on the gel were transferred to the 
PVDF membrane at 22 volts for a period of 36 minutes.  
 
2.2.6 Membrane blocking and incubation with antibodies  
Following the transfer, the PVDF membrane was removed from the electroblotting cassette 
and rinsed briefly in TBST [Tris buffered saline (50 mM Tris-HCl pH 7.4 and 150 mM NaCl) 
containing 0.1% (v/v) Tween 20]. The non-specific binding sites on the membrane were blocked by 
incubation in 15 ml of blocking buffer [5% (w/v) skim milk power and 0.05% Tween 20 (v/v) in TBS 
(50 mM Tris-HCl pH 7.4 and 150 mM NaCl)] for one hour at room temperature with gentle shaking.  
The membranes were then incubated in anti-Actin (Calbiochem, VWR CANLAB, 
Mississauga, Ontario, Canada), anti-Bad (Cell Signaling Technology, New England Biolabs Ltd., 
Pickering, Ontario), anti-Bax (Cell Signaling Technology), anti-Bcl-2 (Cell Signaling Technology), 
anti-Bid (Cell Signaling Technology), anti-Bim (Cell Signaling Technology), anti-cytochrome c (BD 
Biosciences, Mississauga, Ontario, Canada), anti-eIF5A1 (BD Biosciences), anti-eIF5A2 (Novus 
Biologicals Inc., Littleton, Colorado, USA), anti-HA (Roche Applied Science, Roche Diagnostics, 
Laval, Quebec, Canada), anti-p53 (Cell Signaling Technology) or anti-Puma (Cell Signaling 
Technology) which were diluted 1:20000, 1:2000, 1:1000, 1:1000, 1:1000, 1:1000, 1:500, 1:20000, 
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1:1000, 1:1000, 1:1000 or 1:1000, respectively, with primary antibody dilution buffer [0.05% (v/v) 
Tween 20 and either 5% (w/v) skim powder milk or BSA (Sigma-Aldrich) in TBS] for either 1 hour 
at room temperature or overnight at 4 oC with gentle agitation. The blots were then washed with 
TBST 3 times for 10 minutes each and incubated for 1 hour at room temperature with gentle agitation 
in HRP-conjugated secondary antibody, which was anti-mouse IgG (Sigma-Aldrich), anti-mouse IgM 
(Calbiochem) or anti-Rabbit IgG (Calbiochem) diluted according to the manufacturers’ instructions in 
secondary antibody dilution buffer [0.05% (v/v) Tween 20 and 1% (w/v) skim powder milk in TBS]. 
The membranes were then washed with TBST 3 times for 10 minutes each at room temperature 
before detection. 
 
2.2.7 Detection of protein 
ECL Plus Western blotting detection reagents (Amersham Health Inc.) were used following 
the manufacturer’s instructions. Basically, detection solution A and B were mixed in a ratio of 40:1, 
and 2 ml of the mixture was used for each 8 cm x 10 cm membrane. Excess wash buffer was drained 
off the membrane, and the membrane was placed in a clean, dry Petri dish with the protein side facing 
up. The membrane was incubated in the detection mixture at room temperature for 5 minutes and then 
removed from the Petri dish and placed between two layers of transparent plastic wrap. Air bubbles 
were smoothed out with a glass rod. The wrapped blot was then placed in an X-ray film cassette with 
the protein side up. In a dark room with only the duplex super safelight (Thomas Instrument 
Company, Inc., Palmyra, Virginia, USA) on, a piece of clear blue X-ray film (Fuji Photo Film Canada 
Inc., Mississauga, Ontario, Canada) was exposed to the membrane for 30 seconds in the cassette. The 
film was then developed and dried in the AGFA CP 1000 X-ray films processor (AGFA Inc., 
Toronto, Ontario, Canada). The exposure time was adjusted as necessory.     
 
2.2.8 Stripping and reprobing the membrane 
In order to probe the same membrane with different antibodies, the membrane was stripped of 
bound antibody and re-probed several times. In detail, the membrane was submerged in 50 ml of 
stripping buffer (100 mM 2-mercaptoethanol, 2% (w/v) SDS and 62.5 mM Tris-HCl pH 6.7) and 
incubated at 50 oC for 30 minutes with occasional agitation. The membrane was then briefly rinsed 
with distilled water and washed in large volumes of TBST twice for 15 minutes each with gentle 
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shaking. The membrane was then incubated in blocking buffer for 1 hour and re-probed with another 
antibody. 
 
2.3 Plasmid construction and transfection 
2.3.1 Cloning and construction of pHMeIF5A1 and pHMeIF5A2 
The plasmids, pHMeIF5A1 and pHMeIF5A2, were constructed by Catherine Taylor in Dr. 
Thompson’s laboratory. For this purpose, human eIF5A1 (access number: NM_001970) and human 
eIF5A2 (access number: NM_020390) were cloned by RT-PCR from total RNA isolated from RKO 
human colorectal carcinoma cells using the GenElute mammalian RNA miniprep kit (Sigma-Aldrich) 
according to the manufacturer's protocol for adherent cells. The primers used for eIF5A1 were: 
forward, 5’-CGAGTTGGAATCGAAGCCTC-3’; and reverse, 5’-GGTTCAGAGGATCACTGCTG-
3’. The primers used for eIF5A2 were: forward, 5’-AAACTACCATCTCCCCTGCC-3’; and reverse, 
5’-TGCCCTACACAGGCTGAAAG-3’. The resulting products were subcloned into pGEM-T Easy 
vector and sequenced. The resulting plasmid containing eIF5A1 was used as a template for PCR 
using the following primers: forward, 5’-GCCAAGCTTAATGGCAGATGATTTGG-3’; and reverse 
5’-CCTGAATTCCAGTTATTTTGCCATGG-3’. The resulting plasmid containing eIF5A2 was used 
as a template for PCR using the following primers: forward, 5’-
ATCAAGCTTGCCCACCATGGCAGACG-3’; and reverse 5’-
AACGAATTCCATGCCTGATGTTTCCG-3’. The PCR products were subcloned into the Hind III 
and EcoR I sites of pHM6 (restriction enzymes as well as the vectors were all purchased from Roche 
Applied Science), which is a mammalian epitope tag expression vector, thereby generating 
pHMeIF5A1 and pHMeIF5A2, respectively. eIF5A in this plasmid has HA, a nonapeptide epitope tag 
from influenza hemagglutinin, attached to its N-terminus. pHMeIF5A1 and pHMeIF5A2 were 
validated by sequencing. pHMlazZ6, which was supplied by the manufacturer (Roche Applied 
Science), was used as the control vector. It features a 3 kb fragment containing the β-galactosidase 
gene cloned in frame with the N-terminal HA tag and C-terminal His6 (six histidine residue epitope). 
Protein expressions of pHMeIF5A1, pHMeIF5A2 and pHMlacZ6 are enhanced by the efficient 
immediate-early human cytomegalovirus (CMV) promoter sequence. In addition, both vectors 




2.3.2 Preparation of eIF5A1 with a point-mutation 
A site-specific mutation of eIF5A1 at a specific lysine residue was obtained by PCR using 
pHMeIF5A1 DNA as the template. Using the forward and reverse primers, 5’-
GCCAAGCTTAATGGCAGATGATTTGG-3’ and 5’-GTGCGCGCCAGTCTTCGAAGTAG-3’, 
respectively, a 158 bp portion of the coding region of eIF5A1containing a point-mutation converting 
lysine50 to alanine (indicated by a rectangle) as well as the Sfu I restriction enzyme site (underlined) 
was obtained. Using the forward and reverse primers, 5’-CTACTTCGAAGACTGGCGCGCAC-3’ 
and 5’-CCTGAATTCCAGTTATTTTGCCATGG-3’, respectively, the remaining 347 bp segment of 
the coding region of eIF5A1 also bearing a point mutation converting lysine50 to alanine (indicated by 
a rectangle) and the restriction enzyme site for Sfu I (underlined) was synthesized. The two PCR 
products were isolated on a 2 % (w/v) agarose gel in 1 x TAE buffer (40 mM Tris, 2 mM Na2EDTA, 
glacial acetic acid to pH 8.3) at 80 volts. DNA fragments were cut from the gel and purified using 
Perfectprep gel clean-up kit (Eppendorf Canada) according to the manufacturer’s instructions. 
Extracted 158 bp and 347 bp fragments were both digested with Sfu I (Roche Applied Science) at 37 
oC for 3 hours, and then incubated together with T4 ligase (Fermentas Canada Inc.) overnight at 16 
oC. The ligation product was isolated on a 2 % (w/v) agarose gel in 1 x TAE buffer at 80 volts and 
purified using the Perfectprep gel clean-up kit. The purified ligation product was subsequently sub-
cloned into the Hind III and EcoR I sites of the pHM6 vector. This construct of mutated eIF5A1 was 
validated by sequencing and referred to as pHMeIF5A1(K50A). 
 
2.3.3 Escherichia coli transformation  
pHMeIF5A1, pHMeIF5A2, pHMeIF5A1(K50A) and pHMlacZ6 plasmids were separately 
transformed into competent Escherichia coli DH5α cells. Briefly, 10 μl of plasmid was added to 200 
μl of DH5α cell suspension, and the mixture was incubated on ice for 30 minutes. The mixture was 
then heat-shocked at 42 oC for 90 seconds. The cells were chilled on ice for 1 to 2 minutes before 
being mixed with 800 μl 2 x YT medium (16 g/l Tryptone, 10 g/l Yeast extract and 5 g/l NaCl, pH 
7.0) and incubated at 37 oC for 45 minutes with shaking. The cells were then quickly spun down and 
resuspended in 200 μl of 2 x YT medium. The transformation culture was transferred onto a Luria-
Bertani (LB) agar plate (10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl and 15g/l agar, pH 7.0) 
supplemented with 50 μg/ml ampicillin. The plate was incubated overnight at 37 oC. Only the 
transformants were able to grow on the antibiotic-containing plate because of the ampicillin resistance 
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that is provided by the pHM6 vector. A single colony was inoculated into 5 ml of LB broth (10 g/l 
tryptone, 5 g/l yeast extract and 10 g/l NaCl, pH 7.0) supplemented with 50 μg/ml ampicillin and 
incubated overnight at 37 oC with shaking. Plasmid DNA was isolated using the Wizard plus 
miniprep DNA purification system (Promega, Fisher Scientific Ltd., Nepean, Ontario, Canada), and 
then digested with EcoR I and Hind III for one hour at 37 oC. The digestion product was fractionated 
on a 1% (w/v) agarose gel and visualized under a UV lamp to verify the presence of the eIF5A1 or 
eIF5A1(K50A) insert. Plasmid DNA was sequenced by the sequencing facility of York University 
(Toronto, Ontario, Canada).  
 
2.3.4 Purification of plasmid DNA  
Escherichia coli cells transformed with pHMeIF5A1, pHMeIF5A2, pHMeIF5A1(K50A) or 
pHMlacZ6 were aseptically streaked on LB agar plates containing 50 μg/ml ampicillin. The plates 
were incubated overnight at 37 oC and stored at 4 oC for up to a month. Single fresh colonies were 
aseptically inoculated into 50 ml 2 x YT medium supplemented with 50 μg/ml ampicillin and 
incubated overnight at 37 oC with gentle shaking. Plasmid DNA was then harvested using the 
GenElute high performance plasmid miniprep kit (Sigma-Aldrich) following the manufacturer’s 
instructions. DNA product was purified by mixing with 100 mM sodium acetate (pH 5.2) and 64.5% 
(v/v) ethanol and incubation at -20 oC for at least one hour. The mixture was centrifuged at 14,000g 
for 30 minutes at 4 oC. The supernatant was carefully removed without disturbing the pellet, which 
was then washed twice by resuspension in 70% (v/v) ethanol and centrifugation at 14,000g for 30 
minutes at 4 oC. The final supernatant was aspirated off carefully, and the pellet was air-dried in a 
fume hood to allow the ethanol to evaporate thoroughly. The dry DNA pellet was resuspended in 
tissue-culture-grade water (Sigma-Aldrich). DNA concentration and purity were determined 
spectrophotometrically by measuring the absorbance at 260 nm, 280 nm and 320 nm using a DU-64 
spectrophotometer (Beckman). 
 
2.3.5 Transfection of mammalian cells using electroporation 
COS-7 cells were trypsinized and resuspended in DMEM containing 10% FBS at a 
concentration of 1.5 x 106 cells/ml. 15 μg of pHMeIF5A1, pHMeIF5A1(K50A) or pHMlacZ6 DNA 
was diluted in 50 μl Opti-MEM I reduced medium (Gibco), and then mixed with 650 μl of diluted 
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COS-7 cells. The mixture was transferred to a 2 mm gap electroporation cuvette (BTX Technologies 
Inc., Hawthorne, New york, USA), which was then inserted in the slide of the pulser chamber of a 
T820 ElectroSquarePorator (BTX Technologies Inc.). DNA was electroporated into the cells at 1.5 
kilovolts and 90 microseconds per pulse for 1 to 2 pulses. The cells were then transferred into one 
well of a 6-well plate, which was pre-loaded with complete medium, and the concentration of FBS 
was brought up to 10%. The medium was changed 24 hours after the transfection. Cell lysates were 
harvested 48 hour after electroporation and subjected to analysis. 
 
2.3.6 LacZ staining 
Forty-eight hours after electroporation, COS-7 cells transfected with pHMlacZ6 were stained 
in order to determine the transfection efficiency. The medium was removed, and the cells were 
washed with PBS twice, fixed with 0.5% (w/v) glutaraldehyde in PBS at room temperature for 10 
minutes, and then washed twice with PBS containing 1 mM MgCl2. They were then incubated in lacZ 
staining solution [5 mM K4Fe(CN)6.3H2O, 5 mM K3Fe(CN)6, 1 mM MgCl2 and 0.1% (w/v) X-gal in 
PBS] at 37 oC until the desired level of staining was achieved. The staining solution was then 
removed, and the cells were washed with PBS. Numbers of stained cells and unstained cells were 
counted separately to determine the transfection efficiency. 
 
2.3.7 Labeling eIF5A with [3H]-spermidine 
COS-7 cells were transfected with pHMeIF5A1, pHMeIF5A1(K50A) or pHMlacZ6 by 
electroporation as described above. Six hours after transfection, 40 μCi/ml [terminal methylene 3H 
(N)]-spermidine (PerkinElmer Life Science, Boston, Massachusetts, USA) with or without 1 mM 
aminoguanidine (AM) was added to each well. Forty-two hours later, the cells were washed three 
times with PBS to remove free [3H]-spermidine. Cell lysates were then harvested as described in 
section 2.2.1. Proteins as well as protein markers were fractionated on an SDS-PAGE gel containing a 
15% resolving gel and a 5% stacking gel, and subsequently transferred to a piece of Hypond-P PVDF 
membrane as described in section 2.2.6. The membrane was incubated in Amplify fluorographic 
reagent (Amersham Health Inc.) for 30 minutes to enhance the radioactivity signal. A piece of 
Hyperfilm (Amersham Health Inc.) was incubated with the membrane in a cassette for 10 days at -80 
oC, and then developed to visualize the [3H]-labeled protein. The membrane was then wetted with 
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methanol, washed twice for 10 minutes with PBS, and subjected to Western blot analysis using anti-
eIF5A1 and anti-HA as described in section 2.2.7. 
 
2.3.8 Immunoprecipitation of eIF5A 
COS-7 cells transfected with pHMeIF5A1 were incubated in complete medium supplemented 
with 40 μCi/ml [terminal methylene 3H (N)]-spermidine as well as 1 mM AM. At 48 and 72 hours 
after transfection, the cells were washed twice with ice-cold PBS and lysed by incubation in ice-cold 
IP lysis buffer [150 mM NaCl, 1% (v/v) NP40, 50 mM Tris-HCl pH 8.0 and 1 x protease inhibitor 
cocktail] for 30 minutes on ice with gentle shaking. The cells were scraped from the bottom of the 
plate and, together with the lysis buffer, transferred to an Eppendorf tube and centrifuged at 14,000g 
for 10 minutes at 4 oC. The supernatant was transferred to a fresh Eppendorf tube. Cellular proteins 
were pre-cleared by incubation with Protein G plus-agarose suspension (Calbiochem) as well as anti-
mouse IgG (Sigma), and the supernatant was then incubated in anti-eIF5A1 (BD Biosciences) at a 
ratio of 100:1 (v/v) at 4 oC overnight with gentle rotation. Protein G-plus agarose was added to the 
mixture the next morning, and the combined mixture was incubated at 4 oC for 2 hours with gentle 
rotation. The mixture was spun down at 14,000g for 10 seconds, and the beads were washed five 
times with ice-cold PBS. The protein associated with the agarose beads was then eluted by boiling in 
1 x SDS PAGE gel loading buffer at 100 oC for 10 minutes. Immunoprecipitation (IP) product was 
then subjected to SDS-PAGE, autoradiography and immunoblot analysis as described in section 
2.3.7. 
 
2.4 Induction of apoptosis  
HT-29 cells or Hela S3 cells were treated with Actinomycin D, sodium nitroprusside or MG-
132, a proteasome inhibitor, in order to induce apoptosis. Specifically, cells were incubated in 0.5 
μg/ml Actinomycin D (Calbiochem), 3 mM sodium nitroprusside (Sigma-Aldrich) or 5 μM MG-132 
(Sigma-Aldrich) in complete medium for periods of up to 24 hours. Serum starvation was used as a 
means of inducing cell stress leading to apoptosis. For this purpose, cells were cultured under normal 
growth conditions until they reached about 30 to 40% confluence. The medium was then removed, 




2.5 siRNA studies 
2.5.1 Designing siRNA  
siRNA specifically targeted to human eIF5A1 as well as a control siRNA were designed by 
Catherine Taylor and obtained from Dharmacon (Chicago, Illinois, USA). The eIF5A1 siRNA, which 
targets the 3′UTR of eIF5A1 mRNA (GenBank Accession No BC085015), has the following 
sequence: sense strand, 5’-GCUGGACUCCUCCUACACAdTdT-3’; and antisense strand, 3’-
dTdTCGACCUGAGGAGGAUGUGU-5’. The control siRNA has the reverse sequence of the 
eIF5A1 siRNA and is not identical to any known human gene product. The control siRNA has the 
following sequence: sense strand, 5’-ACACAUCCUCCUCAGGUCGdTdT-3’; and antisense strand, 
3’-dTdTUGUGUAGGAGGAGUCCAGC-5’.  
 
2.5.2 siRNA transfection using Lipofectamine 2000 
HT-29 or Hela S3 cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen 
Canada Inc.) following the protocol provided by the manufacturer. On the day before the transfection, 
cells were seeded in either a 96-well plate for cell proliferation and viability studies or a 24-well plate 
for Western blot analysis so that they would reach 30-50% confluence at the time of transfection. For 
the reaction in each well of the 96-well plate, 4.08 pmol siRNA and 0.16 μl Lipofectamine 2000, 
which were separately diluted in 8 μl Opti-MEM I reduced serum medium (Gibco), were mixed 
together and incubated at room temperature for 20 minutes to allow the formation of siRNA-
Lipofectamine 2000 complex. For the reaction in each well of the 24-well plate, 25.5 pmol siRNA 
and 1 μl Lipofectamine 2000, which were separately diluted in 50 μl Opti-MEM I reduced serum 
medium (Gibco), were used. The medium was removed from the cells, and the cells were incubated in 
the siRNA-Lipofectamine 2000 complexes at 37 oC in a CO2 incubator to initiate transfection. Four to 
six hours later, the medium was diluted 1:2 with RPMI 1640 containing 30% FBS, so that the 
concentration of FBS was brought up to 10%. The medium was replaced with RPMI 1640 containing 





2.5.3 XTT cell viability assay 
XTT [2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide)] allows 
measurement of cell viability. This is made possible by the fact that XTT, a yellow-colored 
tetrazolium salt, is cleaved to a soluble orange-colored formazan dye by the mitochondrial 
succinatetetrazolium reductase system of metabolically active cells, a reaction that can be quantified 
by measuring the absorbance at 490 nm using a microplate reader. 
For measurements of viability, HT-29 cells were seeded on a 96-well plate, transfected with 
either eIF5A1 siRNA or control siRNA, and then subjected to either no further treatment or to 
apoptotic stimuli (see section 2.4). The XTT reagent solution and the activation solution (both 
provided in the kit from Roche Applied Science) were thawed in a 37 oC water bath and mixed at a 
ratio of 50:1. 50 μl of the mixture was loaded into each well and incubated with the cells in a 37 oC 
incubator until color had formed. Absorbance values were measured at 490 nm and 630 nm (the latter 
is used as reference absorbance) using a Versamax Tunable microplate reader (Molecular Devices). 
 
2.5.4 BrdU cell proliferation assay 
BrdU (5-bromo-2’-deoxyuridine) was used to measure cell proliferation. In proliferating 
cells, BrdU is incorporated into DNA, and the incorporation can be detected by immunoassay. Thus, 
whereas XTT is a cell proliferation assay that measures cell metabolic activity, BrdU measures cell 
proliferation by detecting newly synthesized DNA in the cells.  
The BrdU cell proliferation ELISA colorimetric assay (Roche Applied Science) was 
performed following the manufacturer’s instructions. HT-29 cells seeded in a 96-well plate were 
treated with eIF5A1 siRNA or control siRNA and then incubated with diluted BrdU labeling solution 
at 37 oC for 2 hours to allow incorporation of BrdU into the DNA of proliferating cells. After 
removing the labeling medium, the cells were fixed, and the DNA was partially denatured by 
incubation in FixDenat for 30 minutes at room temperature. The cells were then incubated in anti-
BrdU-POD for 90 minutes at room temperature to allow binding of the antibody to BrdU incorporated 
into newly synthesized DNA. Then, excess antibody was removed, and the 96-well plate was rinsed 
three times for five minutes with gentle shaking using washing solution provided in the kit. Finally, 
substrate solution was added to the cells. In the presence of hydrogen peroxide, peroxidase (POD) 
catalyzed the oxidation of diacylhydrazides-like luminal, emitting light. The signal was quantified by 
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measuring the absorbance at 370 nm and 492 nm (the latter is used as reference wavelength) using a 
Versamax Tunable microplate reader (Molecular Devices). 
  
2.5.5 ELISA detection of cell death  
During apoptosis, mono- and oligo-nucleosomes consisting of cores of histones and DNA 
chains coiled around histones are released into the cytoplasm coincident with the degradation of 
chromosomal DNA. The cell death detection ELISA kit purchased from Roche Applied Science was 
used to measure apoptotic cell death by detection of these cytoplasmic histone-associated-DNA-
fragments.  
HT-29 cells seeded on a 96-well plate were treated with eIF5A1 siRNA or control siRNA and 
subjected to apoptotic stimuli (see section 2.4). To measure apoptosis, the microplate was centrifuged 
at 200g using an IEC 21000R centrifuge (IEC, Needham Heights, Maryland, USA) for 10 minutes. 
The supernatant was carefully removed, and the cell pellet was resuspended in the lysis buffer 
provided in the kit and incubated for 30 minutes at room temperature to release the cytoplasmic 
fraction. The plate was then centrifuged at 200g for 10 minutes, and 20 μl of supernatant, which was 
the cytoplasmic fraction, was carefully transferred into a streptavidin-coated microplate for analysis. 
Eighty μl of mixture containing anti-histone-biotin and anti-DNA-POD was also loaded into each 
well. The plate was tightly sealed with adhesive cover foil and incubated at room temperature for 2 
hours with gentle shaking. During the incubation, the antibody mixture bound to the histone and DNA 
components of the nucleosomes, and the immunocomplex was thus bound to the streptavidin-coated 
microplate by biotin. Unbound antibodies were removed, and the plates were rinsed 3 times with 
incubation buffer provided in the kit. ATBS (2,2-Azino bis-3-ethylbenzothiazoline-6-sulforic acid 
diammonium salt) solution was added to each well. The reaction between ATBS and POD-linked 
complex allowed color formation; therefore, the amount of apoptosis-associated nucleosomes was 
detected and quantified by measuring the absorbance value at 405 nm using a Versamax Tunable 
microplate reader (Molecular Devices). 
      
2.5.6 Cell cycle analysis 
Hela S3 cells were transfected with eIF5A1 siRNA or control siRNA as described above. At 
24, 48 and 72 hours after transfection, the medium was collected, and the cells were treated with 
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0.25% Trypsin-EDTA for one minute or until they began to detach. Detached cells were combined 
with the media collected previously, and the mixture was centrifuged at 300g for 3 minutes using an 
IEC Centra CL2 centrifuge (IEC). The cells were washed once with PBS, and then resuspended in 0.5 
ml PBS. The cell suspension was transferred into a 14 ml Corning tube (Lowell, Massachusetts. 
USA), and cells were fixed by adding with 4.5 ml ice-cold 70% (v/v) ethanol. The fixed cells were 
stored at -20 oC for up to four weeks. On the day of analysis, cells were centrifuged for 5 minutes at 
300g. Ethanol was decanted thoroughly, and the cells were resuspended in 1.5 ml PBS and allowed to 
recover by incubation at room temperature for 10 minutes. The recovered cells were spun down at 
300g for 5 minutes, resuspended in PI staining solution [40 μg/ml propidium iodide (Sigma-Aldrich) 
and 200 μg/ml RNase A ((Bioshop Canada Inc.) in PBS] at 1 x 106 cells/ml and incubated at room 
temperature in darkness for 45 minutes. The final cell suspension was pipetted through a nylon 6/6 
mesh screen cloth with 50 micron openings (Small Parts Inc., Miami lakes, Florida, USA) to remove 
large multicellular aggregates. Subsequently, the treated cells were analyzed using a BD 
FACSVantage SE system (BD Bioscience) with an argon laser source. 15,000 cells per sample were 
acquired in list mode and analyzed with WinMDI 2.8 software (Flow cytometry core facility, Purdue 
University, West Lafayette, Indiana, USA).  
 
2.5.6.1 Cell cycle arrest using GC7 
GC7, which is an inhibitor of hypusination, was used as a control for the cell cycle analysis. 
Hela S3 cells were incubated in 50 µM GC7 (Biosearch Technologies Inc., Novato, California, USA) 
in complete medium for 24, 48 or 72 hours, and then subjected to cell cycle analysis.  
 
2.6 Adenovirus studies 
2.6.1 Generation of adenovirus expressing eIF5A 
Adenovirus (Adenovirus 5 serotype, E1, E3-deleted) expressing human eIF5A1, eIF5A2 or 
eIF5A1 bearing a single point mutation (K50→A50) [eIF5A(K50A)] that inhibits hypusination were 
constructed using the AdMax™ Hi-IQ system (Microbix Biosystems Inc., Toronto, Canada) by Dr. 
Songmu Jin in Dr. Thompson’s laboratory.  
The eIF5A cDNAs were amplified by PCR using pHMeIF5A1, pHMeIF5A2 and 
pHMeIF5A1(K50A) plasmid DNAs as template and ligated into the Sma I site of the adenovirus 
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shuttle vector pDC516(μio). The sequences of the PCR primers were: forward, 5′-
GCCAAGCTTAATGGCAGATGATTTGG-3′; and reverse, 5′-
CCTGAATTCCAGTTATTTTGCCATGG-3′. The adenovirus genomic plasmid vector 
pBHGfrt(del)E1,3FLP and the shuttle vectors were propagated in Escherichia coli DH5α and purified 
using Qiagen EndoFree plasmid mega kit (Qiagen Inc., Mississauga, Ontario, Canada). 293-IQ cells 
(Microbix Biosystems Inc.) in 60 mm culture plates that were 60 to 80% confluent were transfected 
with 5 μg each of the adenovirus genomic plasmid pBHGfrt(del)E1,3FLP and shuttle vector, 
pDC516(io)-eIF5A1, pDC516(io)-eIF5A2 or pDC516(io)-eIF5A1(K50A) using the CaCl2 method 
recommended by Microbix Biosystems Inc.. Plaques appeared after 7 to 10 days of incubation at 37 
oC, and the resulting adenoviral particles [Ad-eIF5A1, Ad-eIF5A2 and Ad-eIF5A1(K50A)] were 
amplified in 293-IQ cells. Pure adenovirus stocks were prepared by CsCl gradient ultracentrifugation 
according to the protocol provided by Microbix Biosystems Inc. An adenovirus vector expressing 
LacZ (Ad-LacZ; serotype 5; E1,E3-deleted) was purchased from Qbiogene Inc. (Irvine, California, 
USA) and used as a control and reporter in these experiments. The Ad-LacZ adenovirus was 
amplified and purified in the same manner as the Ad-eIF5A1, Ad-eIF5A2 and Ad-eIF5A1(K50A) 
virus constructs. 
 
2.6.2 Induction of apoptosis by infection with adenovirus eIF5A 
In order to induce apopotosis, HT-29 or Hela S3 cells were seeded at 1 × 105 cells per well on 
a 6-well tissue culture plate and infected with adenovirus constructs the next day with 4000 plaque 
forming units per cell (pfu/cell) for HT-29 cells or 500 pfu/cell for Hela S3 cells in medium 
containing 2% FBS. Additional medium was added to the cells at four hours after infection, and the 
concentration of FBS was brought to 10%.  
 
2.6.3 DeadEnd fluorometric TUNEL assay of apoptosis 
TdT-mediated dUTP Nick-End Labeling (TUNEL) enables specific detection and 
quantitation of apoptosis within a cell population. The enzyme terminal deoxynucleotidyl transferase 
(TdT) binds to exposed 3’-OH ends of DNA fragments generated in response to apoptotic signals and 
then catalyzes the addition of fluorescein-12-dUTP which allows the direct visualization of cells 
containing fragmented DNA by fluorescence microscopy.  
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The TUNEL assay was carried out using a Promega kit and following the manufacturer’s 
instructions. HT-29 cells were seeded on an eight-chamber culture slide (Falcon, BD Biosciences, 
Mississauga, Ontario, Canada). After treatment with adenovirus eIF5A constructs to induce apoptosis, 
the medium was removed, and the cells were washed twice with PBS, fixed by incubation in freshly 
diluted 3.7% (v/v) methanol-free formaldehyde solution (Polysciences Inc., Warrington, 
Pennsylvania, USA) in PBS at 4 oC for 20 minutes, and then permeabilized in 0.2% (v/v) Triton X-
100 for 5 minutes. The cells were then equilibrated in equilibration buffer provided in the kit for 5 
minutes and then incubated in the TdT incubation buffer, which is a mixture of the equilibration 
buffer, nucleotide mixture and TdT enzyme, in a humidified environment at 37 oC for 60 minutes. 
The cells were immersed in 2 x SSC (300 mM NaCl, 30 mM sodium citrate pH 7.0) for 15 minutes at 
room temperature to terminate the reaction, and then washed three times with PBS to remove 
unincorporated fluorescein-12-dUTP. The cells were subsequently stained with 5 μg/ml Hoechst 
33358 (Sigma-Aldrich) for 10 minutes at room temperature. The slide was covered with Crystoseal 
60 (Richard-Allan Scientific, Kalamazoo, Michigan, USA) as the mounting medium, and the edge 
was sealed with clear nail polish (Revlon Canada Inc., Mississauga, Ontario, Canada). The cells were 
visualized directly by fluorescence microscopy (Carl Zeiss Canada Ltd., Toronto, Ontario, Canada) 
using a UV filter (UV-G 365, filter set 487902) to observe the nucleus and a fluorescein filter (Green 
H546, filter set 48915) to observe the apoptotic cells. Pictures were taken with a camera connected to 
the microscope, and total cells and apoptotic cells, respectively, were counted. The percentage of 
apoptotic cells was calculated by dividing the number of apoptotic cells by the total number of cells. 
 
2.6.4 Annexin V/PI assay of apoptosis 
Apoptosis was also measured using Annexin V/PI. This assay detects the translocation of the 
phospholipid, phosphatidylserine (PS), from the inner leaflet of the plasma membrane to the outer 
leaflet during the early stage of apoptosis.  
The assay was performed using the Annexin V-FITC apoptosis detection kit I (BD 
Bioscience) according to manufacturer’s instructions. In detail, after the induction of apoptosis by 
treatment with adenovirus eIF5A constructs, Hela S3 cells were detached by trypsinization, washed 
twice with cold PBS and resuspended in 1 x binding buffer provided in the kit at a concentration of 1 
x 106 cells/ml. One hundred μl of diluted cells (1 x 105 cells) were transferred to a FACs tube 
(Falcon), and mixed with 5 μl of Annexin V-FITC and 5 μl of propidium iodide (PI). The mixture 
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was incubated at room temperature for 15 minutes in the dark, and then combined with 400 μl of 1 x 
binding buffer to terminate the reaction. The cells were sorted using a BD FACSVantage SE system 
(BD Bioscience) with an argon laser source. 15,000 cells were counted for each sample. The data 
were analyzed using WinMDI 2.8 software. Unstained cells, cells stained with Annexin V-FITC 
alone (no PI), cells stained with PI alone (no Annexin V-FITC) and Actinomycin D-treated cells were 
used to set the quadrants. 
 
2.6.5 Trypan blue measurement of cell death 
For measurement of cell death using trypan blue, Hela S3 cells treated with adenovirus eIF5A 
constructs were trypsinized and resuspended in PBS at 1 - 2 x 105 cells/ml. Twenty μl of 0.5% (w/v) 
Trypan blue stain was added to each 100 μl cell suspension, and mixed thoroughly. After 3 to 5 
minutes, the cells were loaded into a hemocytometer, and stained and unstained cells, respectively, 
were counted. Cells that excluded the dye were viable, and the non-viable cells absorbed the dye and 
appeared blue. The percentage of viable cells was calculated by dividing the number of unstained 
cells by the total number of cells. 
 
2.6.6 Measurement of mitochondrial transmembrane potential following induction of apoptosis  
The induction of apoptosis can also be detected by measuring changes in mitochondrial 
transmembrane potential (∆Ψm). In the present study, DiOC6(3), a dye that permeates through the 
plasma membrane, was used to detect loss of ∆Ψm following the induction of apoptosis by treatment 
with adenovirus eIF5A constructs. At low concentration (50 to 100 nM), the dye will accumulate in 
the mitochondrial matrix under the influence of the ∆Ψm. A decrease in ∆Ψm will result in less dye 
binding to the cells, and can be detected by the measurement of fluorescence intensity using flow 
cytometry.  
Hela S3 cells treated with adenovirus eIF5A constructs were trypsinized and diluted in MEM 
containing 10% (v/v) FBS to 2 x 106 cells/ml. One μl of 1.75 x 104 nM DIOC6(3) (Sigma-Aldrich) 
was added to each 350 μl cell suspension so that its working concentration was 50 nM. The cell-dye 
mixture was protected from light and incubated at 37 oC for 20 minutes. After incubation, cells were 
washed twice with PBS, and resuspended in 500 μl of PBS. Samples were kept on ice and analyzed 
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within 1 hour using a BD FACSVantage SE system with an argon laser source. For each sample, 
15,000 cells were acquired in list mode and analyzed with WinMDI 2.8 software.  
 
2.6.7 Caspase assay  
The activation of caspases reflecting the induction of apoptosis by treatment with adenovirus 
eIF5A constructs was measured using the caspase detection kits from Calbiochem and following the 
manufacturer’s instructions. Kits that specifically target caspase 3, 8 and 9 were used in separate 
experiments. The assay is based on the fluorescenct markers, FITC-DEVD-FMK, FITC-IETD-FMK 
and FITC-LEHD, which are cell-permeable, non-toxic inhibitors that bind irreversibly to activated 
caspase 3, 8 and 9 in living cells, respectively. Cells with active caspases are easily detected by 
measuring fluorescence intensity using flow cytometry.  
Hela S3 cells, which had been treated with adenovirus eIF5A constructs to induce apoptosis, 
were trypsinized and resuspended in complete medium containing 10% (v/v) FBS at 1 x 106 cells/ml. 
Three hundred μl of cell suspension was mixed with 1 μl of FITC-DEVD-FMK, FITC-IETD-FMK or 
FITC-LEHD and incubated for 1 hour in a 37 oC incubator with 5% CO2. The cells were then 
centrifuged at 300g for 5 min, and the supernatant was removed. The cells were washed twice with 
the wash buffer provided in the kit, and finally resuspended in 300 μl of wash buffer. Samples were 
kept on ice and protected from light. The cells were sorted using a Coulter Epics XL-MCL flow 
cytometry system (Beckman Coulter Canada Inc., Mississauga, Ontario, Canada) with an argon laser 
source. For each sample, 25,000 cells were acquired in list mode and analyzed with WinMDI 2.8 
software.  
 
2.7  2-Dimensional gel electrophoresis and mass spectrometry 
2.7.1  2-Dimensional gel electrophoresis 
The post-translationally modified forms of eIF5A1 were fractionated by 2-dimensional (2D) 
gel electrophoresis and identified by Western blotting. HT-29 or Hela S3 cells were used for these 
experiments. The growth medium was removed, and the cells were washed twice with ice-cold PBS. 
Lysates were obtained by incubating the cells in cold lysis buffer [7 M Urea, 2 M Thiourea, 30 mM 
Tris, 4% (w/v) CHAPS and 1 x protease inhibitor cocktail] for 30 minutes with gentle shaking 
followed by sonication at 5 volts for 30 seconds using a Sonic Dismembrator Model 100. Debris was 
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removed by centrifugation at 14,000g for 10 minutes. Protein concentration was measured using the 
Bradford method.  
The first dimensional isoelectric focusing (IEF) was performed with an Ettan IPGphor 
Isoelectric Focusing System (Amersham Health Inc.) according to the manufacturer's instructions. 
Immobiline DryStrips (7 cm, pH 4-7; Amersham Health Inc.) were rehydrated in rehydration buffer 
[8 M Urea, 2% (w/v) CHAPS, 0.2% (w/v) DTT, 0.5% (v/v) pH 4-7 IPG buffer and 0.002% (v/v) 
Bromophenol blue] containing 5 μg or 0.3 μg of cell lysate at room temperature for 12 hours. The 
isoelectric focusing was then performed at 500 volts for 30 minutes, 1000 volts for 10 minutes, and 
2500 volts for 100 minutes. Proteins on the IPG strip gel were reduced by incubation in SDS 
equilibration buffer [50mM Tris-HCl pH 8.8, 6M Urea, 30% (v/v) Glycerol, 2% (w/v) SDS and 
0.002% (w/v) bromophenol blue] containing 10 mg/ml dithiothreitol (DTT) (Fermentas Canada Inc.) 
at room temperature for 15 minutes with gentle shaking, and then alkylated by incubation in 25 ml 
SDS equilibration buffer containing 25 mg/ml iodoacetamide (IAA) (Sigma-Aldrich) for 15 minutes 
at room temperature in the dark with gentle shaking. The IPG strip was then carefully put on top of a 
15% SDS-PAGE resolving gel and sealed with agarose sealing solution [0.5% (w/v) agarose and 
0.002% (w/v) bromophenol blue in SDS electrophoresis buffer (25mM Tris, 250mM glycine and 
0.1% (w/v) SDS)]. Proteins on the IPG strips were then separated by SDS-PAGE and transferred to a 
Hypond-P PVDF membrane (Amersham Health Inc.). The membrane was then subjected to Western 
blot analysis using specific antibody for eIF5A1 (BD Bioscience).  
 
2.7.2 Mass spectrometry 
The separated post-translationally modified forms of eIF5A1 were sequenced by Zhenyu 
Cheng from Dr. McConkey’s laboratory using mass spectrometry (MS). For this purpose, the first 
dimensional isoelectric focusing was conducted using 24 cm Immobiline DryStrips (24 cm, pH 4.5-
5.5; Amersham Health Inc.). The strips were rehydrated in rehydration buffer [8 M urea, 2% (w/v) 
CHAPS, 0.2% (w/v) DTT, 0.5% (v/v) pH 4.5-5.5 IPG buffer and 0.002% (w/v) Bromophenol blue] 
containing 400 μg of cell lysate at room temperature for 12 hours. The isoelectric focusing was 
performed at 500 volts for 1 hour, 1000 volts for 3 hours, 5000 volts for 5 hours, and 8000 volts for 
10 hours. Proteins on the IPG strip gel were then separated by SDS-PAGE.  
The 2D gels were then stained with Bio-Safe Coomassie (Bio-Rad Laboratories) for 2 hours 
and destained with water overnight with gentle shaking. Spots of interest were excised from the gel 
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and cut into 1 mm cubes. Gel pieces were washed three times for five minutes each with HPLC-grade 
water and then destained twice for 10 minutes each with 50 mM NH4HCO3/ 50% (v/v) acetonitrile 
(ACN). Gel particles were dehydrated by vortexing in 100 µl 100% (v/v) ACN for 10 minutes. 
Proteins were reduced by incubation of the gel particles in 10 mM DTT in 100 mM NH4HCO3 at 
50°C for 30 minutes, and alkylated by incubation in 55 mM IAA in 100 mM NH4HCO3 for 30 
minutes in the dark. The gel particles were then washed for 10 minutes with 100 mM NH4HCO3 and 
dehydrated again with 100 µl 100% (v/v) ACN. The gel particles were then air-dried and rehydrated 
for ten minutes in 10 µl 20 ng/µl endoproteinase solution [either trypsin or Staphylococcus aureus 
Protease V8 (GluC)] (both from Promega). Then 50 µl of 50 mM NH4HCO3 was added to the gel 
pieces, and the proteins were digested at 37 oC for 16 hours. 
The peptides produced by trypsin digestion were extracted by adding 50 µl HPLC-grade 
water and vortexing for 10 minutes. The supernatant was transferred to a collecting tube that 
contained 5 µl of 5% (v/v) formic acid (FA) in 50% (v/v) ACN. The gel particles were further 
extracted twice with 75 µl of 5% (v/v) FA in 50% (v/v) ACN and vortexing for 5 minutes. The 
supernatants from these extractions were combined with the original extraction. The volume in the 
collecting tube was reduced to 10 µl using a Speedvac. Samples were cleaned using the C-18 ZipTip 
system (Millipore, Billerica, Massachusetts, USA) followed by addition of 2 µl 1% (v/v) FA to 
protonate the peptides for mass spectrometry. 
Mass spectrometry of the peptides was performed on a Waters-Micromass Q-TOF Ultima 
Mass Spectrometer (Waters Ltd., Mississauga, Ontario, Canada) using nano-spray injection as the 
sample delivery method. Both peptide mass fingerprinting analysis and MS/MS profiling using 
PEAKS software (Bioinformatics Solutions Inc., Waterloo, Ontario, Canada) were used to obtain 
amino acid sequence data.  
 
2.8 Confocal microscopy 
Confocal microscopy was used to ascertain the subcellular localization of eIF5A1 protein 
after labeling cells with eIF5A1-specific primary antibody and FITC-labeled secondary antibody. For 
this purpose, Hela S3 cells were seeded in a glass bottom culture dish (MatTek Cooperation, Ashland 
Massachusetts) and incubated in 400 nM MitoTracker Red CMXRos (Invitrogen Canada Inc.) in 
complete medium for 45 minutes under normal growth conditions. After staining, the medium was 
removed, and the cells were washed twice with pre-warmed PBS and fixed at 37 oC for 15 minutes 
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with 3.7% (v/v) formaldehyde (Polysciences Inc.) which was freshly diluted in PBS. After the 
solvents were removed, the cells were rinsed twice with PBS and incubated for 5 minutes in PBS 
solution containing 100 mM glycine. The cell membranes were then permeabilized by incubation in 
0.2% (v/v) Triton X-100 at room temperature for 5 minutes, and the cells were washed twice with 
PBS and incubated for 1 hour at room temperature or overnight at 4 oC in anti-eIF5A1 (BD 
Bioscience), which was diluted either 1:100 or 1:250 in PBS containing 1% (w/v) BSA. After the 
primary antibody was removed, cells were washed with PBS twice and then incubated for 1 hour at 
room temperature in FITC-conjugated anti-mouse IgG (Sigma-Aldrich) diluted 1:200 in PBS. The 
cells were then washed twice with PBS, incubated in 1 μM Sytox Blue (Invitrogen Canada Inc.) at 
room temperature for 15 minutes, washed with PBS twice and covered with PBS. Samples were 
viewed using a LSM 510 META laser scanning confocal microscope (Carl Zeiss Canada Ltd.) 
equipped with Argon, Diode 405, Hene1 and Hene2 laser lines. Images were analyzed using the 





















Chapter 3 Results 
 
3.1 Role of eIF5A1 in cell proliferation and maintenance of cell viability 
3.1.1 Blocking the expression of eIF5A1 has no effect on cell proliferation or cell viability 
There are several reports indicating that eIF5A and hypusine formation are essential for the 
growth of yeast cells (Schnier et al., 1991; Kang and Hershey, 1994; Sasaki et al., 1996; Park et al., 
1998). It has also been reported for mammalian cells that inhibitors of DHS induce cell cycle arrest at 
G1 phase (Park et al., 1993b; Hanauske-Abel et al., 1994; Chen et al., 1996; Shi et al., 1996b; Tome 
and Gerner, 1997). However, the inhibitors of DHS used in these experiments are not specific for the 
DHS reaction and may affect a number of other events in cellular metabolism (Chen et al., 1996; 
Nishimura et al., 2005), and thus there is no direct evidence linking eIF5A to mammalian cell growth.  
In order to determine more definitively whether eIF5A is required for growth of mammalian 
cells, the effects on cell proliferation of siRNA specifically targeting human eIF5A1 were determined. 
HT-29 human colorectal adenocarcinoma cells were transfected with either eIF5A1 siRNA or control 
siRNA. Figure 1A illustrates that eIF5A1 expression is almost completely suppressed by 72 hours 
after transfection. At intervals of 0, 24, 48, 72, 96, and 120 hours after transfection, cell viability was 
measured using the XTT assay which depicts mitochondrial activity, and cell proliferation was 
measured using the BrdU assay which portrays DNA synthesis accompanying cell division. The 
growth curves constructed from both assays revealed that suppressing the expression of eIF5A1 using 
specific siRNA has no effect on cell proliferation or cell viability, suggesting that eIF5A1 is not 
essential for the growth of mammalian cells (Figures 1B and C).  
 
3.1.2 Blocking the expression of eIF5A1 has no effect on cell cycle progression  
To further assess the possibility that eIF5A1 is involved in cell division, the effect of eIF5A 
siRNA on cell cycle progression was examined. Hela S3 cells were transfected with eIF5A1 siRNA 
or control siRNA. Figure 2A demonstrates that eIF5A1 expression was strongly suppressed within 72 
hours. Cell cycle progression was analyzed at 24, 48 and 72 hours after transfection using PI staining. 













Figure 1:  Suppressing the expression of eIF5A1 with specific siRNA has no effect on cell 
proliferation.  
HT-29 cells were transfected with either eIF5A1 siRNA or control siRNA. eIF5A1 expression levels 
were determined at 72 hour after transfection. Cell proliferation and cell viability were measured at 0, 
24, 48, 72, 96, and 120 hours after transfection. A) Western blot probed with anti-eIF5A1 and anti-
actin. Each lane contained 5 µg of protein. Actin served as a loading control. A1: eIF5A1 siRNA- 
transfected cells; con: control siRNA-transfected cells; un: untreated. Results shown are 
representative of those obtained in 3 independent experiments. B) Determination of cell viability 
using the XTT assay. Data are expressed as percentage of the viability of cells before the transfection. 
C) Determination of cell proliferation using the BrdU assay. Data are expressed as percentage of the 
proliferation of cells before transfection. For B and C, each experiment was repeated four times, and 
the values shown are means +/- standard error. Asterisks (**) denote values determined not to be 


























Figure 2:  Suppressing the expression of eIF5A1 with specific siRNA has no effect on cell cycle 
progression.  
Hela S3 cells were transfected with either eIF5A1 siRNA or control siRNA. eIF5A1 expression levels 
were examined 72 hours after transfection. Cell cycle analysis was conducted at 24, 48 and 72 hours 
after transfection. A) Western blot probed with anti-eIF5A1 and anti-actin. Each lane contained 5 µg 
of protein. Actin served as a loading control. A1: eIF5A1 siRNA-transfected cells; con: control 
siRNA-transfected cells; un: untreated. Results shown are representative of those obtained in 3 
independent experiments. B) Flow cytometer analysis of cell-propidium iodide (PI) conjugates 
illustrating cell cycle progression. Cells were harvested at 24, 48 and 72 hours after transfection, 
stained with 40 μg/ml PI and sorted by flow cytometetry. X axis: fluorescence intensity of cell-PI 
conjugates; Y axis: relative cell number. Cells treated with 50 µM GC7 for 24, 48 and 72 hours were 
used as control. M1: apoptotic cells; M2: cells in G1/G0 phase; M3: cells in S phase; M4: cells in 















Figure 2 Suppressing the expression of eIF5A1 with specific siRNA has no effect on cell cycle progression. 
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(Figure 2B). In contrast, cells that were treated with GC7, an inhibitor of DHS, for 72 hours were 
arrested at the G1 phase (Figure 2B). This finding is consistent with previous reports that CG7 
induces cell cycle arrest at the G1 phase (Park et al., 1993b; Hanauske-Abel et al., 1994; Chen et al., 
1996; Shi et al., 1996b; Tome and Gerner, 1997). However, that suppression of eIF5A1 expression 
does not disrupt cell cycle progression suggests that the arrest at G1 is due either to an effect of GC7 
other than its ability to inhibit DHS or to the accumulation of unhypusinated eIF5A. 
 
3.2 Protection against programmed cell death by eIF5A1 siRNA  
There is accumulating evidence suggesting a regulatory role for eIF5A in apoptosis (Tome 
and Gerner, 1997; Tome et al., 1997; Caraglia et al., 1997, 1999 & 2003; Beninati et al., 1998; 
Caraglia et al., 2001; Takeuchi et al., 2002; Jin et al., 2003, Taylor et al., 2004 & 2007). In light of the 
fact that eIF5A appears to have no effect on cell proliferation (Figures 1 and 2), the possibility that 
suppression of eIF5A1 with specific siRNA could protect cells from death induced by pro-apoptotic 
stimuli was examined. 
 
3.2.1 eIF5A1 siRNA reduces SNP-induced cytotoxicity 
In one set of experiments, sodium nitroprusside (SNP), a well known nitric oxide (NO) 
donor, was used to induce apoptosis. SNP generates reactive oxygen species (ROS) during the redox 
cycling of nitroprusside, as well as NO, iron and cyanide (Ramakrishna Rao and Cederbaum, 1996). 
These products induce genotoxicity. At mM concentrations, SNP has been shown to induce apoptosis 
in various cell lines (Cui et al., 1994; Sumitani et al., 1997; Tsi et al., 2001; Olivier et al., 2005; Kwak 
et al., 2006; Gui et al., 2007; Wang et al., 2007).  
HT-29 cells were transfected with eIF5A1 siRNA or control siRNA. After 48 hours, cells 
were treated with 3 mM SNP for another 24 hours under normal conditions of growth. The XTT 
assay was then used to measure cell viability. The data indicate that, whereas SNP has cytotoxic 
effects on cells transfected with eIF5A1 siRNA or control siRNA, there is a 220% enhancement in 
viability for eIF5A1 siRNA-transfected cells compared to those transfected with control siRNA 
(Figure 3A). This corresponded with a strong reduction in eIF5A1 protein levels in eIF5A1 siRNA-













Figure 3: Suppressing the expression of eIF5A1 using specific siRNA reduces SNP- and 
Actinomycin D-induced cell death. 
A) HT-29 cells were transfected with either eIF5A1 siRNA or control siRNA. Forty-eight hours after 
transfection, the cells were treated with 3 mM SNP or 0.5 μg/ml Actinomycin D for an additional 24 
hours. Cell viability was measured using the XTT assay. The data are normalized to the value for 
untransfected cells which was set at 100%. The experiment was repeated three times, and the values 
shown here are means for the three experiments +/- standard error. Asterisks (*) denote values 
determined to be significantly different from the corresponding control values by independent t-test 
(p < 0.001). B) HT-29 cells were transfected with eIF5A1 siRNA or control siRNA. After 48 hours, 
the cells were treated with 3 mM SNP or 0.5 μg/ml of Actinomycin D for 24 hours. Cell lysates were 
collected and subjected to immunoblotting analysis using eIF5A1-specific antibody. Equal loading of 
the samples was evaluated by probing with anti-actin. A1: eIF5A1 siRNA; con: control siRNA; un: 


























3.2.2 eIF5A1 siRNA reduces Actinomycin D-induced cytotoxicity 
Actinomycin D is known to induce apoptosis by binding to DNA duplexes and repressing 
DNA replication and transcription (Clark and Ellem, 1966; Guy and Taylor, 1978; Cherry and Hsu, 
1982; Mori et al., 1984; Sobell, 1985). Accordingly, the effects of eIF5A1 on Actinomycin D-induced 
cytotoxiciy were also examined. HT-29 cells were again transfected with eIF5A1 siRNA or control 
siRNA, and 48 hours later were treated with 0.5 μg/ml Actinomycin D for 24 hours. Cell viability was 
measured using the XTT assay, and although suppression of eIF5A1 expression using specific siRNA 
did not totally block Actinomycin D-induced cytotoxicity, it enhanced cell viability by ~100% in 
comparison with cells transfected with control siRNA (Figure 3A). In addition, Western blot analysis 
showed that the protein level of eIF5A1 in eIF5A1 siRNA-transfected cells was very low in 
comparison with control cells (Figure 3B). 
 
3.2.3 eIF5A1 siRNA reduces MG-132-induced apoptosis 
MG-132 is a potent and irreversible proteasome inhibitor, and has been shown to induce 
apoptosis in several cell lines (Fujita et al., 1996; Drexler, 1997; Kitagawa et al., 1999; Wagenknecht 
et al., 1999; An et al., 2000; Naujokat et al., 2000; MacLaren et al., 2001; Sassone et al., 2006). In 
these experiments, HT-29 cells transfected with eIF5A1 siRNA or control siRNA for either 24 or 48 
hours were treated with 5 μM MG-132 for another 24 hours. Western blot analysis indicated that the 
protein level of eIF5A1 was strongly suppressed in the eIF5A1 siRNA-transfected cells (Figure 4B). 
For cells transfected with siRNA for 24 hours and then exposed to MG-132 for another 24 hours, 
there was no difference in levels of apoptosis between the eIF5A1 siRNA-transfected cells and those 
transfected with control siRNA (Figure 4A). In contrast, for cells which were transfected with siRNA 
constructs for 48 hours and then exposed to MG-132 for another 24 hours, there was about a 60% 
decrease in the percentage of apoptotic cells in samples transfected with eIF5A1 siRNA compared 
with those transfected with control siRNA (Figure 4A). Moreover, this protection correlated with 
stronger suppression of eIF5A1 protein at 72 hours than at 48 hours. These observations suggest that 

















Figure 4:  Suppressing the expression of eIF5A1 using specific siRNA reduces MG-132-induced 
apoptosis. 
A) Cells were transfected with either eIF5A1 siRNA or control siRNA. After 24 or 48 hours, the cells 
were treated with 5 μM MG-132 for another 24 hours. Apoptosis was measured by using the Cell 
Death Detection ELISA kit. Data are expressed as percentage of the value for cells transfected with 
control siRNA for 48 hours and treated with 5 μM MG-132 for an additional 24 hours. Each 
experiment was repeated four times, and the values shown are means +/- standard error for these four 
experiments. Asterisk (*) denotes value determined to be significantly different from the 
corresponding control value by independent t-test (p < 0.001). B) Immunoblotting analysis of lysates 
of the cells which were treated as in A using specific anti-eIF5A1 and anti-actin. A1: eIF5A1 siRNA; 
























3.2.4 eIF5A1 siRNA reduces serum starvation-induced stress 
The effects of serum starvation on cell cycle arrest and apoptosis have been well described 
(Cherney et al., 1994; Dahm-Daphi et al., 2000; Zolzer, 2000; Oya et al., 2003; Li et al., 2006). Since 
serum-starvation is one of the major stimulants of apoptosis, this treatment was also used to assess the 
efficacy of eIF5A1 siRNA as an agent of protection against cell death. 
 HT-29 cells were transfected with eIF5A1 siRNA or control siRNA in serum-reduced Opti-
MEM without FBS. At 6 hours after transfection, the medium was removed and replaced with RPMI 
with or without FBS. After another 66 hours, the cells were observed under a microscope. 
Untransfected cells as well as those transfected with eIF5A1 siRNA or control siRNA were cultured 
in medium containing 10% FBS and reached 100% confluence within 72 hours after transfection 
reflecting normal growth (Figure 5). In contrast, both untransfected and control siRNA-transfected 
cells cultured in medium without FBS for 72 hours did not reach confluence and were rounded and 
enlarged (Figure 5). However, eIF5A1 siRNA-transfected cells cultured in medium without FBS for 
72 hours grew normally and reached confluence (Figure 5). Indeed, there was no morphological 
difference between eIF5A1 siRNA-transfected cells cultured under conditions of serum-depletion and 
those cultured in the presence of a normal serum supplement (Figure 5). 
 
3.3 Induction of programmed cell death by up-regulation of eIF5A1 expression 
The finding in the present study that suppressing the expression of eIF5A1 with specific 
siRNA provides protection against cell death induced by a variety of pro-apoptotic stimuli supports 
the contention that eIF5A plays a role in apoptosis. In order to investigate this possibility further, the 
possibility that up-regulation of eIF5A might induce apoptosis was examined.   
 
3.3.1 Over-expression of eIF5A using adenovirus  
Adenovirus constructs of wild-type eIF5A1 (Ad-eIF5A1), mutated eIF5A1 with lysine50 
changed to alanine [Ad-eIF5A1(K50A)] and wild-type eIF5A2 (Ad-eIF5A2) were used as gene 
delivery vectors in these experiments. An adenovirus LacZ construct was used as a negative control. 
The optimization of adenovirus infection for HT-29 cells is illustrated in Figure 6. The cells 
















Figure 5: Suppressing the expression of eIF5A1 using specific siRNA reduces serum starvation-
induced cell death. 
HT-29 cells transfected with eIF5A1 siRNA or control siRNA were cultured in growth medium with 
or without 10% FBS for 72 hours. Microscopic images of the cells at the end of 72 hours culturing 
periods are illustrated. The micrographs are representative of those obtained in 3 independent 
























activity at 48 hours after infection (Figure 6C). The infection efficiency was more than 90% when the 
cells were infected with 4000 pfu/cell of adenovirus construct, and there were no apparent adverse 
effects on cell morphology at this level of infection (Figure 6C). In HT-29 cells infected with 4000 
pfu/cell Ad-eIF5A1, Ad-eIF5A1(K50A)) or Ad-eIF5A2, the protein levels of eIF5A1 or eIF5A2 were 
highly up-regulated at 48 and 72 hours after0 infection (Figure 6A). Two eIF5A antibodies were used 
in the Western blot analysis. While they were both able to recognize eIF5A1 as well as eIF5A2, anti-
eIF5A1 (BD Biosciences) appeared to interact with eIF5A1 better, and anti-eIF5A2 (Novus 
Biologicals Inc.) appeared to preferentially bind to eIF5A2 (Figure 6A).  
Another cell line, Hela S3, was also infected with different adenovirus eIF5A constructs. 
However, lower amounts of adenovirus construct were required for this cell line. Indeed, the 
transfection efficiency in Hela S3 cells reached more than 70% when the cells were infected with 500 
pfu/cell of adenovirus constructs (data not shown). The protein levels of eIF5A1 and eIF5A2 in HT-
29 cells and Hela S3 cells infected with 4000 pfu/cell and 500 pfu/cell, respectively, of adenovirus 
constructs are illustrated in Figure 6B, and it is apparent that the adenovirus infection induces strong 
up-regulation of eIF5A in both cell lines. 
  
3.3.2 Over-expression of eIF5A induces apoptosis as well as cytotoxicity in HT-29 cells 
HT-29 cells were infected with different types of adenovirus construct at 4000 pfu/cell, and 
apoptosis was measured 48 hours after infection using the TUNEL assay. Cells infected with Ad-lacZ 
served as control. Ad-eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2 all proved to be strong inducers of 
apoptosis. Within 48 hours of infection, 23%, 22% and 28% of the cells were undergoing apoptosis in 
samples infected with Ad-eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2, respectively (Figures 7 and 
8). Virtually no apoptosis was observed in cells infected with Ad-lacZ (Figures 7 and 8). 
Infection of HT-29 cells with eIF5A adenovirus constructs also induced strong cytotoxic 
effects. In these experiments, HT-29 cells were infected with different adenovirus constructs at 4000 
pfu/cell. After 4 days, cell viability was measured using the XTT assay. The viability of cells infected 
with Ad-eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2 was reduced by 77%, 77% and 80%, 















Figure 6: Infection with Ad-eIF5A1, Ad-eIF5A1(K50A) or Ad-eIF5A2 induces up-regulation of 
eIF5A expression. 
A) HT-29 cells were infected with 4000 pfu/cell of adenovirus constructs. At indicated times after 
infection, cell lysates were collected and subjected to immunoblot analysis using specific antibodies 
against eIF5A, eIF5A2 and actin. A1: Ad-eIF5A1; A1M: Ad-eIF5A1(K50A); A2: Ad-eIF5A2; Z: 
Ad-lacZ; 48: 48 hours after infection; 72: 72 hours after infection. The results shown are 
representative of those obtained in 3 independent experiments. B) Hela S3 cells and HT-29 cells were 
infected with 500 pfu/cell and 4000 pfu/cell adenovirus constructs, respectively. At 48 hours after 
infection, cell lysates were collected and subjected to immunoblot analysis using specific antibodies 
against eIF5A and actin. A1: Ad-eIF5A1; A1M: Ad-eIF5A1(K50A); A2: Ad-eIF5A2; Z: Ad-lacZ. 
The results shown are representative of those obtained in 3 independent experiments. C) HT-29 cells 
were infected with Ad-lacZ at 500, 1000, 2000 or 4000 pfu/cell. At 48 hours after infection, the cells 
were stained for β-galactosidase activity. The results shown are representative of those obtained in 3 


























Figure 7:  TUNEL labeling of HT-29 cells infected with adenovirus-eIF5A. 
HT-29 cells were infected with different types of adenovirus construct. After 48 hours, the cells were 
fixed and stained with TUNEL and Hoechst 33258. For each sample, the same field was observed by 
fluorescence microscopy using two different filters. A fluorescein filter was used to visualize TUNEL 
stained apoptotic cells (green-colored, left column); a UV filter was used to visualize nuclei (blue-
colored, right column). The results shown are representatives of those obtained in 3 independent 





























Figure 8:  Quantitation of apoptosis induced in HT-29 cells by infection with adenovirus-eIF5A. 
HT-29 cells were infected with different types of adenovirus construct. After 48 hours, the cells were 
fixed and stained with TUNEL and Hoechst 33258. For each sample, the same field was observed by 
fluorescence microscopy using two different filters. The percentage of cells undergoing apoptosis was 
calculated by dividing the number of apoptotic cells by the number of Hoechst-stained cells. Four 
different fields were randomly chosen for each experiment, and the whole experiment was repeated 
three times. Values are means +/- standard error. Asterisks (*) denote values determined to be 
significantly different from the corresponding control value (Ad-lacZ) by one-way ANOVA followed 















































Figure 9: Effect of over-expression of eIF5A on cell growth and viability. 
A) HT-29 cells were infected with different types of adenovirus construct. After 4 days, cell viability 
was measured using the XTT assay. The values for Ad-eIF5A infected cells are normalized to that for 
Ad-lacZ infected cells, which was set at 100%. Values are means +/- standard error for 3 independent 
experiments. Asterisks (*) denote values determined to be significantly different from the 
corresponding control value (Ad-lacZ) by one-way ANOVA followed by post hoc Scheffe’s test 
(p < 0.001). B) Hela S3 cells were infected with different types of adenovirus constructs. Cells were 
harvested 24, 48 and 72 hours after infection, and stained with trypan blue. The percentage of viable 
cells was calculated by dividing the number of unstained (viable) cells by total number of cells 



















3.3.3 Over-expression of eIF5A induces apoptosis as well as cytotoxicity in Hela S3 cells  
Ad-eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2 also had strong pro-apoptotic effects in Hela 
S3 cells. Cells were infected with different types of adenovirus construct at 500 pfu/cell. At intervals 
of 24, 48 and 72 hours after infection, they were harvested, stained with Annexin V-FITC/PI and 
analyzed by flow cytometry. This analysis enables quantitation of viable cells, cells at an early stage 
of apoptosis, cells at a late stage of apoptosis as well as dead cells. Representative data presented as 
dot plots are illustrated in Figure 10. The fluorescence intensity of cell-Annexin V-FITC conjugates is 
plotted on the X axis and fluorescence intensity of cell-PI conjugates on the Y axis. Quadrants were 
set using the data for unstained cells, cells stained with Annexin V-FITC alone, cells stained with PI 
alone and Actinomycin D-treated cells.  
Analysis of the dotplot data indicated that there was no induction of apoptosis in cells treated 
with Ad-eIF5A within 24 hours of infection. (Figures 10 and 11). The treatment with Actinomycin D 
served as a positive control. However by 48 hours after infection there was clear evidence of 
apoptosis for cells infected with Ad-eIF5A1, Ad-eIF5A1(K50A) or Ad-eIF5A2. Specifically, the 
proportion of cells at early and late stages of apoptosis was ~20% for Ad-eIF5A1 infected cells and 
~40% for Ad-eIF5A1(K50A)- and Ad-eIF5A2-infected cells (Figure 11). At 72 hours after infection, 
the percentage of viable cells had decreased to less than 30% for all of the Adenovirus-eIF5A-
infected cells, the percentage of cells at the early stage of apoptosis was ~12% and the percentage of 
cells at the late stage of apoptosis was about 50 to 60% (Figure 11). Interestingly, although Ad-
eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2 all proved to be potent inducers of apoptosis, the pro-
apoptotic activity of eIF5A2 appeared to be stronger than those for eIF5A1 and eIF5A1(K50A), and 
eIF5A1(K50A) appeared to be a slightly stronger inducer of apoptosis than eIF5A1 (Figure 11). It 
should be noted, however, that although the number of plaque forming units (pfu) of adenovirus used 
for infection was the same for each of the adenovirus constructs, their infection forming units (ifu) 
may be different, and this could explain the observed differences in pro-apoptotic activities of Ad-
eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2. In addition, Ad-lacZ was used as the control vector, and 
it is clear that it did not induce apoptosis in Hela S3 cells (Figures 10 and 11).  
The viability of Hela S3 cells infected with different adenovirus construct was measured by 
trypan blue-staining. Cells were infected with different types of adenovirus construct at 500 pfu/cell. 
At 24, 48, and 72 hours after infection, cells were collected and stained with trypan blue. The 
















Figure 10: Annexin V/PI staining of adenovirus-infected cells. 
Hela S3 cells were infected with adenovirus constructs as indicated. The cells were harvested at 24, 
48 and 72 hours after infection, stained with Annexin V-FITC and PI, and analyzed by flow 
cytometry. Cells treated with 0.5 μg/ml Actinomycin D served as a positive control. X axis: 
fluorescence intensity of cell-Annexin V-FITC conjugates; Y axis: fluorescence intensity of cell-PI 
conjugates. Quadrants designate the following: (1) lower left: viable cells; (2) lower right: early-stage 
apoptotic cells; (3) upper right: late-stage apoptotic cells; (4) upper left: dead cells. Results shown are 





































Figure 11: Percentages of cells sorted into quadrants by flow cytometry. 
Hela S3 cells were infected with different types of adenovirus construct. Cells were harvested at 24, 
48 and 72 hours after infection, stained with Annexin V-FITC and PI, and analyzed by flow 
cytometry. Cells treated with 0.5 μg/ml Actinomycin D served as a positive control. Quantitation of 
flow cytometric cell counts in 4 different quadrants is illustrated. UL: upper left, dead cells. UR: 
upper right, late-stage apoptotic cells. LL: lower left, viable cells. LR: lower right, early stage 
















Figure 11 Percentages of cells sorted into quadrants by flow cytometry. 
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hours after infection (Figure 9B). However, the viability decreased dramatically between 24 hours 
and 72 hours after infection in a time-dependent manner. At 72 hours, up to 80% of the cells were 
non-viable, whereas virtually 100% of the control cells infected with Ad-lacZ were viable (Figure 
9B). Cells treated with Actinomycin D served as a positive control (Figure 9B).  .  
 
3.4 Pro-apoptotic molecular targets of eIF5A 
It is clear that eIF5A1, eIF5A1(K50A) and eIF5A2 are all capable of inducing apoptosis in 
cancer cell lines. In light of this, additional studies were undertaken to identify molecular targets in 
the various pathways leading to apoptosis that are regulated by eIF5A. 
 
3.4.1 Over-expression of eIF5A induces activation of caspases 3, 8 and 9 
Activation of caspases is a well established index of apoptosis (Reviewed by Cohen, 1997; 
Nicholson, 1999). In order to determine whether Ad-eIF5A1-, Ad-eIF5A1(K50A)- or Ad-eIF5A2- 
induced apoptosis is caspase-dependent, the effects of infection with these adenovirus constructs on 
the activities of executioner caspase 3 as well as initiator caspases 8 and 9 were examined. Hela S3 
cells were infected with different types of adenovirus construct at a concentration of 500 pfu/cell. At 
48 and 72 hours after infection, cells were collected and stained with fluorescence-conjugated 
peptides specifically targeting caspase 3, caspase 8 or caspase 9.   
At 48 hours after infection, all three caspases were activated in Ad-eIF5A1-, Ad-
eIF5A1(K50A)- and Ad-eIF5A2- infected cells (Figures 12, 13 and 14). In Ad-eIF5A1 and Ad-
eIF5A1(K50A)- infected cells, up to 25% of the cells exhibited activated caspase 3, up to 30% 
exhibited activated caspase 8 and up to 25% exhibited activated caspase 9 (Figure 15). For Ad-
eIF5A2- infected cells, the incidence of activation was higher (~47%) for each of caspase 3, 8 and 9 
(Figure 15). By 72 hours after infection, 65 to 70% of cells infected with Ad-eIF5A1 or Ad-
eIF5A1(K50A) exhibited activated caspases 3, 8 and 9, and ~90% of cells infected with Ad-eIF5A2 
exhibited activated caspases 3, 8 and 9 (Figure 15). Cells treated with Actinomycin D and cells 

















Figure 12: Over-expression of eIF5A activates caspase 3. 
Hela S3 cells were infected with different types of adenovirus construct for 48 or 72 hours, or treated 
with 0.5 μg/ml Actinomycin D for 24 hours. Cells were subsequently collected, incubated with FITC-
DEVD-FMK, which is a fluorescent dye-conjugated inhibitor against caspase 3, and then analyzed by 
flow cytometry. The data are presented as histograms of FITC-DEVD-FMK-labeled cells. X axis: 
fluorescence intensity of cell-FITC-DEVD-FMK conjugates; Y axis: relative cell number. Cells with 
inactivated caspase 3 are sorted within the second log decade of the X axis, and cells with activated 
caspase 3 are sorted within the third and forth log decades. Results shown are representative of those 




























Figure 13: Over-expression of eIF5A activates caspase 8. 
Hela S3 cells were infected with different types of adenovirus construct for 48 or 72 hours, or treated 
with 0.5 μg/ml Actinomycin D for 24 hours. Cells were subsequently collected, incubated with FITC-
IETD-FMK, which is a fluorescent dye-conjugated inhibitor against caspase 8, and then analyzed by 
flow cytometry. The data are presented as histograms of FITC-IETD-FMK-labeled cells. X axis: 
fluorescence intensity of cell-FITC-IETD-FMK conjugates; Y axis: relative cell number. Cells with 
inactivated caspase 8 cells are sorted within the second log decade of the X axis, and cells with 
activated caspase 8 are sorted within the third and forth log decades. Results shown are representative 



























Figure 14: Over-expression of eIF5A activates caspase 9. 
Hela S3 cells were infected with different types of adenovirus construct for 48 or 72 hours, or treated 
with 0.5 μg/ml Actinomycin D for 24 hours. Cells were subsequently collected, incubated with FITC- 
LEHD-FMK, which is a fluorescent dye-conjugated inhibitor against caspase 9, and then analyzed by 
flow cytometry. The data are presented as histograms of FITC-LEHD-FMK-labeled cells. X axis: 
fluorescence intensity of cell-FITC-LEHD-FMK conjugates; Y axis: relative cell number. Cells with 
inactivated caspase 9 cells are sorted within the second log decade of the X axis, and cells with 
activated caspase 9 are sorted within the third and forth log decades. Results shown are representative 




























Figure 15:  Quantitation of flow cytometric data portraying activation of caspase 3, caspase 8 
and caspase 9. 
Hela S3 cells were infected with adenovirus constructs as indicated for 48 or 72 hours, or treated with 
Actinomycin D for 24 hours. Cells were collected, labeled with FITC-DEVD-FMK, FITC-IETD-
FMK or FITC-LEHD-FMK, and analyzed by flow cytometry. The data were analyzed using WinMDI 
2.8. Percentages of cells with activated caspase 3, 8 or 9 were calculated. Each experiment was 

















Figure 15 Quantitation of flow cytometric data portraying activation of caspase 3, caspase 8 and caspase 9. 
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3.4.2 Over-expression of eIF5A induces loss of mitochondrial transmembrane potential (∆Ψm) 
It is clear from the data in Figures 14 and 15 that caspase 9, which is the initiator caspase for 
the mitochondria-based apoptotic pathway, is activated in Ad-eIF5A1-, Ad-eIF5A1(K50A)- and Ad-
eIF5A2-infected cells. In an effort to further understand the involvement of eIF5A in the changes in 
mitochondria that accompany the onset of apoptosis, the possibility that up-regulation of eIF5A 
results in loss of mitochondrial transmembrane potential (∆Ψm), a well established apoptotic trait 
(Vayssiere et al., 1994; Petit et al., 1994; Zamzami et al., 1995; Marchetti et al., 1996), was examined. 
∆Ψm was measured using the membrane potential-sensitive dye, DiOC6(3). Hela S3 cells were 
infected with different types of adenovirus construct at a concentration of 500 pfu/cell. At 24, 48 and 
72 hours after infection, the cells were stained with DiOC6(3) and analyzed by flow cytometry.  
Over the entire 72 hours experimental period, the dye was retained within mitochondria in 
~98% of untreated cells and cells infected with Ad-lacZ reflecting structural integrity of the 
mitochondrial membrane system and retention of ∆Ψm (Figure 16). By 24 hours, Ad-eIF5A1-, Ad-
eIF5A1(K50A)- and Ad-eIF5A2-infected cells still exhibited normal ∆Ψm values (Figure 16A). 
However, after 48 hours of infection reductions in ∆Ψm were evident for all of the Ad-eIF5A-infected 
cells. The percentage of cells with normal ∆Ψm decreased by ~25% for Ad-eIF5A1-infected cells and 
by ~40% for Ad-eIF5A1(K50A)- and Ad-eIF5A2-infected cells (Figure 16B). By 72 hours, only 
about 50% of cells infected with Ad-eIF5A1, Ad-eIF5A1(K50A) or Ad-eIF5A2 exhibited normal 
∆Ψm (Figure 16B). Cells treated with Actinomycin D and cells infected with Ad-lacZ served as 
positive and negative controls, respectively (Figure 16).  
 
3.4.3 Over-expression of eIF5A induces release of cytochrome c 
The release of cytochrome c from mitochondria into the cytosol is an early event in the 
mitochondrial pathway of apoptosis. Once in the cytosol, cytochrome c binds to Apaf-1 to form the 
cytochrome c: Apaf-1 complex which directly induces activation of caspase 9 (Li et al., 1997; 
Srinivasula et al., 1998; Zou et al., 1999). To determine whether the effects of up-regulated eIF5A on 
mitochondria included induction of cytochrome c release, Hela S3 cells were infected with 500 
pfu/cell Ad-eIF5A1. At 7, 24, 31, 48, 55 and 72 hours after infection, cytosolic and membrane 
fractions were isolated and subjected to immunoblot analysis using specific antibody against 
cytochrome c. In untreated cells as well as in cells infected with Ad-eIF5A1 for up to 31 hours, 












Figure 16: Effect of over-expression of eIF5A on mitochondrial transmembrane potential. 
A) Hela S3 cells were infected with different types of adenovirus construct. At intervals of 24, 48 and 
72 hour after infection, cells were collected and incubated in growth medium containing 50 nM 
DiOC6(3) for 45 minutes at 37 oC in a humidified chamber. The cells were then analyzed by flow 
cytometry. X axis: fluorescence intensity of cell-DiOC6(3) conjugates; Y axis: relative cell number. 
Cells with normal mitochondrial transmembrane potential register within the third and forth log 
decade of the X axis, whereas cells with decreased mitochondrial transmembrane potential register 
within the first and second log decade. Cells treated with Actinomycin D or infected with Ad-lacZ 
served as positive and negative controls, respectively. Results shown are representative of those 
obtained in 4 independent experiments. B) Quantitation of flow cytometric data illustrating changes 
in mitochondrial transmembrane potential following infection with different types of adenovirus 
construct. Cells treated with Actinomycin D or infected with Ad-lacZ served as positive and negative 
controls, respectively. Each experiment was repeated 4 times, and the results shown are means +/- 











Figure 16  Effect of over-expression of eIF5A on mitochondrial transmembrane potential. 
 
  101
mitochondrial intermembrane space (IMS) (Figure 17). However, by 48 hours after infection 
translocation of cytochrome c from the mitochondria to the cytosol was evident, and after 55 hours 
there were almost equal proportions of cytochrome c in the membrane fraction and in the cytosol 
(Figure 17).  
 
3.4.4 Over-expression of eIF5A induces translocation of Bax 
Bax, which is a pro-apoptotic Bcl-2 family protein, usually resides as a monomer in the 
cytosol and, to a lesser extent, loosely associates with the mitochondrial outer membrane (Suzuki et 
al., 2000; Schinzel et al., 2004). In response to some apoptotic stimuli, Bax forms oligomers and 
translocates to the mitochondrial outer membrane (Schinzel et al., 2004). To determine whether 
eIF5A influences Bax migration, Hela S3 cells were infected with Ad-eIF5A1 at 500 pfu/cell. 
Cytosolic and membrane fractions were isolated at 7, 24, 31, 48, 55 and 72 hours after infection and 
subjected to Western blot analysis using specific antibody against Bax. In keeping with the 
established cytosolic localization of Bax in cells that are not undergoing apoptosis (Suzuki et al., 
2000; Schinzel et al., 2004), in untreated cells most of the Bax protein was localized in the cytosol, 
with only a small amount located in the membrane fraction (Figure 17). However, within 24 hours of 
infection with Ad-eIF5A1 there was clear evidence for migration of Bax from the cytosol to the 
membrane fraction, and by 31 hours after infection, there were almost equal proportions of Bax in the 
cytosol and in the fraction containing mitochondria (Figure 17). By 48 hours after infection, almost 
all of the Bax protein was associated with the membrane fraction (Figure 17). 
 
3.4.5 Effects of eIF5A over-expression on other proteins of the Bcl-2 family 
Other members of the Bcl-2 family of proteins are also known to be involved in apoptosis 
(Reviewed by Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003). Accordingly, the 
effects of eIF5A up-regulation on levels of the Bcl-2 proteins, Bid, Puma, Bim, Bad as well as Bax 
were examined. Specifically, Hela S3 cells were infected with Ad-eIF5A1, Ad-eIF5A1(K50A), Ad-
eIF5A2 and Ad-lacZ, which served as a negative control. Cell lysates were harvested at 24, 48 and 72 
hours after infection and subjected to Western blot analysis using antibodies for Bid, Puma, Bim, Bad 
and Bax. Bim, a pro-apoptotic BH3-only Bcl-2 family protein, was up-regulated within 48 hours in 















Figure 17:  Over-expression of eIF5A1 induces translocation of cytochrome c and Bax.  
Hela S3 cells were infected with 500 pfu/cell of Ad-eIF5A1. At the indicated times after infection, 
cytosolic and membrane fractions were isolated, and the proteins were fractionated by SDS-PAGE 
and analyzed by Western blotting using anti-cytochrome c and anti-Bax. Each lane was loaded with 5 
μg of protein. Equal loading of the samples was evaluated by blotting the membrane with antibody 
for Actin. C: cytosolic fraction; M: membrane fraction containing mitochondria. Results shown are 






















there was also induction of the alternative splicing forms of Bim (Figure 18). However, Bid and 
Puma, which are also pro-apoptotic BH3-only proteins, were down-regulated in Ad-eIF5A1-, Ad-
eIF5A1(K50A)- and Ad-eIF5A2-infected cells (Figure 18). Moreover, cleaved Bid was not observed 
(Figure 18) indicating that eIF5A-induced activation of caspase 8 does not directly lead to activation 
of the intrinsic apoptotic pathway. No significant changes in the levels of Bad were apparent 
following infection (Figure 18). Nor was there a change in the level of Bax (Figure 18) 
notwithstanding the fact that up-regulation of eIF5A induced migration of Bax from the cytosol to 
mitochondria (Figure 17). However, it has been suggested previously that the localization of Bax on 
the mitochondrial outer membrane is in itself sufficient to induce mitochondrial outer membrane 
permeabilization (Jurgensmeier et al., 1998; Marzo et al., 1998; Narita et al., 1998; Shimizu et al., 
1999; Tikhomirov and Carpenter, 2005). 
 
3.4.6 Over-expression of eIF5A2 induces up-regulation of cleaved Bcl-2 
The effects of eIF5A2 on levels of Bcl-2, which is a pro-survival member of the Bcl-2 family, 
were also examined in Hela S3 cells. In light of the apparent pro-apoptotic effect of eIF5A, one might 
have expected a down-regulation of Bcl-2 following infection with Ad-eIF5A. However, the basal 
level of Bcl-2 proved to be very low even in untreated Hela S3, and this precluded any assessment of 
down-regulation (Figure 19). This notwithstanding, there was a strong up-regulation/induction of a 
cleaved form of Bcl-2 in Ad-eIF5A2-infected cells. This cleaved Bcl-2 was weakly expressed at 24 
hours after infection, and strongly upregulated in a time-dependent manner thereafter (Figure 19). 
Furthermore, there was a slight change in its size between 31 and 48 hours after infection. In addition, 
this cleaved Bcl-2 was only induced in Ad-eIF5A2-infected cells, not in Ad-eIF5A1-, Ad-
eIF5A1(K50A)- or Ad-lacZ-infected cells. Nor was it apparent in cells treated with Actinomycin D 
(Figure 19). 
 
3.4.7 Over-expression of eIF5A induces up-regulation of p73, a homolog of p53 
The tumor suppressor gene, p53, is one of the most important oncogenes discovered to date. 
It is activated in the event of DNA damage-induced apoptosis, and it also protects normal cells by 
induction of cell cycle arrest and DNA repair (Reviewed by Fuster et al., 1997; Sionov and Haupt, 















Figure 18: Effect of the over-expression of eIF5A on p53 and pro-apoptotic Bcl-2 family 
proteins. 
Hela S3 cells were infected with different types of adenovirus construct. At the indicated times after 
infection, cell lysates were collected and subjected to Western blot analysis for p53, Bid, Puma, Bim, 
Bax, and Bad. Each lane contained 7 μg of protein. Equal loading was evaluated by blotting the 
membrane with antibody for Actin. A1: Ad-eIF5A1; M: Ad-eIF5A1(K50A); A2: Ad-eIF5A2; Z: Ad-





































Figure 19: Over-expression of eIF5A2 induces cleaved Bcl-2 protein. 
A) Hela S3 cells were infected with different types of adenovirus construct. Cell lysates were 
harvested at indicated times and subjected to Western blot analysis for Bcl-2. Each lane contained 7 
μg of total cellular protein. Results shown are representative of those obtained in 3 independent 
experiments. B) Hela S3 cells were either treated with Actinomycin D for 24 hours or infected with 
500 pfu/cell of Ad-eIFA2. Cell lysates were harvested at indicated times and subjected to immunoblot 
analysis using antibodies for Bcl-2. Equal loading of the samples was evaluated by blotting the 
membrane with antibody for Actin. Un: untreated; ActD: treated with Actinomycin D for 24 hours. 



























p53 alleles and p53 mRNA is translationally active in Hela cells, their basal level of p53 is very low, 
and thus p53 is effectively inactive (Scheffner et al., 1991). This reflects the fact that Hela cells are 
transformed with human papillomavirus (HPV) whose E6 gene product interacts with p53, resulting 
in its rapid degradation through the ubiquitin-proteasome pathway (Scheffner et al., 1990; Liang et 
al., 1993 & 1995; Thomas et al., 1996; Song et al., 1998; Talis et al., 1998). As a clonal derivative of 
Hela cells, Hela S3 cells also contain functionally inactive p53 (Bai et al., 2004). 
To evaluate the effect of eIF5A up-regulation on p53 and its homologs, Hela S3 cells were 
infected with different types of adenovirus constructs and subjected to Western blot analysis using 
polyclonal antibody against p53 at 24, 48 and 72 hours after infection. The level of p53 was low and 
remained essentially unchanged during apoptosis induced by the over-expression of eIF5A1, 
eIF5A1(K50A) or eIF5A2 (Figure 18). However, there was strong up-regulation of a protein with a 
MW of about 70 to 80 kDa in Ad-eIF5A1- and Ad-eIF5A1(K50A)-infected cells (Figure 18). This 
protein is deemed to be p73, which has high homology with p53, inasmuch as the p53 antibody used 
in this analysis is polyclonal and very likely to cross-react with p73. There are two alternatively 
spliced p73 mRNA isoforms, giving rise to p73α (full length form; MW ~80 kDa) and p73β (shorter 
from; MW ~70 kDa) (Kaghad et al., 1997; Marin et al., 1998). Assuming this tentative identification 
of the protein is correct, the data in Figure 18 indicate that p73α and β were highly up-regulated in 
Ad-eIF5A1-infected cells at 72 hours after infection and in Ad-eIF5A1(K50A)-infected cells at 48 
and 72 hours after infection. (Figure 18). 
 
3.5 Post-translationally modified forms of eIF5A 
eIF5A is post-translationally modified by two enzymes, deoxyhypusine synthase (DHS) and 
deoxyhypusine hydroxylase (DHH), which mediate the formation of deoxyhypusinated eIF5A and 
hypusinated eIF5A, respectively. Specifically, lysine50 is converted to deoxyhypusine by DHS, which 
in turn is converted to hypusine by DHH (Maoka and Nakajima, 1973; Park et al., 1981, 1982 & 
1988; Abbruzzese et al., 1986 & 1988; Wolff et al., 1990). In light of this, a series of experiments 
were conducted to determine whether the pro-apoptotic activity of eIF5A is attributable to a specific 




3.5.1 Over-expression of eIF5A1(K50A) induces an accumulation of lysine50 eIF5A 
eIF5A is the only protein known to contain the unique amino acid, hypusine (Cooper et al., 
1983). Hypusine-containing eIF5A is essential for the growth of yeast (Schnier et al., 1991; Sasaki et 
al., 1996; Park et al., 1998). For mammalian cells, there are reports that inhibition of hypusine 
formation induces cell cycle arrest as well as apoptosis (Park et al., 1993b; Hanauske-Abel et al., 
1994; Chen et al., 1996; Shi et al., 1996b; Tome and Gerner, 1997). In order to determine whether 
apoptosis induced by the over-expression of eIF5A1 is associated with hypusine modification, 2-
dimensional (2D) electrophoresis combined with Western blot analysis was used to resolve the 
different post-translationally modified forms of eIF5A1 protein.  
Initially, cell lysates of untreated cells, cells treated with GC7, an inhibitor of DHS which 
mediates the first step in the hypusine modification, and cells treated with DFO, an inhibitor of the 
enzyme DHH which mediates the second step in the hypusine modification, were analyzed in order to 
identify tentatively the post-translationally modified forms of eIF5A in the 2D Western blot. Three 
spots of eIF5A1 with different pI values were observed (Figure 20). Based on the effects of the 
inhibitors on the relative levels of the eIF5A spots, the one on the right (spot C) was tentatively 
designated as hypusine-containing eIF5A1; the one on the left (spot A) was tentatively designated as 
eIF5A1 with unmodified lysine50; and the one in the middle (spot B) was tentatively designated as 
deoxyhypusine-containing eIF5A. In cells treated with DHS or DHH inhibitor, although there was the 
expected accumulation of unmodified and deoxyhypusine-containing eIF5A, respectively, the amount 
of hypusine-containing eIF5A was almost the same as in untreated cells (Figure 20). This presumably 
reflects the long half-life of hypusinated eIF5A protein, which has been shown to be more than seven 
days in mouse mammary carcinoma FM3A cells (Nishimura et al., 2005) and to be very long as well 
in CHO and JURKAT T-cells (Torrelio et al., 1987; Bergeron et al., 1998). In Ad-eIF5A1(K50A)- 
infected cells, there was an accumulation of lysine50-unmodified eIF5A1 (spot A) (Figure 20), which 
is consistent with the fact that this mutated form of eIF5A1 is incapable of interacting with DHS. 
However, in Ad-eIF5A1-infected cells there was a large accumulation of both lysine50-unmodified 
eIF5A1 (spot A) and deoxyhypusine-containing eIF5A1 (spot B) (Figure 20). At face value and 
assuming the tentative identities of these spots are correct, this suggests that the high levels of eIF5A 















Figure 20: Ad-eIF5A1 and Ad-eIF5A1(K50A) induce over-expression of unhypusinated eIF5A1. 
HT-29 cells were infected with Ad-eIF5A1 or Ad-eIF5A1(K50A), and cell lysates were harvested 48 
hours after infection. Lysates of untreated cells, cells treated for 72 hours with 50 µM GC7, an 
inhibitor of DHS, and cells treated for 72 hours with 500 µM DFO, an inhibitor of DHH, were also 
collected. The lysates were fractionated by 2D electrophoresis and subjected to immunoblot analysis 
using specific antibody against eIF5A1. For both Ad-eIF5A1- and Ad-eIF5A1(K50A)-infected cells, 
0.3 μg of proteins was loaded onto pH 3-10 7 cm Immobiline DryStrips for the first dimension 
separation by isoelectric focussing; for the other cell lysates, 5 μg of protein was loaded onto the 
DryStrips. A: acidic form (tentatively identified as lysine50-containing eIF5A); B: intermediate form 
(tentatively identified as deoxyhypusine-containing eIF5A); C: basic form (tentatively identified as 























3.5.2 HA-tagged eIF5A1 is not hypusinated in vitro 
That eIF5A1(K50A) is able to induce apoptosis as effectively as wild-type eIF5A1 suggests 
that eIF5A1-lysine50 is the form of eIF5A that exhibits pro-apoptotic activity. Pertinent to this is the 
fact that, using the plasmid, pHMeIF5A1, Dominic Cliché from Dr. Thompson’s laboratory found 
that expression of HA-tagged eIF5A1 in human colorectal carcinoma RKO cells also induced 
apoptosis (unpublished data). Indeed, this finding raised the possibility that the HA-tag prevents 
hypusination of eIF5A1.   
In order to determine whether HA-tagged eIF5A1 protein is, in fact, incapable of being 
hypusinated, cells transfected with pHMeIF5A1 were labeled with [3H]-spermidine which gives rise 
to [3H]-eIF5A during the hypusination reaction. Only hypusine-containing eIF5A can be labeled by 
[3H]-spermidine since it is the only known protein to be modified by a structural contribution from 
spermidine (Clement et al., 2003). COS-7 cells were used for these experiments because they contain 
the SV40 T antigen that allows for episomal replication, and hence high expression, of pHM6 
constructs containing the SV40 origin of DNA replication. Cells were transfected with pHMeIF5A1, 
pHMeIF5A1(K50A) or pHMlacZ6 (Figure 21), and then incubated in medium containing [3H]-
spermidine. During hypusination, the 4-aminobutyl moiety of [3H]-spermidine is transferred to the 
lysine50 residue of eIF5A1 by deoxyhypusine synthase (DHS), thereby labeling eIF5A1. At intervals 
of 48 and 72 hours after the introduction of [3H]-spermidine, total cellular proteins were isolated and 
separated by SDS-PAGE. The fractionated proteins were visualized by autoradiography and also 
subjected to Western blot analysis using specific antibodies against eIF5A1 and HA. When the 
autoradiograms and the immunoblots for eIF5A1 and HA were aligned, it was clear that endogenous 
eIF5A1, but not trans-HA-tagged eIF5A1, was labeled (Figure 22A).  
At face value, this can be interpreted as indicating that DHS does not react with HA-tagged 
eIF5A1 and that the HA-tagged protein does not become hypusinated. However, there are other 
possible interpretations. The result could, for example, reflect degradation of [3H]-spermidine in the 
cells by diamine oxidase (DAO) (Holtta et al., 1975) or inadequate protein loading of the gel resulting 
in a radiolabeled signal that was not strong enough to be detected. To eliminate these possibilities, 
after the cells were transfected with pHMeIF5A1 plasmid, aminoguanidine (AG), which is a specific 
and highly effective inhibitor of DAO (Gahl and Pitot, 1978), was added to the growth medium. In 
addition to its inhibitory effect on the degradation of spermidine, AG also completely inhibits serum-















Figure 21:  Maps of vectors used to express eIF5A1.  
Human eIF5A1 and eIF5A1(K50A) were cloned between the Hind III and Eco RI sites of the empty 
pHM6 vector (A), generating pHMeIF5A1 and pHMeIF5A1(K50A) (C), respectively, with 
hemagglutintin (HA) tagged at the N-terminus. pHMlacZ6 (B), which contains an N-terminal HA 
epitope and a C-terminal His6 tag, was used as the control vector. BGH pA, BGH polyadenylation 
signal; f1 ori, f1 origin; SV40 ori, SV40 promoter and origin; Neomycin, Neomycin-resistance gene; 
SV40 pA, SV40 polyadenylation signal; Col E1, Col E1 origin; Ampicillin, Ampicillin-resistance 





















Figure 22:  HA-tagged eIF5A1 is not hypusinated in COS-7 cells. 
A) COS-7 cells were transfected with pHMeIF5A1, pHMeIF5A1(K50A) or pHMlacZ6 using 
electroporation and then incubated in complete medium containing 40 μCi/ml [3H]-spermidine. Cell 
lysates were harvested 48 hours after transfection and proteins were fractionated by SDS-PAGE. 
[3H]-labeled eIF5A1 was visualized by autoradiography. Endogenous and exogenous eIF5A1 were 
detected by incubating the same membrane with specific antibodies against eIF5A1 and HA, 
respectively. Lane 1: untreated; Lane 2: pHMeIF5A1; Lane 3: pHMeIF5A1(K50A); Lane 4: 
pHMlacZ6. Results shown are representative of those obtained in 3 independent experiments. B) 
Cells were transfected with pHMeIF5A1 using electroporation and then incubated in complete 
medium containing 40 μCi/ml [3H]-spermidine and 1 mM aminoguanidine. At 48 hours (Lane 1) and 
72 hours (Lane 2) after transfection, cell lysates were harvested and immunoprecipitated using 
specific antibody against eIF5A1. The IP products were fractionated by SDS-PAGE. [3H]-labeled 
eIF5A1 was visualized by autoradiography. Endogenous and exogenous eIF5A1 were detected by 
incubating the same membrane with specific antibodies against eIF5A1 and HA, respectively. Results 












Figure 22 HA-tagged eIF5A1 is not hypusinated in COS-7 cells. 
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1983). As well, after the cell lysates were harvested, they were subjected to immunoprecipitation (IP) 
using specific antibody for eIF5A1 to concentrate both endogenous and exogenous eIF5A1 proteins. 
The IP product was in turn fractionated by SDS-PAGE, and the gel was then subjected to 
autoradiography and to immunoblotting using antibodies for eIF5A1 and HA. In this case as well, 
HA-tagged eIF5A1 was not labeled by tritium, while endogenous eIF5A1 was strongly labeled 
(Figure 22B).  
There are two possible reasons why HA-tagged eIF5A1 is not hypusinated. First, addition of 
the HA-tag to the N-terminus of eIF5A1 may inhibit its interaction with DHS by masking, or 
rendering inaccessible, its DHS-binding site. Alternatively, the HA-tag may simply reduce the affinity 
of eIF5A1 for DHS and, by doing so, render HA-tagged eIF5A1 unable to compete successfully with 
endogenous eIF5A1 for a limited amount of DHS.   
 
3.5.3 Lysine50-containing eIF5A accumulates during SNP-induced apoptosis 
With a view to further testing the possibility that it is the lysine50-containing form of eIF5A 
that induces apoptosis, levels of the post-translationally modified forms of the protein in cells induced 
to undergo apoptosis by treatment with SNP, a source of NO, were examined. HT-29 cells were 
treated with 3 mM SNP. Total cell proteins were harvested 0.5, 1, 3.5, 6 and 24 hours later and 
subjected to 2D electrophoresis and Western blot analysis using eIF5A1-specific antibody. In the 
untreated cells, all of the eIF5A1 is in the form tentatively identified as hypusine-containing eIF5A1 
(spot C), which is consistent with the contention that this form of eIF5A is not involved in the 
induction of apoptosis (Figure 23). Within 0.5 hours of treatment,  deoxyhypusine-containing eIF5A1 
(tentatively identified as spot B) began to accumulate, and within 3.5 hours there was also an 
accumulation of the spot tentatively identified as lysine50-containing eIF5A (spot A) (Figure 23). This 
trend continued through 6 hours after treatment (Figure 23). These results are consistent with the 
contention that lysine50-containing eIF5A1 is able to induce apoptosis, but don’t rule out a role for 



















Figure 23: Lysine50-containing eIF5A1 accumulates after treatment with SNP. 
HT-29 cells were treated with 3 mM SNP. Cell lysates were harvested at indicated times after the 
treatment and fractionated by 2D electrophoresis. The corresponding Western blot probed with anti-
eIF5A1 is illustrated. A: acidic form (tentatively identified as lysine50-containing eIF5A); B: 
intermediate form (tentatively identified as deoxyhypusine-containing eIF5A); C: basic form 
(tentatively identified as hypusine-containing eIF5A). The results shown are representative of those 




















3.6 Identification of post-translationally modified forms of eIF5A1 by mass 
spectrometry  
The post-translationally modified forms of eIF5A1 separated by 2D electrophesis were 
tentatively identified by Western blot analysis of changes in their relative levels in response to 
inhibitors of DHS and DHH and following transfection with eIF5A1(K50A), which is incapable of 
reacting with DHS. In order to obtain a more definitive identification, the separated spots reacting 
with eIF5A1 antibody in the 2D Western analysis were sequenced by MS and Tandem MS (MS/MS). 
This allowed identification of the post-translationally modified forms of eIF5A1 because the MS/MS 
fragmentation portrays weight differences between modified and unmodified amino acids. The mass 
spectrometry was performed by Zhenyu Cheng from Dr. McConkey’s laboratory. 
 
3.6.1 Lysine47 and lysine50 of eIF5A1 are both post-translationally modified   
Hela S3 cell lysates were fractionated by 2D gel electrophoresis in preparation for mass 
spectrometric analysis. Representative gels stained with Coomassie blue for untreated Hela S3 cells 
and for Hela S3 cells infected with Ad-eIF5A1 for 48 hours are illustrated in Figure 24. eIF5A1 
proteins are approximately 18 kDa in size and have a pI of ~5 (Park, 1988; Klier et al. 1995). Three 
proteins resolved in the 2D gels with molecular weights of ~18 kDa and pIs of 4.9, 5.0 and 5.1 
(indicated by white arrows in Figure 24) were identified as eIF5A1 proteins by probing corresponding 
Western blots with anti-eIF5A1 (Figure 24). These proteins were cut out of the gels, and their identity 
as post-translationally modified forms of eIF5A1 was confirmed by mass spectrometry (Table 1 and 
Figure 25). In addition, however, MS and Tandem MS (MS/MS) revealed that lysine47 and lysine50 of 
eIF5A1 are both post-translationally modified. Lysine47 becomes acetylated, and lysine50 is converted 
to either deoxyhypusine or hypusine (Figure 25).  
In untreated cells, the spot at pI 5.1 (designated as the basic form) was the most abundant 
eIF5A1 protein (Figures 24A and C). It was also present in Ad-eIF5A1-infected cells, but much less 
abundant (Figures 24B and C). Mass spectrometry of this protein revealed that lysine50 is hypusinated, 
whereas lysine47 is unmodified (Figure 25E). The identification score for this form of eIF5A1 was 
















Figure 24: 2-Dimensional gel electrophoresis of Hela S3 cell lysates. 
Lysates of untreated Hela S3 cells (A) and Hela S3 cells infected with Ad-eIF5A1 for 48 hours (B) 
were harvested and fractionated by 2D electrophoresis. The gels were then stained with Coomassie 
blue. Protein spots indicated by white arrows were cut out of the gels and sequenced by mass 
spectrometry. The results shown are representative of those obtained in 3 independent experiments. 
(C) Protein spots indicated by white arrows in A and B were identified as eIF5A1 in corresponding 
Western blot probed with anti-eIF5A1. A: acidic form (tentatively identified as lysine50-containing 
eIF5A); B: intermediate form (tentatively identified as deoxyhypusine-containing eIF5A); C: basic 
form (tentatively identified as hypusine-containing eIF5A). The results shown are representative of 


















Table 1: Mass spectrometric identification of different isoelectric forms of eIF5A1 in Hela S3 
cells. 
* Identification scores are the number of PEAKS analysed using the MS/MS data from trypsin digests 
only.  


























Table 1  Mass spectrometric identification of different isoelectric forms of eIF5A1 in Hela S3 
cells. 
 pI Identification score* Sequence Coverge** 
Acidic form in Ad-eIF5A1- 
infected cells 
4.9 100% 100% 
Intermediate form in Ad-eIF5A1-
infected cells 
5.0 100% 100% 
Intermediate form in  
untreated cells 
5.0 94% 70% 
Basic form in both Ad-eIF5A1-
infected and untreated cells 























Figure 25: MS identification of the post-translational modification of lysine47 and lysine50 of 
eIF5A1 in Hela S3 cells. 
The modifications of lysine47 and lysine50 were identified by MS (panels C, D and E) or Tandem MS 
(MS/MS) (panels A and B). A) Spectrum of the acidic form of eIF5A1 isolated from Ad-eIF5A1-
infected cells (pI 4.9) illustrating that lysine47 is acetylated, and that lysine50 is unmodified. B and D) 
Spectra of the intermediate form of eIF5A1 (pI 5.0) isolated from untreated cells illustrating that it is 
a mixture of two different eIF5A1 proteins: one with lysine47 acetylated and lysine50 
deoxyhypusinated; the other with lysine47 acetylated and lysine50 hypusinated. C) Spectrum of the 
intermediate form of eIF5A1 (pI 5.0) isolated from Ad-eIF5A1-infected cells illustrating that neither 
lysine47 nor lysine50 is modified. E) Spectrum of the basic form of eIF5A1 (pI 5.1) present in both 
untreated and Ad-eIF5A1-infected cells illustrating that lysine47 is unmodified and lysine50 is 
hypusinated. AcetK: acetylated lysine; HypuK: hypusinated lysine; DeHyK: deoxyhypusinated 
lysine; OxeM: oxidized methionine. X axis: ratio of mass to charge; Y axis: intensity relative to 











Figure 25 MS identification of the post-translational modification of lysine 47 and lysine50 of eIF5A1 in Hela S3 cells. 
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The eIF5A1 proteins migrating to pI 4.9 and pI 5.0 were most abundant in Ad-eIF5A1-
infected cells (Figures 24B and C). These two spots were designated as the acidic form and the 
intermediate form, respectively. For the acidic form (pI 4.9), the identification score was 100%, and 
the sequence coverage was also 100% (Table 1). Analyses of the spectra for this protein indicated that 
lysine47 is acetylated, and that lysine50 is unmodified (Figure 25A). For the intermediate form (pI 5.0) 
isolated from Ad-eIF5A1-infected cells, the identification score was 100%, and sequence coverage 
was also 100% (Table 1), and in this case neither lysine47 nor lysine50 is modified (Figure 25C). For 
the intermediate form (pI 5.0) isolated from untreated cells, the identification score was 94% and the 
sequence coverage 70% (Table 1). However in this case there is a mixture of two different eIF5A1 
proteins: one with lysine47 acetylated and lysine50 deoxyhypusinated; the other with lysine47 
acetylated and lysine50 hypusinated (Figures 25B and D).  
The post-translational modifications of lysine47 and lysine50 are summarized in Table 2. 
 
3.6.2 Post-translational modification of other amino acid residues of eIF5A1 
The mass spectrometric analysis indicated that for all of the isoelectric forms of eIF5A1 the 
starting methionine residue was cleaved, and the second alanine residue was acetylated (Figure 26A 
and Table 2). Since the first methionine is cleaved after translation, it is important to clarify that the 
numbering of amino acids used in this study is based on the amino acid sequence inferred from the 
cDNA sequence, with methionine in position 1. These modifications have been reported previously 
(Klier et al. 1995). Of particular interest, however, is the finding of an additional novel post-
translation modification in the endo-proteinase digest which has not been previously reported. 
Specifically, for all of the isoelectric forms of eIF5A1, the asparagine residue at position 28 is 
deamidated (Figure 26 and Table 2). The deamidation of asparagine to aspartic acid or iaoaspartic 
acid is a two-step process involving a succinimide intermediate (Robinson and Rudd, 1974; Geiger 
and Clarke, 1987; Stephenson and Clarke, 1989). However, it is not possible to differentiate between 
aspartic acid and iaoaspartic acid by MS because their masses are identical (Schindler et al., 1996; 
Gonzalez et al., 2000; Lehmann et al., 2000; Luu et al., 2004; Cournover et al., 2005). Based on the 
intensities, the majority (70 to 85%) of peptides in the endo-proteinase digest contained aspartic acid 
or isoaspartic acid, and peptides containing the succinimide intermediate were also detectable 

















Figure 26: Post-translational modifications of other amino acids in eIF5A1 revealed by MS/MS. 
A) Spectrum illustrating acetylation of the N-terminal alanine. B) Spectrum illustrating modification 
of asparagine28 to a succinimide intermediate. C) Spectrum illustrating deamidation of asparagine28 to 
aspartic acid or isoaspartic acid. AcetylA: Acetylated alanine. SuccN: succinimide intermediate. 











































Table 2: Summary of the post-translational modifications of human eIF5A1. 
“—”: no modification.  A2: alanine at position 2; N28: asparagine at position 28; K47: lysine at 





















Table 2  Summary of the post-translational modifications of human eIF5A1. 
Residues 
Forms 
pI A2 N28 K47 K50 
Acid form in Ad-eIF5A1-
infected cells 
4.9 Acetylation Deamidation Acetylation — 
Intermediate form in Ad-
eIF5A1-infected cells 
5.0 Acetylation Deamidation — — 
Intermediate form in  
untreated cells 
5.0 Acetylation Deamidation Acetylation 
Hypusination or 
deoxyhypusination 
Basic form in both Ad-eIF5A1-
infected and untreated cells 












3.7 The subcellular localization of eIF5A  
Immunofluorescence staining and confocal microscopy of untreated Hela S3 cells indicated 
that eIF5A1 is mainly localized in the cytoplasm (Figure 27). Human eIF5A1 antibody and FITC-
conjugated anti-mouse IgG were used to label eIF5A, MitoTracker Red CMXRos to label 
mitochondria, and Sytox blue to label nucleic acids (Figure 27C). In addition, cells were stained only 
with human eIF5A1 antibody and FITC-conjugated anti-mouse IgG to show that the staining of 
mitochondria and nucleic acids did not affect the location of eIF5A1 (Figure 27A). Cells were also 
stained only with FITC-conjugated anti-mouse IgG to show that the FITC-labeled proteins were truly 
eIF5A (Figure 27B).   
Localization of eIF5A1 in the cell cytoplasm has been observed previously for both 
mammalian cells and yeast (Shi et al., 1996a & 1997; Valentini et al., 2002; Cracchiolo et al., 2004). 
However, when Hela S3 cells were infected with Ad-eIF5A1 or Ad-eIF5A1(K50A) to induce 
apoptosis, this localization changed. Specifically, although eIF5A1 was still in the cytoplasm, there 
was a distinct clustering of the protein in the vicinity of the plasma membrane within 24 hours of 
infection (Figure 28). By 48 hours after infection with Ad-eIF5A1 or Ad-eIF5A1(K50A), the 
clustering of eIF5A1 protein at the plasmalemma was more pronounced (Figure 29), whereas the 
localization pattern in cells infected with Ad-lacZ was indistinguishable from that for untreated cells 
(Figures 28 and 29).  
It was not possible to distinguish between endogenous eIF5A1 and transgenic eIF5A1 in 
confocal microscopic images of cells infected with Ad-eIF5A1 or Ad-eIF5A1(K50A). Accordingly, 
the localization of eIF5A1 in Hela S3 cells induced to undergo apoptosis by treatment with 
Actinomycin D was also examined. The cells were treated with 0.5 μg/ml Actinomycin D for 12, 18 
or 24 hours, and then stained to label eIF5A1, mitochondria and nucleic acids. Only endogenous 
eIF5A1 was present is these cells, and there was clear evidence for a progressive translocation of the 
protein from the cytoplasm to the nucleus coincident with the induction of apoptosis. eIF5A1 was 
localized in the cytoplasm in untreated cells, and it began to migrate into the nucleus within 12 hours 
after the treatment (Figure 30). This redistribution into the nucleus continued in a time-dependent 
manner such that by 18 hours after treatment, the intensity of eIF5A1 staining was approximately 
equal in the cytoplasm and in the nucleus, and by 24 hours, the concentration of eIF5A1 appeared to 
















Figure 27: Visualization by laser scanning confocal microscopy of the subcellular localization of 
eIF5A1 in untreated Hela S3 cells. 
A) Untreated Hela S3 cells were fixed and then treated with mouse polyclonal antibody against 
human eIF5A1 and FITC-conjugated anti-mouse IgG (green). Results shown are representative of 
those obtained in 2 independent experiments. B) Untreated Hela S3 cells were fixed and then treated 
only with FITC-conjugated anti-mouse IgG. Results shown are representative of those obtained in 2 
independent experiments. C) Untreated Hela S3 cells were fixed and then treated with mouse 
polyclonal antibody against human eIF5A1 and FITC-conjugated anti-mouse IgG as well as with 
SYTOX Blue nucleic acid stain (blue) and Mitotracker Red CMXRos mitochondrial stain (red). 

























Figure 28: Visualization by laser scanning confocal microscopy of the subcellular localization of 
eIF5A1 in Hela S3 cells infected with adenovirus-eIF5A1 constructs for 24 hours. 
Hela S3 cells were either untreated or infected with Ad-eIF5A1 or Ad-eIF5A1(K50A). After 24 
hours, the cells were fixed and then treated with mouse polyclonal antibody against human eIF5A1 
and FITC-conjugated anti-mouse IgG (green) as well as SYTOX Blue nucleic acid stain (blue) and 
Mitotracker Red CMXRos mitochondrial stain (red). Results shown are representative of those 
















Figure 28 Visualization by laser scanning confocal microscopy of the subcellular localization of eIF5A1 in Hela S3 cells infected 















Figure 29: Visualization by laser scanning confocal microscopy of the subcellular localization of 
eIF5A1 in Hela S3 cells infected with adenovirus constructs for 48 hours. 
Hela S3 cells were infected with Ad-eIF5A1, Ad-eIF5A1(K50A) or Ad-lacZ. After 48 hours, the cells 
were fixed and then treated with mouse polyclonal antibody against human eIF5A1 and FITC-
conjugated anti-mouse IgG (green) as well as SYTOX Blue nucleic acid stain (blue) and Mitotracker 
Red CMXRos mitochondrial stain (red). Results shown are representative of those obtained in 3 















Figure 29 Visualization by laser scanning confocal microscopy of the subcellular localization of eIF5A1 in Hela S3 cells infected 















Figure 30: Visualization by laser scanning confocal microscopy of the subcellular localization of 
eIF5A1 in Actinomycin D-treated Hela S3 cells. 
Hela S3 cells were either untreated or incubated with 0.5 μg/ml of Actinomycin D for 12, 18, or 24 
hours. The cells were subsequently fixed and then treated with mouse polyclonal antibody against 
human eIF5A1 and FITC-conjugated anti-mouse IgG (green) as well as SYTOX Blue nucleic acid 
stain (blue) and Mitotracker Red CMXRos mitochondrial stain (red). Results shown are 




















Figure 30 Visualization by laser scanning confocal microscopy of the subcellular localization of eIF5A1 in Actinomycin D-treated 





Chapter 4 Discussion 
4.1 eIF5A1 is not required for mammalian cell growth 
Although eIF5A was originally proposed to be a general translation initiation factor (Kemper 
et al., 1976; Benne et al., 1978; Schnier, et al., 1991), subsequent gene deletion experiments have 
indicated that it may not be required for global translation (Kang and Hershey, 1994; Zuk and 
Jacobson, 1998). Rather, based on the findings that eIF5A and its hypusine modification are required 
for growth of yeast (Schnier et al., 1991; Kang and Hershey, 1994; Sasaki et al., 1996; Park et al., 
1998) and that inhibition of hypusine formation in mammalian cells causes growth arrest (Park et al., 
1993b; Hanauske-Abel et al., 1994; Chen et al., 1996; Shi et al., 1996; Tome and Gerner, 1997), it has 
been suggested that eIF5A might be responsible for the translation of a subset of genes required for 
growth and proliferation (Kang and Hershey, 1994). However, in the present study when eIF5A1 
siRNA was used to suppress the expression of eIF5A1 in human colon adenocarcinoma HT-29 cells 
and human cervical adenocarcinoma Hela S3 cells, cell growth was not affected.  
Two methods were used to examine the effect of eIF5A1 siRNA on cell growth. One of them 
employed XTT, which measures cell viability by quantifying mitochondrial activity and, indirectly, 
reflects cell growth. In the second method, cell growth was scored using BrdU, which provides a 
measure of DNA synthesis commensurate with growth. Data from both assays indicated that 
inhibiting the expression of eIF5A1 by ~90% using eIF5A1 siRNA has no effect on mammalian cell 
growth. Further evidence supporting this contention came from experiments showing that although 
inhibition of hypusine formation using GC7 induces cell cycle arrest at the G1 phase, suppression of 
eIF5A1 using specific siRNA has no effect on cell cycle progression. GC7 is an inhibitor of DHS, the 
enzyme that mediates the first step leading to hypusination of eIF5A, and has been shown previously 
to induce G1 arrest (Park et al., 1993a & 1994; Shi et al., 1996b; Jansson et al., 2000). However, the 
findings of the present study raise the very real possibility that disruption of the cell cycle in the 
presence of CG7 is attributable to an effect of GC7 other than its ability to inhibit the formation of 
hypusinated eIF5A. 
RNA interference (RNAi), which is an evolutionarily conserved process of gene silencing, 
has become a powerful tool for investigating gene function by reverse genetics (Reviewed by Caplen 
et al., 2001; Tuschl., 2001; Kawasaki et al., 2005). The eIF5A1 siRNA used in the present study 
proved to be a highly efficient suppressor of translation, reducing the level of eIF5A1 protein by up to 
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90%. However, since eIF5A1 is an abundant protein with a long half life (Benne et al., 1978; Gerner 
1986; Nishimura et al., 2005), it is possible that even the remaining 10% of eIF5A1 protein is 
sufficient to guarantee its full function in the cells. Furthermore, transfection with synthesized siRNA 
oligonucleotides or siRNA-encoding plasmids to induce RNAi in mammalian cells only provides 
short-term gene silencing (Hao et al., 2005). Indeed, it has been suggested that RNAi is not equivalent 
to, and cannot be used as a replacement for, gene knockout approaches (McCaffrey and Kay, 2003). 
Thus, although the siRNA results obtained in the present study strongly indicate that eIF5A1 is not 
required for cell division, additional studies with an eIF5A1 gene knock-out cell line would provide 
important confirmation of this contention.  
 
4.2 eIF5A1 is involved in the induction of apoptosis 
Although suppression of eIF5A1 expression using siRNA had no discernible effect on cell 
proliferation, there was a pronounced inhibitory effect on apoptosis. This finding is in keeping with 
previous studies which, on the basis of different experimental approaches, also suggest an 
involvement of eIF5A in apoptosis (Caraglia et al., 1997, 1999, 2001 & 2003; Takeuchi et al., 2002; 
Jin et al., 2003; Li et al., 2004; Taylor et al., 2004 & 2007). In the present study, the efficacy of 
eIF5A1 siRNA as an inhibitor of apoptosis was tested using a variety of pro-apoptotic stimuli 
including sodium nitroprusside (SNP), Actinomycin D, a proteasome inhibitor and serum depletion, 
which induce programmed cell death in different ways. In every case, suppression of eIF5A1 
expression provided considerable protection against the induction of programmed cell death.   
 SNP [Na2[Fe(CN)5NO]2H2O] is a "spontaneous" NO donor in that it releases NO (and NO+) 
in aqueous solvents in the absence of enzymatic reduction or hydrolysis (Yamamoto and Bing, 2000; 
Al-Sa'doni and Ferro, 2006). However, degradation of SNP generates cyanide (CN-) and free iron as 
well, which are also biologically active (Ramakrishna Rao and Cederbaum, 1996). Thus as noted 
previously (Kim et al., 2006), SNP should not be regarded simply as a NO donor. It is well 
established that, when used at mM concentration, SNP induces apoptosis in a variety of cell lines (Cui 
et al., 1994; Sumitani et al., 1997; Tsi et al., 2001; Olivier et al., 2005; Kwak et al., 2006; Gui et al., 
2007; Wang et al., 2007). The fact that SNP is capable of triggering apoptosis is consistent with the 
ability of two of its products, iron and NO, to generate reactive oxygen and reactive nitrogen species 
(ROS and RNS), respectively, both of which induce DNA damage. Free iron released by SNP induces 
the formation of ROS through iron-catalyzed free radical formation known as the Fenton reaction 
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(Schroder, 2006). ROS are in turn capable of damaging several cellular components including DNA, 
lipids and proteins, thereby engendering both cytotoxic and genotoxic effects (Reviewed by Blokhina 
et al., 2003; Valko et al., 2005). The NO released from SNP not only directly damages cellular 
components, but also reacts with superoxide (O2-) to form peroxynitrite (ONOO-) which is highly 
toxic (Wink et al., 1991; Liu and Hotchkiss, 1995). Although these RNS are capable of modifying 
multiple cellular signaling pathways through reversible S-nitrosation reactions (Reviewed by Akaike, 
2000; Miersch and Mutus, 2005), they can also induce genotoxicity by causing direct DNA damage 
such as single strand breaks (Reviewed by Felley-Bosco, 1998). Through the induction of DNA 
damage, NO indirectly stimulates expression and accumulation of the tumor suppressor, p53, which is 
responsible for the transactivation of Bax and cyclin-dependent kinase inhibitor, p21, as well as the 
transrepression of Bcl-2 (Brockhaus and Brune, 1999; Pinsky et al., 1999; Kolb, 2000; Li et al., 2002) 
and thus serves as a strong inducer of apoptosis. SNP also activates the cAMP-PKA pathway, which 
is linked to the MAPK pathway, especially ERK1/2 and JNK (Kim et al., 2006).  
The finding in the present study that eIF5A1 siRNA reduces SNP-induced cell death 
implicates eIF5A1 in ROS- and RNS-induced cytotoxicity and genotoxicity. It also complements a 
previous report from our laboratory that eIF5A1 is up-regulated during SNP-induced apoptosis in 
human colorectal cancer RKO cells (Taylor et al., 2007). Since eIF5A1 is upregulated in a p53-
dependent manner in response to DNA damage and over-expression of eIF5A1 induces up-regulation 
of p53 and p53-dependent apoptosis, it has been suggested that eIF5A is involved in the p53-
dependent apoptotic pathway (Li et al., 2004; Rahman-Roblick et al., 2007). At face value, this 
suggests that eIF5A1 involvement in SNP-induced apoptosis is through p53. However, the cell line, 
HT-29, used in these experiments only has mutant, non-functional p53, and thus apoptosis of HT-29 
cells can only be p53-independent (Rodrigues et al., 1990; Violette et al., 2002). It seems clear, 
therefore, that the involvement of eIF5A1 in SNP-induced apoptosis is independent of p53. Indeed, it 
is known that NO can inhibit cell growth and induce apoptosis in p53-null cell lines (Messmer and 
Brune, 1996; Kawahara et al., 2001; Chao et al., 2004), and that ROS and RNS derived from SNP can 
directly induce mitochondria-mediated apoptosis through their inhibitory effect on respiration leading 
to reduction of ∆Ψm, PT pore opening and the release of cytochrome c (Reviewed by Boyd and 
Cadenas, 2002; Brookes and Darley-Usmar, 2000; Moncada and Erusalimsky, 2002). In addition, NO 
induces release of ER Ca2+ resulting in ER stress and apoptosis through the induction of 
CHOP/GADD153, a C/EBP family transcription factor involved in the ER stress pathway (Kawahara 
et al., 2001; Oyadomari et al. 2001; Gotoh et al., 2002). Therefore, both mitochondrial dysfunction 
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and activation of the ER stress-CHOP pathway may account for p53-independent NO-induced cell 
death (Brune, 2003), and it is conceivable that eIF5A1 is involved in either or both of these apoptotic 
pathways. 
The finding in the present study that eIF5A1 siRNA inhibits Actinomycin D-induced 
apoptosis in HT-29 cells in which p53 is defective further supports the contention that eIF5A1 protein 
is involved in mediating p53-independent apoptosis. Actinomycin D is an antineoplastic antibiotic 
that binds to DNA, inhibiting transcription and DNA replication (Guy and Taylor, 1978; Sobell, 
1985) as well as inducing chromosomal aberrations and DNA strand breaks (Cherry and Hsu, 1982). 
Indeed, treatment with Actinomycin D is known to up-regulate p53 (Kastan et al., 1991) as well as 
enhance its DNA binding activity (Tishler et al., 1993). However, Actinomycin D also induces up-
regulation of Bax, activation of the JNK pathway and apoptosis through a p53-independent 
mechanism (Kleeff et al., 2000). Furthermore, low concentrations of Actinomycin D can potentiate 
TRAIL-, Fas- and TNF-induced apoptosis, although this effect is cell type-dependent (Itoh and 
Nagata, 1993; Mori et al., 1999; Kim et al., 2002 & 2003; Park et al., 2003). It has been shown in 
another study from our laboratory that Actinomycin D induces apoptosis coincident with up-
regulation of eIF5A1 and p53 in the human colorectal cancer cell line, RKO, which contains 
functional wild-type p53,  and that siRNA-induced suppression of eIF5A1 inhibited Actinomycin D-
induced up-regulation of p53 (Taylor et al., 2007). These observations collectively implicate eIF5A1 
in Actinomycin D-induced apoptosis that is both p53-dependent and p53-independent. 
The proteasome inhibitor, MG-132, which was also used as a pro-apoptotic agent in the 
present study, blocks the ubiquitin-proteasome (UP) pathway, the route by which a large number of 
proteins, including those involved in apoptosis, are degraded (Reviewed by Glickman and 
Ciechanover, 2002). Indeed, the use of proteasome inhibitors has recently emerged as an effective 
anticancer strategy since cancer cells are much more sensitive to proteasome inhibition than normal 
cells (Reviewed by Kisselev and Goldberg, 2001; Adams, 2002; Montagut et al., 2006). MG-132 not 
only induces cell cycle arrest at the G2/M interface, but also activates caspase 3, a key agent of 
apoptosis (Fujita et al., 1996; Drexler, 1997; Kitagawa et al., 1999; Wagenknecht et al., 1999; An et 
al., 2000; Naujokat et al., 2000; MacLaren et al., 2001; Sassone et al., 2006). In more general terms, 
MG-132 increases the lifespan of short-lived proteins which are often toxic and blocks the 
modification of proteins involved in signaling pathways, resulting in changes that inhibit cell survival 
and promote apoptosis (Reviewed by Drexler, 1998; Orlowski, 1999; Yang and Yu, 2003; Zhang et 
al., 2004; Vlahakis and Badley, 2006). The levels of p53, for example, are generally quite low in 
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normal cells due to its well-regulated degradation by the 26S proteasome (Chowdary et al., 1994; 
Meki et al., 1996), MG-132-induced inhibition of the 26S proteasome results in accumulation of p53 
with all of its attendant downstream pro-apoptotic effects including transcriptional activation of Puma 
and Bim, and translocation of Bax and cytochrome c (Kitagawa et al., 1999; Lopes et al., 1997; 
MacLaren et al., 2001; Concannon et al., 2007; Ding et al., 2007). However, there is also evidence 
that UP inhibitors such as MG-132 are able to induce apoptosis through a p53-indendent pathway (An 
et al., 1998; Herrmann et al., 1998; Wagenknecht et al., 1999), possibly through the formation of ROS 
which then activate the mitochondrial apoptotic pathway leading to activation of the caspase cascade 
(Emanuele et al., 2002; Wu et al., 2002; Ling et al., 2003; Fribley et al., 2004; Yu et al., 2004; Lee et 
al., 2005; Nawrocki et al., 2005; Perez-Galan et al., 2006). The mechanism underlying ROS 
generation induced by UP inhibitors is not clear, but it has been proposed that they may do so by 
enhancing the ROS generating capability of mitochondria (Ling et al., 2003). In addition, however, 
UP inhibitors have been shown to engender the accumulation of misfolded proteins in the ER, thereby 
activating the ER stress pathway which not only initiates the caspase cascade directly, but also 
generates ROS leading to release of Ca2+ and a consequent activation of the mitochondrial apoptotic 
pathway (Fribley et al., 2004; Nawrocki et al., 2005; Perez-Galan et al., 2006). Inhibiting the UP 
pathway also decreases turnover of the pro-apoptotic proteins, Bim and Bik (Nikrad et al., 2005), as 
well as inhibitory κB (IκB) which inhibits the translocation and activation of nuclear factor kappa B 
(NF-κB), a key survival transcription activator (Liu et al., 1996; Maniatis, 1999; Chen et al., 2002). 
Therefore, treatment with a UP inhibitor such as MG-132 not only induces the accumulation of pro-
apoptotic molecules, but also inhibits the pro-survival pathway (Liu et al., 1996; Maniatis, 1999; 
Chen et al., 2002; Nikrad et al., 2005).  
The finding in the present study that eIF5A1 siRNA inhibits the induction of MG-132-
induced apoptosis of HT-29 cells supports the contention that eIF5A1 is a key element of 
programmed cell death. It is also consistent with a previous report that treatment of Mo7e cells, a 
leukemia cell line, with UP inhibitors induces up-regulation of eIF5A1 (Jin et al., 2003). Interestingly, 
the protective effect of eIF5A1 siRNA against MG-132-induced apoptosis proved to be stronger at 72 
hours after transfection than at 48 hours. This is consistent with the fact that the cellular eIF5A1 
protein level is lower at 72 hour after transfection and suggests a correlation between the amount of 
eIF5A1 protein and the extent of apoptosis. Furthermore, cells transfected with eIF5A1 siRNA and 
treated with MG-132 for 24 hours had higher eIF5A1 protein levels than corresponding cells cultured 
in the absence of MG-132, indicating that eIF5A1 is degraded through the UP pathway.  
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Finally, eIF5A1 siRNA was also shown to inhibit cell death attributable to stress stemming 
from serum starvation. Serum, which is a commonly used supplement to cell culture media, contains 
a broad spectrum of molecules including hormones, growth factors, low-molecular-weight nutrients, 
carrier proteins for lipoid substances, trace elements as well as attachment and spreading factors 
(Reviewed by Griffiths, 1987). It has been shown that withdrawal of stimulatory growth factors 
present in serum, many of which play dual roles as mitogens and survival factors, induces cell cycle 
arrest and apoptosis in several cell types in vitro (Galli and Fratelli, 1993). Serum starvation causes 
cells to round-up leading to detachment and death and, at the molecular level, induces up-regulation 
of p53 (Koo et al., 2002). Indeed, it has been suggested that in the event of serum starvation p53 plays 
an essential role in the induction of G1 cell cycle arrest and in the activation of caspases 3, 6 and 12, 
key mediators of apoptosis (Kilic et al., 2002; Oya et al., 2003; You et al., 2006). However, serum 
deprivation also induces apoptosis in a p53-independent manner (Pützera et al., 2000; Takamatsu et 
al., 2001).  
In the present study, untransfected HT-29 cells and HT-29 cells transfected with control 
siRNA exhibited typical nutrient stress symptoms when subjected to serum starvation including 
rounding-up and cessation of growth. By contrast, HT-29 cells transfected with eIF5A1 siRNA 
displayed strong resistance to serum starvation-induced stress. They continued to grow and divide 
normally, and were morphologically indistinguishable from cells cultured in media containing normal 
levels of FBS. Indeed, the finding that eIF5A1 siRNA inhibits the pro-apoptotic effects of serum 
starvation as well as apoptosis induced by SNP, Actinomycin D and MG-132 suggests that eIF5A1 
protein is a key apoptotic regulator. 
 
4.3 Molecular basis for the involvement of eIF5A in apoptosis     
4.3.1 Over-expression of eIF5A induces p53-independent apoptosis 
That suppression of eIF5A1 in HT-29 cells, which do not contain functional p53, inhibited 
cell death induced by serum deprivation as well as several pro-apoptotic agents suggests that eIF5A1 
is able to respond to a number of apoptotic stimuli and to induce cell death in a p53-independent 
manner. To further test this concept, the effects of eIF5A1 over-expression on apoptosis were 
examined using adenovirus as an expression vehicle. Adenovirus constructs bearing wild-type 
eIF5A1 (Ad-eIF5A1), mutant eIF5A1 with lysine50 switched to alanine which abolishes hypusine 
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modification [Ad-eIF5A(K50A)] and wild-type eIF5A2 (Ad-eIF5A2) were used for this purpose. The 
Ad-eIF5A(K50A) enabled assessment of whether hypusination of eIF5A1 is a prerequisite for its pro-
apoptotic activity. Ad-lacZ was used as a negative control. Interestingly, Ad-eIF5A1, Ad-
eIF5A1(K50A) and Ad-eIF5A2 all induced apoptosis in a time- and dose-dependent manner in HT-29 
colon cancer cells and in Hela S3 cervical cancer cells. Moreover, neither of these cell lines have 
active p53. HT-29 cells contain mutant, non-functional p53 (Rodrigues et al., 1990; Violette et al., 
2002), and Hela S3 cells are phenotypically null for p53 due to the presence of the HPV E6 oncogene 
(Scheffner et al., 1990 & 1991; Liang et al., 1993 & 1995; Thomas et al., 1996; Song et al., 1998; 
Talis et al., 1998).  
Apoptosis is characterized by internucleosomal cleavage of DNA into fragments of 180-200 
bp as a result of endonuclease activity as well as chromatin condensation, reduction of cell volume 
and formation of apoptotic bodies (Reviewed by Arends and Wyllie, 1991; Schwartzman and 
Cidlowski, 1993; Häcker, 2000). In this study, two methods were used to measure different aspects of 
apoptosis induced by Ad-eIF5A. One of these, the terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP Nick-End Labeling (TUNEL) method, labels cells in which DNA fragmentation, a 
late event in apoptosis, has occurred (Gorczyca et al., 1993; Kasagi et al., 1994; Collins et al., 1997). 
Based on TUNEL assay results, it was clear that Ad-eIF5A1, Ad-eIF5A1(K50A) and Ad-eIF5A2 all 
strongly induce DNA fragmentation in HT-29 cells within 48 hour of infection. However, it has been 
suggested that DNA fragmentation also occurs during necrosis in a random instead of 
internucleosomal pattern (Gold et al., 1994; Mundle et al., 1995). Accordingly, detection of 
fragmented DNA using the TUNEL assay may fail to discriminate between necrosis and apoptosis 
(Grasl-Kraupp et al., 1995; Mundle et al., 1995). Furthermore, it has been shown that the 
morphological features of apoptosis can occur in the absence of internucleosomal DNA fragmentation 
(Falcieri et al., 1993; Cohen et al., 1992). Thus, using only TUNEL to measure apoptosis may not be 
sufficient. 
 To address this concern, the Annexin V/PI method was used to confirm that cells infected 
with different types of Ad-eIF5A constructs are undergoing apoptosis. During the course of apoptosis, 
phosphatidylserine, which is normally confined to the inner plasma membrane leaflet, is translocated 
to the outer leaflet of the plasma membrane (Martin et al., 1995b). This externalization of 
phosphatidylserine is an early signature of apoptosis that occurs before loss of cell membrane 
integrity and nuclear changes (Koopman et al., 1994; Martin et al., 1995). It can be detected using 
Annexin V, which binds to phosphatidylserine with high affinity (Andree et al., 1990; Koopman et 
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al., 1994). In the same assay, propidium iodide (PI), a cell-impermeable nucleic acid dye, is also used 
to distinguish between cells with intact and permeable plasma membranes (Taylor, 1980). As the cell 
membrane becomes increasingly permeable during the later stages of apoptosis, PI can readily move 
across the cell membrane and bind to cellular DNA, providing a means of identifying cells which 
have lost membrane integrity (Vermes et al., 1997; Herault et al., 1999). Thus, when cells are stained 
with fluorescein labeled Annexin V and PI and analyzed by flow cytometry, it is possible to 
distinguish viable cells, early stage-apoptotic cells, late stage-apoptotic cells and dead cells (Vermes 
et al., 1997; Herault et al., 1999). When Hela S3 cells were assayed by Annexin V/PI staining at 
different times after infection with different adenovirus constructs, it was apparent that for all of the 
constructs apoptosis was not initiated within the first 24 hours of infection. However, by 48 hours 
after infection 20 to 40 percent of the cells were at an early or late stage of apoptosis, and after an 
additional 24 hours most of the cells were dead. Thus, the Annexin V/PI data were consistent with the 
TUNEL results in indicating that within 48 hours of infection with Ad-eIF5A apoptosis had been 
initiated, and that it progressed in a time-dependent manner.  
The cytotoxic effect of eIF5A on both HT-29 and Hela S3 cells was also measured using the 
XTT assay and Trypan blue staining. Consistent with what was observed using the TUNNEL assay 
and Annexin V/PI staining, both of these assays indicated a dramatic time-dependent decrease in the 
viability of cells over-expressing eIF5A. With Trypan blue, for example, which was used to 
distinguish cells containing intact and permeable plasma membrane, cells infected with adenovirus 
eIF5A constructs were still viable (intact plasma membrane) at 24 hours after infection, but between 
24 and 48 hours viability started to decline, and by 72 hours most of the cells contained ruptured 
plasma membranes.  
These findings collectively indicate that eIF5A1 and eIF5A2 are both capable of inducing 
apoptosis. Moreover, at least for HT-29 cells and Hela S3 cells, they do so through a p53-independent 
mechanism inasmuch as neither of these cell lines contain functional p53. However, these 
observations do not preclude the possibility that eIF5A is also able to effect apoptosis by working 
through p53. Indeed, other studies have demonstrated that the expression of p53 is regulated by 
eIF5A (Li et al., 2004; Taylor et al., 2007). As well, the finding that Ad-eIF5A1 and Ad-
eIF5A1(K50A) proved to be essentially equivalent inducers of apoptosis in HT-29 and Hela S3 cells 
constitutes strong evidence that post-translational conversion of lysine50 in eIF5A to either 




4.3.2 eIF5A activates caspases involved in apoptosis 
The signaling events leading to apoptosis in effect comprise two major pathways, one 
involving death receptors (extrinsic pathway) and the other, changes in mitochondria (intrinsic 
pathway). The death receptor pathway is initiated upon the binding of extracellular death ligands to 
death receptors on the plasma membrane, leading to the formation of DISC that recruits and activates 
caspase 8 (Reviewed by Nagata, 1997; Ashkenazi and Dixit, 1998 & 1999). Caspase 8 then either 
directly cleaves and activates the effector caspases 3, 6, and 7 or induces mitochondrial dysfunction 
by generating the active BH3-only pro-apoptotic protein, tBid (Li et al., 1998; Luo et al., 1998). The 
mitochondrial pathway is activated by various cellular stresses through the regulation of Bcl-2 family 
proteins. Translocation of pro-apoptotic Bcl-2 family proteins to mitochondria induces 
permeabilization of the mitochondrial outer membrane and a consequent release of cytochrome c 
(Reviewed by Adams and Cory, 2001). Cytochrome c associates with Apaf-1 in the presence of 
ATP/dATP, forming the apoptosome which recruits and activates caspase 9. Caspase 9 in turn 
activates the effector caspases 3, 6 and 7 (Li et al., 1997; Hu et al., 1999; Rodriguez and Lazebnik, 
1999).  
The finding in the present study that over-expression of eIF5A1, eIF5A1(K50A) or eIF5A2 
induces activation of the initiator caspases 8 and 9 as well as the effector caspase 3, all of which 
underpin the execution of apoptosis, indicates that eIF5A plays a central role in the induction of 
programmed cell death. Moreover, the activation of caspases by eIF5A proved to be time-dependent. 
Within 48 hours of infection with Ad-eIF5A, about 30% of infected cells exhibited activated caspases 
3, 8, and 9, and by 72 hours the proportion of infected cells with activated caspases had increased to 
~70%. Thus, at some point between 24 and 48 hours after infection, apoptosis signaling was initiated 
by the over-expression of eIF5A through a yet unknown mechanism, leading to the activation of 
death receptor pathway caspase 8 and mitochondrial pathway caspase 9, as well as the effector 
caspase 3 which functions in both pathways. The key apoptotic indices including phosphatidylserine 
externalization, mitochondrial dysfunction, DNA fragmentation and plasma membrane 
permeabilization which were measured in the present study are known to be directly or indirectly 
attributable to the action of capases (Reviewed by Arends et al., 1990; Arends and Wyllie, 1991; 




4.3.3 eIF5A activates the mitochondrial pathway of apoptosis 
4.3.3.1 Dissipation of mitochondrial ∆Ψm and permeabilization of the mitochondrial outer membrane 
The finding that over-expression of eIF5A induces activation of caspase 9 suggests its 
involvement in the mitochondrial pathway of apoptosis. This was confirmed by demonstrating that 
eIF5A plays a role in reduction of mitochondrial ∆Ψm as well as permeabilization of the outer 
mitochondrial membrane, both key features of apoptosis.  
Opening of the permeability transition (PT) pore in the inner mitochondrial membrane at an 
early stage of apoptosis disrupts the electrochemical gradient across the mitochondrial inner 
membrane, a gradient that is critical for normal mitochondrial function (Reviewed by Green and Reed, 
1998). Indeed, dissipation of mitochondrial transmembrane potential (∆Ψm) is a general and early 
feature of apoptosis (Vayssiere et al., 1994; Petit et al., 1994; Zamzami et al., 1995; Marchetti et al., 
1996), even earlier than phosphatidylserine exposure (Castedo et al., 1996). Loss of ∆Ψm can be 
measured using cationic, lipophilic fluorescent dyes such as DiOC6(3) (Petit et al., 1994; Zamzami et 
al., 1995; Waterhouse et al., 2001), which was used for this purpose in the present study. Consistent 
with the Annexin V/PI-portrayal of the progress of apoptosis, cells infected with adenovirus eIF5A 
did not start to lose ∆Ψm until at least 24 hours after infection. At 48 hours, 20-40% of the cells 
exhibited disrupted ∆Ψm, and by 72 hours the ∆Ψm had dissipated in most of the infected cells.  
Loss of ∆Ψm in the event of apoptosis occurs concomitantly with mitochondrial outer 
membrane permeabilization (MOMP) and the resultant release of cytochrome c, Smac/DIABLO, 
Htra2/Omi, AIF and endonuclease G, which are normally compartmentalized in the intermembrane 
mitochondrial space (IMS) (Vander Heiden et al., 1997; Heiskanen et al., 1999; Du et al., 2000; 
Verhagen et al., 2000; Suzuki et al., 2001; Waterhouse et al., 2001; Goldstein et al., 2005; Munoz-
Pinedo et al., 2006). Indeed, cytochrome c plays an important role in the generation of ∆Ψm, which is 
essential for various mitochondrial functions including the production of ATP by oxidative 
phosphorylation (Waterhouse et al., 2001). In the present study, it was clear from Western blot 
analysis of Hela S3 cell fractions that some cytochrome c had been released from the IMS into the 
cytosol ~48 hours after infection with Ad-eIF5A1, which coincided temporally with the dissipation of 
∆Ψm. However, by 55 hours after infection there was still a large amount of cytochrome c associated 
with mitochondria in Ad-eIF5A1-infected cells, reflecting incomplete release during the early stages 
of apoptosis. This has been reported previously (Waterhouse et al., 2001; Ott et al., 2002). In fact, it 
has been shown that BH3-only protein-mediated oligomerization of Bax and Bak at the mitochondrial 
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outer membrane only results in the release of a small percentage of cytochrome c (about 15%) stored 
in the intermembrane space (Scorrano and Korsmeyer, 2003; Tikhomirov and Carpenter, 2005). For 
release of the remaining 85%, there appears to be a requirement for a Bak and Bax-independent inner 
membrane remodelling suggesting that the release of cytochrome c is a two-step process (Scorrano 
and Korsmeyer, 2003). The release of cytochrome c observed following up-regulation of eIF5A in the 
present study did not appear to be biphasic, but the time required for complete release relative to the 
dissipation of ∆Ψm is consistent with a two step process. 
 
4.3.3.2 Translocation of Bax  
Further evidence supporting the contention that eIF5A is involved in activating the 
mitochondrial pathway of apoptosis came from experiments demonstrating complete translocation of 
Bax from the cytosol to a membrane fraction containing mitochondria when Hela S3 human cervical 
cancer cells were infected with Ad-eIF5A1. In normal healthy cells, Bax resides primarily in the 
cytosol, with only a small portion loosely attached to the mitochondrial outer membrane (MOM) 
(Wolter et al., 1997; Suzuki et al., 2000; Schinzel et al., 2004). In response to stress signals that 
induce apoptosis, Bax undergoes a conformational change resulting in its self-oligomerization and 
insertion into the MOM (Wolter et al., 1997; Murphy et al., 1999; Putcha et al., 1999; Antonsson et 
al., 2001; Shou et al., 2003; Schinzel et al., 2004). This intracellular redistribution of Bax is thought 
to be an early feature of apoptosis since it precedes the release of cytochrome c and is coincident with 
loss of mitochondrial respiratory activity (Wolter et al., 1997; Murphy et al., 1999). Once localized on 
the MOM, Bax either interacts with components of the PT pore complex to promote opening of the 
pore and release of cytochrome c (Marzo et al., 1998; Narita et al., 1998; Shimizu et al., 1999), or 
induces the release of cytochrome c independently of the PT pore by forming a channel in the MOM 
(Eskes et al., 1998; Jurgensmeier et al., 1998). In the present study, although over-expression of 
eIF5A1 did not induce up-regulation of Bax, it did trigger the cytosol-to-mitochondria translocation 
of Bax, which is known to be both essential and sufficient for the activation of downstream signaling 
cascades inherent to apoptosis (Ghatan et al., 2000; He et al., 2000; Antonsson et al., 2001; Melino et 
al., 2004). Moreover, the translocation of Bax in response to up-regulation of eIF5A1 preceded the 
release of cytochrome c, which is consistent with reports that the redistribution of Bax leads to 
mitochondrial outer membrane permeablization (Jurgensmeier et al. 1998; Marzo et al., 1998; Narita 




4.3.3.3 Up-regulation of Bim 
The BH3-only protein, Bim, is also pro-apoptotic. Indeed, it is referred to as a Bcl-2 
interacting mediator of cell death, and it appears to function upstream of Bax and Bak inasmuch as  
constitutively active Bim in cells lacking both Bax and Bak fails to induce mitochondrial alterations 
associated with apoptosis (Zong et al., 2001). Recent data have prompted the suggestion that Bim is 
involved in oncogene-induced apoptosis. First, Bim has been shown to be transcriptionally activated 
by the oncogene, E2F-1, in the event of E2F-1-induced apoptosis (Hershko and Ginsberg, 2004; Zhao 
et al., 2004; Biswas et al., 2005). Second, Bim also mediates apoptosis induced by the oncogene, 
Myc, and loss of Bim has been shown to facilitate Myc-induced tumorigenesis (Egle et al., 2004; 
Hemann et al., 2005).  
In keeping with the finding that eIF5A1 appears to regulate the translocation of Bax to 
mitochondria, enhanced expression of eIF5A1 in Hela S3 cells also induced up-regulation of Bim. 
The pro-apoptotic activity of Bim is regulated by association with Bcl-2-like proteins (O'Connor et 
al., 1998). There are three isoforms of Bim generated by alternative splicing: BimEL, BimL and BimS 
which is sometimes undetectable (O'Connor et al., 1998). Bim has been shown to be involved in 
apoptosis induced by several stimuli, including DNA damage, death receptor ligation, growth factor 
or cytokine deprivation and paclitaxel, an anticancer agent that interferes with microtubule dynamics 
(Bouillet et al., 1999; Putcha et al., 2001; Shinjyo et al., 2001; Biswas and Greene, 2002; Dijkers et 
al., 2002; Nijhawan et al., 2003; Opferman et al., 2003; Sunters et al., 2003; Zong et al., 2003; Chen 
and Zhou, 2004; Wang et al., 2004; Gomez-Bougie et al., 2005; Tan et al., 2005; Han et al., 2004, 
2005 & 2006). Although all isoforms are able to induce apoptosis (O'Connor et al., 1998; Terradillos 
et al., 2002; Wilson-Annan et al., 2003), the shortest isoform, BimS, is thought to be the most potent 
(O'Connor et al., 1998). In healthy cells, all three major Bim isoforms are strongly associated with 
anti-apoptotic Bcl-2 family proteins localized on the mitochondrial outer membrane including Mcl-1, 
Bcl-2 and Bcl-xL. In addition, there is a small amount of BimEL and BimL weakly interacting with 
LC8, a component of the microtubule-associated dynein complex (Puthalakath et al., 1999; Chen and 
Zhou, 2004; Zhu et al., 2004; Gomez-Bougie et al., 2005; Liu et al., 2006). Among the complexes 
Bim forms with Bcl-2 proteins, the Mcl-1:Bim complex appears to be the most abundant and most 
critical for the initiation of apoptosis (Gomez-Bougie et al., 2005). Under non-apoptotic conditions, 
Bim is sequestered by Mcl-1, which effectively neutralizes its pro-apoptotic activity (Opferman et al., 
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2003; Gomez-Bougie et al., 2004 & 2005; Han et al., 2004, 2005 & 2006). However, in response to 
pro-apoptotic stimuli such as UV, granzyme B, melphalan or TRAIL, Mcl-1 is degraded either 
proteasomally or by activated caspases, and Bim is released (Nijhawan et al., 2003; Opferman et al., 
2003; Zong et al., 2003; Chen and Zhou, 2004; Gomez-Bougie et al., 2005; Han et al., 2004, 2005 & 
2006). Released Bim is then thought to mediate apoptosis by inducing Bax activation (Gomez-Bougie 
et al., 2004; Zhu et al., 2004; Liu et al., 2006). However, since direct association between Bim and 
Bax has not yet been demonstrated (Gomez-Bougie et al., 2004; Zhu et al., 2004; Liu et al., 2006), it 
has been suggested that free Bim may exercise its pro-apoptotic function by participating in what has 
been called “hit and run” activation of Bax, (Wei et al., 2001; Gomez-Bougie et al., 2004; Zhu et al., 
2004; Liu et al., 2006). 
In addition to being sequestered by anti-apoptotic Bcl-2-like proteins, Bim is also regulated 
by phosphorylation. In healthy cells, Bim is phosphorylated by the ERK1/2 pathway which directly 
inhibits its pro-apoptotic function (Biswas and Greene, 2002) and also targets it for degradation by 
the ubiquitin-proteasome pathway (Weston et al., 2003; Ley et al., 2004 & 2005). In response to pro-
apoptotic stimuli such as paclitaxel-treatment and growth factor or cytokine withdrawal, activation of 
the Forkhead transcription factor, FoxO3a, leads to elevated Bim expression coincident with 
dephosphorylation and activation of pre-existing Bim (Shinjyo et al., 2001; Dijkers et al., 2002; Stahl 
et al., 2002; Gilley et al., 2003; Sunters et al., 2003).  
In the present study, up-regulation of both BimL and BimS was evident within 24 hours in Ad-
eIF5A infected Hela S3 cells, and by 72 hours the up-regulation was more prominent with all three 
isoforms, BimEL, BimL and BimS being detectable. Bim is known not to be a p53 target (Villunger, et 
al., 2003). These findings are, therefore, consistent with the fact that eIF5A has been shown capable 
of inducing apoptosis in HT-29 cells and Hela-S3 cells, neither of which contain functional p53. 
Moreover, over-expression of eIF5A not only induced Bim up-regulation, but also appeared to 
facilitate alternative splicing of Bim, an intrinsic signal that promotes translocation of Bax and release 
of cytochrome c. 
 
4.3.3.4 Puma, Bid and Bad 
The Western blot analyses conducted in the present study indicated that Puma, Bid and Bad 
are not upregulated during eIF5A-induced apoptosis. This presumably reflects the fact that these 
proteins are p53 targets and that p53 is inactivated in Hela S3 cells (Sax et al., 2002; Villunger et al., 
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2003; Melino et al., 2004; Jiang et al., 2006). In addition, however, there was no detectable cleavage 
of Bid in the eIF5A-up-regulated cells, which is surprising in light of the finding the eIF5A plays a 
role in the activation of caspase 8, the protease that cleaves Bid (Li et al., 1998; Luo et al., 1998). 
This is, however, consistent with previous reports indicating that activation of caspase 8 does not 
always correlate with strong, or even any, cleavage of Bid (Park et al., 2003; Sohn et al., 2005). 
Furthermore, there is evidence that the susceptibility of Bid to cleavage by caspase 8 is cell-type 
specific (Desagher et al., 2001; Degli Esposti et al., 2003). This finding, together with the fact that 
over-expression of eIF5A induces loss of mitochondrial transmembrane potential, release of 
cytochrome c into the cytosol and activation of caspase 9, suggests that activation of the 
mitochondrial apoptotic pathway by eIF5A is not initiated by Bid and activated caspase 8, but rather 
by up-regulation of Bim. 
 
4.3.3.5 Cleavage of Bcl-2 
Bcl-2, which is anti-apoptotic, is a ~26 kDa membrane-associated protein localized at 
multiple sites in the cell including the mitochondrial outer membrane, the endoplasmic reticulum 
(ER) and the nuclear envelope (Tsujimoto et al., 1987; Hockenbery et al., 1990; Alnemri et al., 1992). 
Mitochondrial Bcl-2 is known to abrogate the release of cytochrome c (Kluck et al., 1997; Adrain et 
al., 2001), whereas Bcl-2 on the ER and nuclear envelope functions to regulate cytosolic and nuclear 
calcium levels, thereby maintaining cellular calcium homeostasis (Marin et al., 1996). There have 
been several reports of effector caspase-mediated cleavage of Bcl-2 during apoptosis (Cheng et al., 
1997; Fujita and Tsuruo, 1998; Fadeel et al., 1999; Hirotani et al., 1999). Specifically, effector 
caspases catalyze the cleavage of Bcl-2 at aspartate34 resulting in loss of the N-terminal BH4 domain 
which is involved in the heterodimerization of Bcl-2 with Bax/Bak and thus essential for the anti-
apoptotic activity of Bcl-2 (Cheng et al., 1997; Hirotani et al., 1999). Indeed, deletion of the BH4 
domain by effector caspases not only inactivates the pro-survival activity of Bcl-2, but also releases a 
22 to 23 kDa potent pro-apoptotic Bax-like fragment (Cheng et al., 1997). This Bax-like fragment 
cleaved from Bcl-2 acts as a death-agonist, inducing mitochondrial outer membrane permeabilization 
(MOMP) and release of cytochrome c into the cytosol, thereby amplifying the apoptotic cascade 
through a positive feedback loop of caspase activation (Cheng et al., 1997; Kirsch et al., 1999). 
Cleavage of Bcl-2 has been demonstrated in response to a variety of pro-apoptotic stimuli including 
Fas ligation, treatment with IL-2 or IL-3, GM-CSF withdrawal, alphavirus infection, anticancer drug 
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treatment, antimitotic agent treatment, oxidative stress and treatment with the DNA-damaging agent, 
cisplatin (Cheng et al., 1997; Fujita and Tsuruo, 1998; Grandgirard et al., 1998; Fadee et al., 1999; 
Hirotani et al., 1999; Lin et al., 2000; Del Bello et al., 2001; Fortney et al., 2002; Liang et al., 2002 & 
2003; Mi et al., 2006). Moreover, HIV protease cleaves Bcl-2 at phenylalanine112, yielding a 12-14 
kDa proteolytic fragment which is also capable of inducing apoptosis (Strack et al., 1996).  
The transcriptional activity of Bcl-2 has been reported to be very low in Hela cells resulting 
in low levels of Bcl-2 protein (Cleary et al., 1986; Liang et al., 1995; Liang et al., 1995; Odin et al., 
2001; Hara et al., 2005). This was confirmed in the present study. However, over-expression of 
eIF5A2, but not eIF5A1 or eIF5A1(K50A), in Hela S3 cells resulted in the formation of a Bcl-2 
protein distinguishable on the basis of its size (19-20 kDa) from the cleavage products of Bcl-2 
formed by effector caspases and HIV protease. This cleaved Bcl-2 was clearly discernible within 24 
hours of Ad-eIF5A2 infection, and was strongly up-regulated between 24 and 72 hours after 
infection. Previous reports have indicated that this 19-20 kDa Bcl-2-derived cleavage product is 
formed by a novel non-caspase cysteine protease acting at aspartate64 of Bcl-2 (Yamamoto et al., 
1998; Hoetelmans et al., 2003). The action of this protease thus removes the N-terminus of the Bcl-2 
protein, which contains the BH4 domain, thereby inactivating the ability of Bcl-2 to suppress 
apoptosis (Yamamoto et al., 1998; Hoetelmans et al., 2003). Moreover, the resultant 19-20 kDa Bcl-2 
fragment has been shown previously to be up-regulated following the induction of apoptosis and is 
thought to amplify the cell death program (Yamamoto et al., 1998). Of note with respect to the 
present study is that formation of this 19-20 kDa Bcl-2 fragment in Ad-eIF5A2-infected cells is 
accompanied by the release of mitochondrial cytochrome c, disruption of ∆Ψm and activation of 
caspases,  which is consistent with the contention that removal of the BH4 domain of Bcl-2 abolishes 
its anti-apoptotic activity. In addition, however, the 19-20 kDa product of Bcl-2 cleavage proved to be 
strongly up-regulated during Ad-eIF5A2-induced apoptosis, to much higher amounts than the level of 
uncleaved Bcl-2 in untreated cells. This can be interpreted as indicating that in response to eIF5A2 
up-regulation Hela S3 cells over-express Bcl-2 leading to enhanced levels of its 19-20 kDa cleavage 
product which in turn performs a pro-apoptotic function. It is not clear why Ad-eIF5A2 induces the 




4.3.4 eIF5A up-regulates p73 
Hela cells, as well as many other human cervical carcinoma cell lines that are positive for 
high risk human papillomaviruses (HPV), contain inactive p53 due to the presence of HPV-encoded 
E6 (Scheffner et al., 1991). E6, together with E6-associated protein factor (E6AP) which is a cellular 
ubiquitin-protein ligase, binds p53. This not only ultimately results in p53 degradation through the 
ubiquitin-proteasome pathway, but also prevents p53 from entering the nucleus of cells to perform its 
tumor suppressor activity (Scheffner et al., 1990; Liang et al., 1993 & 1995; Thomas et al., 1996; 
Song et al., 1998; Talis et al., 1998). E6 has been shown to overcome p53-mediated apoptosis 
(Thomas et al., 1996) and also to suppress p53 induction by ionizing radiation (Song et al., 1998). 
Indeed, E6/E6AP-mediated p53 degradation is believed to be the major mechanism leading to 
cervical carcinomas associated with high risk HPVs (Mantovani and Banks, 2001). Accordingly, even 
though the Hela cell line contains wild-type p53, it is considered as a p53 null cell line. However, 
treatments of Hela cells that either prevent the association of E6 with p53 or repress the expression of 
E6 have been shown to induce up-regulation and nuclear accumulation of p53 and ensuing cell cycle 
arrest or apoptosis (Koivusalo et al., 2002; Wesierska-Gadek et al., 2002; Wei et al., 2005; Zhang et 
al., 2005).  
In the present study, the lysates of cells infected with adenovirus-eIF5A constructs were 
fractionated by SDS-PAGE and examined by Western blot analysis using polyclonal p53 antibody. In 
keeping with the fact that these cells contain active E6/E6AP, there was little or no up-regulation of 
p53 in Hela S3 cells undergoing Ad-eIF5A-induced apoptosis. However, there was prominent over-
expression of a protein with a MW of ~70-80 kDa which, because it cross-reacted with the p53-
specfic antibody, is deemed to be p73, a p53-related protein that shares a high degree of sequence and 
structural homology with p53 (Jost et al., 1997; Kaghad et al., 1997). The homology between p53 and 
p73 is particularly extensive within the most conserved p53 domains. Indeed, p73 can be roughly 
divided into three domains: (1) the N-terminal transactivation domain (TAD) (29% identity between 
p53 and p73); (2) the sequence-specific DNA binding domain (DBD) (63% identity between p53 and 
p73); and (3) the oligomerization domain (OD) (42% identity between p53 and p73) (Kaghad et al., 
1997). The high homology in the DBD between p73 and p53 has been interpreted as indicating that 
they bind to the same DNA sequences and transactivate the same genes (Levrero et al., 2000). Indeed, 
p73 has been shown to transactivate a number of p53 target genes including p21, p27, GADD45, 14-
3-3σ, cyclin G, insulin-like growth factor-binding protein 3, Bax and Puma (Zhu et al., 1998; Melino 
et al., 2002). Although p73 and p53 have a number of target genes in common, p73 exhibits promoter 
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selectivity and has a number of unique target genes which are involved in cell cycle arrest, DNA 
repair or apoptosis and are not regulated by p53 (Fontemaggi et al., 2002). Thus, p73 is able to induce 
cell cycle arrest and apoptosis in response to genotoxic stress irrespective of the p53 status (Jost et al., 
1997; Melino et al., 2002 & 2004). 
Like p53, p73 is able to induce apoptosis through multiple mechanisms (Reviewed by Rossi 
et al., 2004; Ramadan et al., 2005). First, p73 can activate the mitochondrial apoptotic pathway via 
Puma transactivation and Bax translocation (Melino et al., 2004). Second, p73 can activate the death 
receptor pathway by transactivating Fas, thereby up-regulating its expression at the cell surface 
(Terrasson et al., 2005). In addition, p73 is able to induce ER stress by transcriptionally activating 
Scotin (Terrinoni et al., 2004), an ER protein that can induce apoptosis (Bourdon et al., 2002).  
The molecular mechanism underlying the regulation of p73 activity is still poorly understood. 
There are reports that p73 is involved in DNA damage-induced apoptosis. However, it is only 
activated in response to ionizing-radiation and cisplatin, treatments that cross-link DNA (Agami et 
al., 1999; Gong et al., 1999; Yuan et al., 1999), and exhibits no response to treatment with 
Actinomycin D or methylmethane sulfonate or to UV irradiation (Kaghad et al., 1997; Levrero et al., 
1999). There is evidence that when p73 is involved in DNA damage-induced apoptosis, it becomes 
phosphorylated and/or acetylated by modifying enzymes that include c-Abl tyrosine kinase, the 
mismatch repair protein, PMS2, p300 acetyltransferase, p38 stress-activated protein kinase and Yes-
associated protein 1 (Yap1) (Gong et al., 1999; Agami et al., 1999; Yuan et al., 1999; Costanzo et al., 
2002; Sanchez-Prieto et al., 2002; Shimodaira et al., 2003; Levy et al., 2007). These DNA damage-
induced interactions between p73 and these proteins are thought to stabilize p73 and enhance its 
apoptotic activity.  
p73 can also be activated by oncogenes through E2F1, the best-characterized member of the 
E2F family of transcription factors. E2F1 plays an essential role in cell cycle progression by 
regulating a large group of genes involved in G1/S transition including cyclin E, cdc25A and DNA 
polymerase α (Johnson et al., 1993; Sala et al., 1994; DeGregori et al., 1995; Ohtani et al., 1995). 
E2F1 is also able to induce apoptosis (Reviewed by Phillips and Vousden, 2001; Ginsberg, 2002; 
Pützer, 2007). Deregulation of E2F1 by mitogenic oncogenes including Ras, Myc, v-Abl and E1A 
triggers p53-dependent or p53-independent apoptosis, thus protecting the organism against oncogenic 
transformation (Qin et al., 1994; Palmero et al., 1998; Zindy et al., 1998; de Stanchina et al., 1999). In 
the p53-dependent pathway, E2F1 indirectly activates p53 through the tumour-suppressor, ARF, 
which interacts with Mdm2, thereby protecting p53 from degradation (Bates et al., 1998). Activated 
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p53 then regulates apoptosis either by transactivating pro-apoptotic molecules such as Puma, Noxa, 
Fas and DR5 or by directly translocating to the mitochondrial outer membrane to induce 
mitochondrial outer membrane permeabilization (Reviewed by Levine, 1997; El-Deiry, 1998; 
Marchenko et al., 2000; Sansome et al., 2001; Vousden and Lu, 2002; Sax and El-Deiry, 2003; 
Mihara and Moll, 2003; Erster et al., 2004; Endo et al., 2006). In the p53-independent pathway, E2F1 
regulates apoptosis by inducing the expression of p73, Apaf-1, caspase proenzymes (e.g.,  
procaspases 2, 3, 7, 8 and 9) and pro-apoptotic BH3-only proteins including Puma, Noxa, Bim, Bik 
and Hrk/DP5 through direct transcriptional activation (Stiewe and Putzer, 2000; Irwin et al., 2000; 
Furukawa et al., 2002; Nahle et al., 2002; Hershko and Ginsberg, 2004; Real et al., 2005). There are 
several reports on the activation of p73 expression by E2F1 or its activators including adenovirus-
E1A and c-Myc (Stiewe and Putzer, 2000; Irwin et al., 2000; Lissy et al., 2000; Zaika et al., 2001; 
Kang et al., 2002; Seelan et al., 2002; Das et al., 2003; Matsumura et al., 2003; Flinterman et al., 
2005). These data collectively indicate that induction of p73 is required for E2F1-induced apoptosis 
and have prompted the proposal that p73 activation by deregulated E2F1 activity might constitute a 
p53-independent, anti-tumorigenic safeguard mechanism (Dobbelstein et al., 2005).  
The present study indicates that p73, a pro-apoptotic p53-like protein, is activated during 
eIF5A-induced apoptosis of Hela S3 cells. Of particular relevance to this finding is the fact that p73 is 
known to be functional in Hela cell lines because, unlike p53, it is not inactivated by the products of 
viral oncogenes such as SV40 T antigen and HPV E6 (Marin et al., 1998; Das et al., 2003a; Melino et 
al., 2004; Das and Somasundaram, 2006; Kim et al., 2006). In light of this, it seems reasonable to 
propose that up-regulation of p73 may be a key element of eIF5A1-induced signaling that invokes 
apoptosis. That p73 appears not to be up-regulated in Ad-eIF5A2-infected cells suggests that although 
eIF5A1 and eIF5A2 are both able to induce apoptosis and have many common targets of up-
regulation, there are, nonetheless, distinctive elements in the signaling pathways they activate.  
 
4.3.4.1 Possible mechanisms for the up-regulation of p73 by eIF5A1 
The mechanism underlying the activation of p73 by eIF5A1 and eIF5A1(K50A) is unknown. 
It has been shown that p38 can directly phosphorylate p73, thereby stabilizing and activating the p73 
protein (Sanchez-Prieto et al., 2002). It has also been shown that infection of A549 human lung 
adenocarcinoma cells with Ad-eIF5A1 induces phosphorylation of p38, thereby activating the p38 
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signaling pathway (Catherine Taylor, unpublished data). It is, therefore, possible that the activation of 
p38 by Ad-eIF5A1 is responsible for the up-regulation of p73. 
A second possibility is that p73 may be transactivated by E2F1 in Ad-eIF5A1- and Ad-
eIF5A1(K50A)-infected cells. Bim, another molecule that is up-regulated by Ad-eIF5A, is also a key 
mediator of oncogene-induced apoptosis and can be transactivated by E2F1 (Egle et al., 2004; 
Hershko and Ginsberg, 2004; Zhao et al., 2004; Biswas et al., 2005; Hemann et al., 2005). Therefore, 
E2F1 may play an important role in Ad-eIF5A1- and Ad-eIF5A1(K50A)-induced apoptosis by 
transactivating two key molecules, p73 and Bim, both of which are able to induce translocation of 
Bax and activation of the mitochondrial pathway, leading to the activation of caspase 9 and, 
subsequently, caspase 3 (Gomez-Bougie et al., 2004; Melino et al., 2004; Zhu et al., 2004; Liu et al., 
2006). Furthermore, E2F1 can activate the p38 MAPK pathway by modulating the phosphorylation of 
p38 (Hershko et al., 2006), which could also account for the activation of p73 in Ad-eIF5A1-infected 
cells (Sanchez-Prieto et al., 2002; Catherine Taylor, unpublished data).  
It is significant that Bim and p73, which are both involved in oncogene-induced apoptosis 
(Stiewe and Pützer, 2001; Zhao et al., 2004), are upregulated in Ad-eIF5A1- and Ad-eIF5A1(K50A)- 
infected Hela cells, for it raises the possibility that eIF5A1 itself may be an oncogene. Further to this, 
it has been shown that eIF5A1 is up-regulated not only in response to activation of the Myc oncogene 
in vitro (Coller et al., 2000; Boon et al., 2001), but also in lung adenocarcinomas compared to normal 
lung tissue (Chen et al., 2003). Higher levels of eIF5A1 protein are also a characteristic of lung 
tumors showing poor differentiation and have been associated with K-ras mutations, p53 nuclear 
accumulation and patients with low survival potential (Chen et al., 2003). It has already been 
proposed that eIF5A2, which unlike eIF5A1 is rarely expressed at detectable levels in healthy cells, is 
an oncogene based on its over-expression in several primary ovarian cancers and many ovarian 
cancer cell lines (Guan et al., 2001; Jenkins et al., 2001; Guan et al., 2004). It would appear from the 
present study that eIF5A1 may as well be oncogene, and that over-expression of eIF5A induces 
apoptosis by activating transcription factor E2F1 which in turn induces the expression of p73 and 
Bim, both of which are able to induce caspase activation leading to apoptosis. 
The proposed oncogenic role of eIF5A is not in conflict with its pro-apoptotic function. It is 
well known that E2F1, which is not only an oncogene but also a tumor suppressor gene, has both 
positive and negative effects on tumorigenesis (Reviewed by Johnson, 2000; Bell and Ryan, 2004). 
There are reports that eIF5A also influences survival and death (Schnier et al., 1991; Park et al., 
1993b; Hanauske-Abel et al., 1994; Kang and Hershey, 1994; Chen et al., 1996; Sasaki et al., 1996; 
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Shi et al., 1996; Caraglia et al., 1997, 1999, 2001 & 2003; Tome and Gerner, 1997; Park et al., 1998; 
Takeuchi et al., 2002; Jin et al., 2003; Li et al., 2004; Taylor et al., 2004 & 2007), which may be due 
to the fact that pathways controlling cell proliferation and apoptosis are coupled (Harrington et al., 
1994). Thus eIF5A may have both oncogenic and tumor-suppressive properties, although how these 
two opposing functions are regulated remains to be elucidated. 
 
4.3.4.1.1 Possible interaction among eIF5A, p73 and caspase 8 
Although caspase 8 activation is classically linked to the activation of receptors of the TNF 
receptor family, some recent data suggest that caspase 8 is not restricted to apoptosis mediated by 
death receptors, and that it can be activated by staurosporine, anticancer drugs, cycloheximide, Shiga 
toxin and γ radiation in a death receptor-independent manner (Ferrari et al., 1998; Wesselborg et al., 
1999; Ding et al., 2000; Engels et al., 2000; Ferreira et al., 2000; Tang et al., 2000; Jones et al., 2001; 
Fujii et al., 2003; Sohn et al., 2005). Several mechanisms are involved in the FADD-independent 
activation of caspase 8. First, caspase 8 can be cleaved and activated by other caspases including 
caspases 3, 6, and 9 in the mitochondrial pathway (Slee et al., 1999; Viswanath et al., 2001; Sohn et 
al., 2005) and subsequently involved in the amplification of caspase-mediated cell death. This entails 
either cleaving Bid, thereby enhancing the mitochondrial pathway (Engels et al., 2000; Tang et al., 
2000; Viswanath et al., 2001), or directly translocating into the nucleus to cleave and inactivate 
poly(ADP-ribose) polymerase-2 (PARP-2) (Tang et al., 2000; Benchoua et al., 2002). PARP-2 plays 
a critical role in the maintenance of genomic integrity by modulating DNA repair and cell survival 
programs (Ame et al., 1999). Second, caspase 8 can be cleaved by non-caspase proteases such as 
HIV-1 protease and granzyme B (Medema et al., 1997; Nie et al., 2002). Indeed, activation of caspase 
8 is thought to play a central role in mediating HIV-1- or granzyme B-induced apoptosis (Medema et 
al., 1997; Nie et al., 2002). Third, p53 can induce activation of caspase 8. It has been shown that p53 
plays an important role in FADD-independent activation of caspase 8 by facilitating the assembly of a 
600 kDa caspase 8-activating complex through protein-protein interactions (Ding et al., 2000). p53 
can also transactivate Fas and/or KILLER/DR5, both of which belong to the TNF receptor family 
(Wu et al., 1997 & 1999; Muller et al., 1998). In some cases, over-expression of these death receptors 
alone is sufficient for the initiation of apoptosis (Papoff et al., 1999; Shinoura et al., 2000; Sax and 
El-Deiry, 2003).  
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Since Hela S3 cells, which contain inactive p53, were used in the present study, the 
possibility that eIF5A-induced activation of caspase 8 is achieved through p53 would appear to be 
ruled out. However, p73, a p53 homolog, which is functional in Hela cells and up-regulated following 
infection with Ad-eIF5A, can also transactivate Fas, thereby inducing up-regulation of Fas at the cell 
surface (Terrasson et al., 2005). Thus, in Ad-eIF5A-infected Hela S3 cells caspase 8 might be 
activated either directly by the upstream caspases 9 and 3, which are activated through the Bim-
initiated mitochondrial pathway, or indirectly through p73 which can up-regulate Fas expression at 
the cell surface. Furthermore, caspase 8 may be activated in a FADD-dependent, but death receptor-
independent manner, during Ad-eIF5A-induced apoptosis.  
Both caspase 8 and caspase 9 are activated during eIF5A-induced apoptosis. Since there is no 
cleavage of Bid, caspase 8 may not be responsible for activation of the mitochondrial pathway. 
However, activation of caspases 9 and 3 may be responsible for the activation of caspase 8. Indeed, 
proteolytic processing of caspase 8 during death receptor-independent apoptosis has been proposed to 
be a positive post-mitochondrial feedback loop in many cell types (Slee et al., 1999; Ding et al., 2000; 
Besnault et al., 2001; Tang et al., 2002; Sohn et al., 2005).  
 
4.4 Over-expression of eIF5A induces the accumulation of lysine50 eIF5A 
The finding that both Ad-eIF5A1 and Ad-eIF5A1(K50A) are able to induce apoptosis in HT-
29 and Hela S3 human cancer cell lines raises the question of whether hypusination is required for the 
pro-apoptotic activity of eIF5A1. eIF5A1 is an abundant protein with a MW ~18 kDa and a pI of 5.1-
5.5 (Cooper et al., 1982). It has been demonstrated previously that three distinct forms of human 
eIF5A1 can be separated by 2D electrophoresis on the basis of different pI values (Klier and 
Lottspeich, 1992; Wohl et al., 1995; Takeuchi et al., 2002; Jin et al., 2003; Dong et al., 2005; 
Nishimura et al., 2005). These previous studies indicated that one of these, which is hypusinated at 
lysine50 and is referred to as the main form, comprises ~95% of the total eIF5A in untreated cells. An 
intermediate form has been shown to be acetylated at lysine47 and either deoxyhypusinated or 
hypusinated at lysine50. The third acidic form is acetylated at lysine47 and unmodified at lysine50 
(Klier et al., 1995).  
In the present study, 2D Western blotting and mass spectrometry were used to isolate and 
identify the post-translationally modified forms of eIF5A1. The three forms previously identified, the 
main form, the intermediate form and the acidic form were discernible. Of particular interest, 
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however, is the finding that over-expression of eIF5A1 using either wild-type eIF5A1 or mutant 
eIF5A1 adenovirus constructs failed to result in an accumulation of hypusinated eIF5A. Rather, the 
acidic form of eIF5A1 and, to a lesser extent, the intermediate form accumulated under these 
conditions. This can be interpreted as indicating that the high concentration of over-expressed 
precursor eIF5A1 overwhelms, and essentially inhibits, endogenous DHS. Similar results have also 
been demonstrated in yeast and human 293T cells. Specifically, over-expressed yeast HYP2, human 
eIF5A1 or human eIF5A2 proteins were not stoichiometrically deoxyhypusinated or hypusinated 
(Wohl et al., 1995; Clement et al., 2006), prompting the view that co-expression of DHS is needed for 
post-translational modification of all of the over-expressed eIF5A precursor protein (Clement et al., 
2006). 
It was also established in the present study that adding an influenza hemagglutin (HA) tag to 
the N-terminus of eIF5A1 renders it incapable of serving as a substrate for DHS. In these 
experiments, COS-7 African green monkey kidney cells were transfected with pHMeIF5A1 plasmid 
to form HA-tagged recombinant eIF5A1 and then treated with [H3]-spermidine to radiolabel 
deoxyhypusine formed by DHS. Whereas endogenous eIF5A1 was clearly labeled by [H3]-spermidine 
indicating that it had participated as a substrate in the DHS reaction, the recombinant HA-tagged 
eIF5A1 protein was not labeled. Thus, as is the case for most enzymatic reactions, the association of 
DHS with at least one of its substrates, specifically eIF5A, appears to be dependent upon the 
structural integrity of the substrate. It is also likely that an over-abundance of either substrate for 
DHS, spermidine or eIF5A, impedes its ability to associate with its substrates in the correct 
stoichiometry, and that this underlies the inhibition of the reaction observed under conditions in 
which eIF5A1 is strongly over-expressed. 
 
4.5 eIF5A1-lysine50 appears to be an apoptogenic protein  
Reports that inhibition of hypusine formation by inhibiting DHS or depleting the endogenous 
pool of spermidine causes cell cycle arrest and that the treated cells ultimately die have prompted the 
suggestion that hypusinated eIF5A1 is required for cell growth and proliferation (Schnier et al., 1991; 
Byers et al., 1992; Park et al., 1993b; Hanauske-Abel et al., 1994; Kang and Hershey, 1994; Chen et 
al., 1996; Sasaki et al., 1996; Shi et al., 1996; Tome and Gerner, 1997; Park et al., 1998; Choi et al., 
2000; Kramer et al., 2001). However, GC7 and other inhibitors of DHS used in these studies have 
been shown to be non-specific (Lee et al., 1995; Chen et al., 1996; Nishimura et al., 2005). Moreover, 
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spermidine belongs to family of polyamines which participate in a large number of cellular reactions, 
including DNA synthesis and gene expression, and play a critical role in the proliferation, migration 
and differentiation of cells (Reviewed by Goyns, 1982; Pegg and McCann, 1982). Accordingly, it is 
not clear whether the suppression of cell proliferation in these types of experiments is attributable to 
inhibition of eIF5A hypusination or to a different unrelated effect of the treatment. This contention is 
supported by data obtained in the present study indicating suppression of eIF5A1 by up to 90% has no 
effect on cell proliferation.  
The present study also provides strong evidence that eIF5A1-lysine50 is able to induce 
apoptosis. In particular, over-expression of eIF5A1, which results in an accumulation of lysine50-
containing eIF5A1 was shown to be strongly pro-apoptotic. Further evidence supporting the 
contention that post-translational hypusination of lysine50 in eIF5A1 is not required for its pro-
apoptotic activity is the finding that eIF5A1(K50A), a mutated form of eIF5A1 in which lysine50 is 
replaced by alanine, proved to be equally as effective at inducing apoptosis as wild-type eIF5A1. It 
thus seems reasonable to propose that eIF5A-lysine50 is an apoptogenic protein. 
Numerous functions for eIF5A have been proposed including involvement in protein 
translation initiation or elongation (Kang and Hershey, 1994; Lipowsky et al., 2000; Zanelli et al., 
2006), nucleocytoplasmic shuttling of mRNA (Ruhl et al., 1993; Hanauske-Abel et al., 1995; 
Katahira et al., 1995; Liu and Tartakoff, 1997; Jin et al., 2003), mRNA turnover (Zuk and Jacobson, 
1998; Zuk and Jacobson, 1998; Veress et al., 2000; Nishimura et al., 2002; Valentini et al., 2002; 
Schrader et al., 2006) and maintenance of actin cytoskeleton organization and microtubule stability 
(Weir and Yaffe, 2004; Zanelli and Valentini, 2005; Chatterjee et al., 2006). There have also been 
several reports suggesting that eIF5A1 is involved in apoptosis (Caraglia et al., 1997, 1999, 2001 & 
2003; Takeuchi et al., 2002; Jin et al., 2003; Li et al., 2004; Taylor et al., 2004 & 2007). However, it 
is not clear from any of these reports whether hypusination of eIF5A is required for its pro-apoptotic 
activity. The finding in the present study that siRNA-mediated suppression of eIF5A1 inhibits 
apoptosis induced by serum deprivation or treatment with SNP, Actinomycin D or MG-132 further 
supports the contention that eIF5A is involved in apoptosis. Of particular interest, though, is the fact 
that the acidic isoform of eIF5A1, which contains lysine50 as shown by mass spectrometry, 
accumulates within 3.5 hours of treatment with SNP. Moreover, eIF5A1 is known to be strongly up-
regulated following treatment of cells with SNP (Taylor et al., 2007). These observations collectively 
suggest that lysine50-containing eIF5A1 is a key facilitator of apoptosis induced by SNP. This 
possibility is consistent with the additional finding in the present study that over-expression of 
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eIF5A1(K50A), which cannot be either deoxyhypusinated or hypusinated, activates both the 
mitochondrial and death receptor pathways of apoptosis.   
These data collectively support the contention that lysine50-containing eIF5A1 is a pro-
apoptotic protein. Of particular note in this context is the fact that hypusinated eIF5A is by far the 
dominant form of eIF5A in normal healthy cells, comprising ~95% of the total eIF5A. In the event of 
exposure to an apoptotic stimulus, there is new synthesis of eIF5A, and it seems reasonable to 
propose that this newly synthesized eIF5A is not post-translationally modified at lysine50 and, as such, 
is able to induce apoptosis. Whether pre-existing hypusinated eIF5A can be converted back to lysine50 
in response to an apoptotic stimulus is not clear. 
 
4.6 eIF5A1 is post-translationally modified at lysine47 and lysine50  
An initially perplexing feature of experiments in the present study in which apoptosis was 
induced by infection with Ad-eIF5A was the finding that over-expression of eIF5A1(K50A), which 
cannot serve as a substrate for DHS, resulted not only in an accumulation of the acidic form of 
eIF5A1 (eIF5A1-lysine50), but also, to a lesser extent, of the intermediate form thought to be 
deoxyhypusinated eIF5A1 (eIF5A1-deoxyhypusine50). This apparent paradox was resolved when the 
various forms of post-translationally modified eIF5A1 were analyzed by mass spectrometry. 
Specifically, the three forms of eIF5A1 protein, the acidic form (pI 4.9), the intermediate form (pI 
5.0) and the dominant form (pI 5.1), were isolated from Ad-eIF5A1-infected cells and from untreated 
cells and sequenced by mass spectrometry. This analysis indicated that lysine47 and lysine50 of eIF5A 
are both post-translationally modified. Lysine47 becomes acetylated, and lysine50 is converted to 
deoxyhypusine or hypusine. The acidic form of eIF5A1 (pI 4.9) in Ad-eIF5A1-infected cells isolated 
by 2D electrophoresis proved to be acetylated at lysine47 and unmodified at lysine50. The predominant 
form of eIF5A1 (pI 5.1) in both untreated and Ad-eIF5A1-infected cells proved to be unmodified at 
lysine47 and hypusinated at lysine50.  The intermediate form (pI 5.0) in Ad-eIF5A1-infected cells was 
unmodified at both lysine47 and lysine50, whereas the intermediate form isolated from untreated 
control cells proved to be acetylated at lysine47 and either dexoyhypusinated or hypusinated at 
lysine50.  
Thus, the finding that eIF5A1 acetylated at lysine47 and unmodified at lysine50 has a pI of 4.9 
and that eIF5A1 unmodified at both lysine47 and lysine50 has a pI of 5.0 explains why over-expression 
of eIF5A1(K50A), which cannot serve as a substrate for DHS, gave rise to two forms of eIF5A1 in 
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2D Western blots. Moreover, the 2D Western blots are consistent with the view that eIF5A1-lysine50 
is the form of eIF5A1 that is apoptogenic. eIF5A1 unmodified at both lysine47 and lysine50 has not 
previously been detected in cells and would appear to be the precursor form of eIF5A1 that through 
post-translational modification becomes acetylated at lysine47 and deoxyhypusinated or hypusinated at 
lysine50. A possible pathway by which these modifications may occur is illustrated in Figure 31. This 
pathway is consistent with the post-translationally modified forms of eIF5A1 detected by mass 
spectrometry in cells infected with Ad-eIF5A1 and purports that: (1) newly synthesized eIF5A1 
containing unmodified lysine47 and lysine50 is first post-translationally modified to eIF5A1-acetylated 
lysine47-lysine50; (2) lysine50 is then converted to deoxyhypusine by DHS and to hypusine by DHH 
while lysine47 remains acetylated; and (3) lysine 47 is de-acetylated and lysine 50 remains 
hypusinated. The proposed pathway is also consistent with the observation that the intermediate form 
of eIF5A1 on 2D gels (pI 5.0), determined to be eIF5A1-lysine47-lysine50 by mass spectrometry, 
accumulates within 30 minutes of treatment with SNP and before accumulation of the acidic form of 
eIF5A1 on 2D gels (pI 4.9) determined to be to eIF5A1-acetylated lysine47-lysine50 by mass 
spectrometry. However, the possibility that precursor eIF5A1 can be modified at lysine50 by DHS in 
the absence of lysine47 acetylation is not precluded. Indeed, it has been suggested that acetylation of 
lysine47 might reduce the rate of hypusine synthesis (Klier et al., 1995). If this is so, acetylation of 
lysine47 could constitute a means of regulating the pro-apoptotic function of eIF5A1. Specifically, it 
seems clear from experiments in the present study demonstrating essentially equivalent pro-apoptotic 
activities of Ad-eIF5A1(K50A) and Ad-eIF5A1 that eIF5A1-lysine50 rather than eIF5A1-

























Figure 31: Proposed post-translational modification scheme for eIF5A1.  
The newly synthesized precursor eIF5A1 contains unmodified lysine47 and lysine50. In response to 
apoptotic stimuli (e.g., SNP), newly synthesized precursor eIF5A1 is acetylated on lysine47, and 
remains unmodified on lysine50, giving rise to the form of eIF5A that is apoptogenic [step (1)]. In 
normal cells that are not undergoing apoptosis, lysine50 of eIF5A1-acetylated lysine47-lysine50 is 
quickly converted to deoxyhypusine and then to hypusine by deoxyhypusine synthase (DHS) and 
deoxyhypusine hydroxylase (DHH), respectively [step (2)]. Thereafter, lysine47 is deacetylated giving 
rise to eIF5A1-lysine47-hypusine50 [step (3)]. Under normal conditions in healthy cells, the precursor 
eIF5A1 may also be directly post-translationally modified at lysine50 to give rise to eIF5A1-lysine47-































4.7 eIF5A1 is N-terminally modified 
It was also established by mass spectrometry in the present study that eIF5A1 is N-terminally 
modified irrespective of its state of post-translational modification at lyinse47 and lysine50. 
Specifically, the methionine at position 1 is removed, and the alanine residue at position 2 is 
acetylated. Loss of the methionine at position 1 is not uncommon. Indeed, it has been estimated that 
55-70% of eukaryotic cell proteins have lost this initial amino acid (Reviewed by Giglione et al., 
2003). The process by which this methionine is removed is termed N-terminal methionine excision 
(NME). It occurs co-translationally and is mediated by methionine amino peptidase, leaving smaller 
residues such as alanine, cysteine, glycine, proline, serine, threonine and valine exposed at the N-
terminus (Sherman et al., 1985; Frottin et al., 2006). As predicted from the N-end rule of protein 
stability, proteins possessing these small N-terminal residues, which are known as stabilizing 
residues, have relatively longer half-lives compared with proteins possessing bulky N-terminal 
residues such as arginine, lysine, leucine, phenylalanine, tyrosine and tryptophan, which are known as 
destabilizing residues (Gonda et al., 1989; Tobias et al., 1991). Furthermore, proteins with an N-
terminal methionine are unstable and are targets for N-terminal ubiquitinylation (Meinnel et al., 
2005). Therefore, it has been suggested that NME plays a crucial role by enhancing the half life of 
many proteins (Richo and Conner, 1994; Wakayama et al., 1995; Giglione et al., 2003; Liao et al., 
2004). 
NME is normally accompanied by acetylation of the newly exposed N-terminal amino acid, 
and this was found to be the case for eIF5A1 in the present study. For eIF5A1, NME gives rise to an 
N-terminal alanine (alanine2), and for unmodified eIF5A as well as all of the post-translationally 
modified forms of eIF5A1 examined in the present study, alanine2 proved to be acetylated. The 
process by which this occurs is termed N-α-acetylation (NAA). Like NME it occurs co-translationally 
and has been shown to occur in ~30% (by identity) and ~90% (by weight) of the mature proteins in 
the proteomes of some higher eukaryotes (Driessen et al., 1985; Polevoda and Sherman, 2003; 
Meinnel et al., 2005). NAA blocks the N-terminus of the protein, making it resistant to further 
modifications including amino peptidase-directed degradation and N-terminal ubiquitination 
(Meinnel et al., 2006). Thus, a major function of NAA appears to be protecting proteins from 
proteolysis. Indeed, it has been shown that the half lives of proteins co-translationally modified by 




Co-translational N-terminal modification of proteins by NME and NAA are, therefore, 
important mechanisms for regulating protein stability. The fact that eIF5A1 undergoes these N-
terminal modifications during its synthesis is consistent with reports that it has a comparatively long 
half life (Benne et al., 1978; Gerner 1986; Nishimura et al., 2005), and also imply that it has an 
important biological function.   
 
4.8 eIF5A1 undergo deamidation 
The mass spectrometric analysis of eIF5A1 indicated yet another post-translational 
modification of the protein not previously reported, specifically that asparagine28 undergoes 
deamidation. Deamidation entails hydrolysis of the side-chain amide group on an asparagine or 
glutamine residue. The deamidation of asparagine generates succinimide as an intermediate, which is 
subsequently converted to aspartate or isoaspartate (Robinson and Rudd, 1974; Geiger and Clarke, 
1987). The rate of deamidation is dependent on pH, temperature and tertiary structure ("nearest 
neighbor" effect) of the protein (Kossiakoff et al., 1988, Tyler-Cross and Schirch, 1991; Wright, 1991; 
Robinson and Robinson, 2001). For example, an asparagine followed by a glycine is highly 
susceptible to deamidation (Robinson and Rudd, 1974; Tyler-Cross and Schirch, 1991), and this is the 
case for human eIF5A1 in which asparagine28 is followed by a glycine, glycine29. In keeping with 
this, all of the forms of eIF5A1 resolvable by 2D Western blotting exhibited this modification of 
asparagine28.   
Deamidation results in the introduction of a negative charge at the site of modification, and 
this in turn is likely to alter the tertiary structure of the protein and affect its biological properties 
(Robinson and Rudd, 1974; Wright, 1991b). Indeed, for some proteins deamidation has been linked to 
loss of bioactivity (Wingfield et al., 1987; Friedman et al., 1991; Orru et al., 2000; Gupta and 
Srivastava, 2004b; Zomber et al., 2005). Moreover, deamidation at different sites in the same protein 
appears to have different effects on both structure and function (Gupta and Srivastava, 2004a). There 
is also evidence that deamidation is linked to protein degradation (Wingfield et al., 1987). Indeed, it 
has been hypothesized that deamidation functions as an internal clock, regulating the half-life of 
proteins (Robinson and Robinson, 2001 & 2004). The finding in the present study that for all 
resolvable forms of eIF5A1 asparagine28 is deamidated suggests that deamidation of this asparagine 
may be a prerequisite either for eIF5A1 function or for subsequent post-translational modification 
such as acetylation or hypusination. 
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4.9 Subcellular localization of eIF5A1  
p53 is known to localize on mitochondria in response to apoptotic stimuli and perform direct 
apoptogenic functions independently of its transactivation activity (Erster et al., 2004). It has been 
shown, for example, that in the event of apoptotis a fraction of the total p53 protein redistributes to 
the mitochondrial outer membrane and, by directly inducing Bax/Bak oligomerization and 
mitochondrial outer membrane permeablization, facilitates the release of cytochrome c leading to 
activation of caspases 9 and 3 (Mihara et al., 2003; Erster et al., 2004; Leu et al., 2004; Jiang et al., 
2006). Since over-expression of eIF5A induces apoptosis by activating the mitochondrial pathway, 
the possibility that it also localizes in or on mitochondria was examined by confocal microscopy.  
However, this proved not to be the case. In untreated cells, endogenous eIF5A1 was predominantly in 
the cytoplasm, and there were smaller amounts of the protein in the nucleus. Following the induction 
of apoptosis by infection with Ad-eIF5A1, eIF5A1 was again detectable in the cytoplasm, but with 
time after infection it became increasingly clustered in the vicinity of the inner cellular face of the 
plasma membrane. It was not possible to distinguish endogenous eIF5A1 from trans-eIF5A1 in these 
experiments, but there is no apparent reason to assume that they would have different subcellular 
localizations. Nor was it possible to distinguish between the localization of eIF5A1-lysine50 and 
eIF5A1-deoxyhypusine50 or eIF5A1-hypusine50 because, although the localization pattern of the 
protein was examined in both Ad-eIF5A1- and Ad-eIF5A1(K50A)-infected cells, eIF5A1-lysine50 
proved to be the predominant forms of eIF5A1 in both cases. Indeed, it is likely that the pattern of 
eIF5A1 distribution in both Ad-eIF5A1- and Ad-eIF5A1(K50A)-infected cells largely reflected that 
of eIF5A1-lysine50. 
There have been several previous reports on the localization of eIF5A discerned using both 
immunofluorescence and immunohistochemical staining or GFP-live imaging (Shi et al., 1996; Jao 
and Chen, 2002; Valentini et al., 2002; Jin et al., 2003; Cracchiolo et al., 2004; Taylor et al., 2007). 
The observation in the present study that eIF5A1 in untreated Hela cells is localized in the cytoplasm 
is consistent with most of these studies (Shi et al., 1996; Valentini et al., 2002; Jin et al., 2003; 
Cracchiolo et al., 2004; Taylor et al., 2007), although there is one  report of a whole-cell distribution 
pattern for eIF5A1 (Jao and Chen, 2002). Similarly, the finding in the present study that some eIF5A1 
is also detectable in the nucleus is in keeping with a previous proposal that eIF5A1 may accumulate 
in the nucleus by passive diffusion (Lipowsky et al., 2000; Jao and Chen, 2002). Jin et al (2003) 
reported that blocking the hypusination of eIF5A changed its distribution from cytoplasmic to a 
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whole-cell pattern. However, other groups have suggested that the hypusine residue contributes to the 
nuclear retention of eIF5A1 (Klier et al., 1995; Lipowsky, 2000).  
The clustering of trans-eIF5A1 at the inner surface of the plasma membrane upon induction 
of apoptosis by infection of cells with Ad-eIF5A1 or Ad-eIF5A1(K50A) proved to be time-dependent 
suggesting that it contributes to the proapoptotic function of eIF5A. There have been several reports 
of ligand-independent death receptor clustering leading to subsequent recruitment of FADD and 
activation of death receptor pathway (Rehemtulla et al., 1997; Sheikh et al., 1998; Beltinger et al., 
1999; Zhuang and Kochevar, 2003; Gajate et al., 2004; Gniadecki, 2004). In fact, it has been 
suggested that the activity of Fas is not only regulated by its ligand, but also by its association with 
lipid rafts, which are cholesterol-enriched lipid domains in the plasma membrane (Cremesti et al., 
2001; Gajate et al., 2004; Lincoln et al., 2006). For example, Fas has been shown to translocate 
laterally through the plasma membrane into lipid rafts following antitumor chemotherapy, 
independently of association with FasL (Delmas et al., 2003; Huang et al., 2003; Lou et al., 2003; 
Lacour et al., 2004; Gajate and Mollinedo, 2005). Moreover lipid rafts also recruit apoptotic signaling 
molecules including FADD, procaspase 8, procaspase 10, JNK and Bid (Gajate et al., 2004; Gajate 
and Mollinedo, 2005). Therefore, lipid rafts not only concentrate Fas within the plane of the 
plasmalemma, but also serve as platforms for recruiting adaptor and effector proteins for Fas, thereby 
enhancing DISC formation (Mollinedo and Gajate, 2006). In light of this, it is conceivable that the 
clustering of eIF5A1 on the inside surface of the plasmalemma following the induction of apoptosis 
by its up-regulation may reflect involvement of eIF5A1 protein in the death receptor pathway of 
apoptosis. More specifically, the accumulation of eIF5A1 in the vicinity of the plasma membrane 
may, in a way that is not understood, facilitate the concentration of Fas into lipid rafts, thereby 
activating Fas-mediated downstream signaling. Involvement of eIF5A1 in the death receptor pathway 
is also consistent with the fact that infection with Ad-eIF5A induces up-regulation of the transcription 
factor, p73, which is known to regulate Fas (Terrasson et al., 2005), and also leads to activation of 
caspase 8, which is the initiator caspase for the extrinsic death receptor pathway (Varfolomeev et al., 
1998). 
It has been suggested that the FasL-independent recruitment of Fas into lipid rafts could be 
due to persistent activation of JNK (Revieved by Mollinedo and Gajate, 2006). Relevant to this is 
other data from our laboratory showing that infection with Ad-eIF5A1 does in fact induce 
phosphorylation of JNK (Catherine Taylor, unpublished data). eIF5A has also been implicated in 
organization of the actin cytoskeleton (Zanelli and Valentini, 2005; Chatterjee et al., 2006), which in 
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turn, may regulate lipid raft-mediated signaling including that attributable to the clustering of Fas 
(Harder and Simons, 1999; Parlato et al., 2000; Lozupone et al., 2004; Fais et al., 2005; Gajate and 
Mollinedo, 2005). It is, therefore, conceivable that eIF5A1 impacts Fas aggregation in lipid rafts 
through an association with actin.  
Of particular interest is the finding that when apoptotis was induced by treatment with 
Actinomycin D rather than by infection with Ad-eIF5A1 there was a notable translocation of 
endogenous eIF5A1 from the cytoplasm into the nucleus within 12 hours of treatment. Morover, the 
translocation increased with time through 18 to 24 hours. Permeabilization of the nuclear envelope is 
a key event during apoptosis (Robertson et al., 2000), and the time-dependent nature of eIF5A1 
translocation into the nucleus following treatment with Actinomycin D is consistent with the notion 
that it gains access to the nucleus as the nuclear envelope becomes permeabilized. This contention is 
consistent with earlier reports that entry of eIF5A into the nucleus is insensitive to reagents that block 
the nuclear pore complex (NPC) (Lipowsky et al., 2000; Jao and Chen, 2002). However, by 24 hours 
after treatment with Actinomycin D, the concentration of eIF5A1 in the nucleus appeared to be higher 
than that in the cytoplasm suggesting that there was an active uptake of the protein from the cytosol. 
A similar redistribution of endogenous eIF5A1, but within a much shorter time (10 minutes), was 
noted when apoptosis was induced by treatment with TNFα (Taylor et al., 2007). That endogenous 
eIF5A1 plays a role in apoptotis is supported by the finding in the present study that eIF5A1 siRNA is 
a potent inhibitor of apoptotis induced by a number of pro-apoptotic stimuli including Actinomcyin 
D. The fact that endogenous eIF5A protein progressively localizes to the nucleus following the 
induction of apoptosis by Actinomycin D suggests that the apoptogenic effect of the protein may be 
dependent upon this migration. 
It is noteworthy that the induction of apoptotis by treatment with Actinomcyin D on the one 
hand and infection with Ad-eIF5A1 on the other gave rise to quite different subcellular localizations 
of eIF5A1 protein. In the case of infection with Ad-eIF5A1, there was a distinct clustering of eIF5A1 
protein at the inner surface of the plasmalemma and no evidence for localization in the nucleus. In 
contrast, when apoptosis was induced by treatment with Actinomycin D, endogenous eIF5A1 
progressively translocated to the nucleus, and there was no apparent clustering of the protein at the 
cell surface. At face value, this suggests that eIF5A1 facilitates apoptosis in different ways by 
different mechanisms depending on the nature of the apoptotic stimulus. However, the possibility that 
it functions as an apoptogenic agent in multiple ways through multiple mechanisms no matter what 
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the apoptotic stimulus, and that, depending on the stimulus, a particular mechanism is dominant, is 
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